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ABSTRACT
The aim of this work is primarily to validate the advanced techniques for treatment
planning and dosimetric verification for modern megavoltage x-ray radiotherapy. With the
advent of modern radiotherapy techniques, there is a great need for assuring quality of the
radiation dose distributions generated by the advanced intensity modulated treatments
(IMRT/VMAT). This is typically accomplished by the assessment of the treatment plan quality
at the planning stage and then verification of the dose distributions through measurements on the
phantoms or independent dose calculations prior to the actual delivery of these plans to patients.
The major focus of this work is to clinically evaluate the modern 2D and 3D dose verification
techniques.
The measurement-based dosimetry systems investigated were ArcCHECK/3DVH and
SRS MapCHECK. AcrCHECK/3DVH system uses the measurement-guided dose reconstruction
algorithm to correct the predicted dose in the patient dataset. The system was intended for
VMAT/IMRT QA. SRS MapCHECK was investigated for SRS treatments. The independent
dose calculation system was DoseCHECK which employed a GPU-accelerated convolutionsuperposition of algorithm for 3D dose reconstruction on the patient dataset. Next, a hybrid dose
verification system (PerFRACTION) was evaluated, which takes input from both the treatment
planning system and the linac EPID and produces a measurement-guided 3D dose distribution
for comparison with the plan. This system was investigated for potential QA applications to a
modern, efficient SRS technique, involving simultaneously treating multiple targets with a single
xvi

isocenter. The performance of all dosimetry systems was validated against well-characterized
independent dosimeters, such as ion chamber, film and scintillator detectors, or 3D arrays
(Delta4), using stringent dose comparison criteria to test their limits for the intended clinical
applications.
For the initial plan quality evaluation of a novel tool (Feasibility DVH) was investigated.
This tool a priori estimates best achievable dose volume histograms for a specific patient, based
on the basic physics properties of the megavoltage x-rays, thus helping the planners to guide
their efforts.
All studied dosimetry systems showed an excellent agreement of the average gamma (a
mathematical combination of DD and DTA) passing rates >98% for most of the plans. The 3%
DD/2mm DTA criteria were used for extracranial plans and 3%/1mm for intracranial SRS plans.
As dictated by the logic of the application, the comparisons were made against TPS calculations,
a bi-planar array, or film measurements. Similarly the average percent point dose errors <2%
were observed against the ion chambers or film. In the rare instances when the deviations were
larger, intuitive explanations were provided, based on either the physics of the plans or
inhomogeneous patient anatomy and resulting algorithm limitations.
Feasibility DVH was shown to reliably predict the best possible organ sparing for clinical
head-and-neck VMAT plans.
Overall the investigated dosimetry systems were found reliable and feasible for their
intended clinical use.
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1.1

INTRODUCTION

Background
Radiation therapy (radiotherapy) is one of the three major modalities of cancer treatment

(the other two are surgery and systemic drug treatments, including chemotherapy, hormonal
therapy, and immunotherapy). The radiotherapy treatment procedure, in simple words, involves
the following steps: 1) diagnosis and delineation of a tumor/target; 2) prescribing and optimizing
the radiation dose such that it, inasmuch as possible, conforms to the target but spares the
surrounding healthy tissue; 3) verifying the treatment plan; and 4) delivering the treatment to the
patient. The treatments are delivered using high energy x-rays and electrons produced by medical
linear accelerators (LINAC), gamma rays from radioactive sources, and protons & heavy ions
from particle accelerators. At a clinical radiation oncology department, the machines are first
commissioned for the intended use and then a rigorous quality assurance (QA) program is
implemented to ensure the mechanical and radiation beam stability for safe clinical use
throughout its life. The routine machine QA in combination with a simple patient-specific point
dose calculation is historically considered sufficient for the safe delivery of two or three
dimensional, forward planned treatments. If required, a single point measurement in a uniform
high dose region could be added [1, 2].
Radiotherapy, with the advent of fast computers and modern LINACs, has undergone
tremendous changes during the last couple decades. Great strides were made in almost every
1

aspect of radiotherapy: treatment optimization through inverse planning, modern & digital
delivery systems, fast dose calculation algorithms and on-board imaging techniques [3]. The
advanced planning techniques (inverse planning) generate beams with fluence modulation across
the radiation field resulting in a complex dose distribution with a high degree of tumor
conformality and steep dose gradients for adjacent organ-at-risk (OAR) sparing. Such treatments
by common sense and various regulations and professional societies’ recommendations, require
detailed verification of the dose distribution by more than just a single point
calculation/measurement. These requirements created a new step, called patient specific quality
assurance (PSQA), in the radiotherapy workflow. PSQA has evolved from point dose assessment
to the planar and volumetric measurements or calculations.
The aim of this work is the validation of advanced techniques for treatment planning and
verification in megavoltage radiotherapy. Majority of this work is focused on the rigorous
clinical evaluation of modern PSQA methods for the advanced treatment techniques. The
modern treatment planning and delivery techniques and their challenges for PSQA are briefly
described in the following sections.
1.2

Intensity Modulated Radiation Therapy
Intensity modulated radiation therapy (IMRT) was one of the most groundbreaking

developments in radiation therapy planning and delivery. During IMRT, inverse planning
technique is used to generate multiple small radiation beams (beamlets) with non-uniform
fluence from different angles. This is radically different from the traditional forward planning,
where a uniform radiation fluence is delivered across the fields and wedges and/or operatordesigned blocks are used to partially block or moderately modulate the fluence. While in forward
planning the beam weights and shapes are controlled by a human, the multitude of beamlets can
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only be generated and optimized by a fast computer algorithm. The fluence modulation is
achieved spatially by multileaf collimators (MLCs) and temporally by varying the accelerator
dose rate [4, 5]. This process is controlled by inverse planning, wherein the dose-volume
objectives serve as the input to generate complex fluence patterns optimized to produce 3D dose
distributions most closely approximating those objectives. The whole process is called IntensityModulated Radiation Therapy, or IMRT. IMRT is vastly superior to the forward treatment
planning in conforming the prescribed dose to the complex concave-shaped targets, while
sparing the adjacent healthy tissues. This is why IMRT is often dubbed as “conformal sparing”.
While inverse planning is paramount to various planning techniques, the field terminology
historically evolved such that the term IMRT is now reserved for so called fixed-beam
techniques, whereby the radiation is turned off when the accelerator gantry is moving. The
irradiation starts only when the gantry stops at one of the planned angles. The clinical IMRT
techniques are further subdivided into: 1) static aperture IMRT (step-and-shoot), in which the
beam is off while the MLC leaves move to form the next segment; and 2) dynamic IMRT
(sliding window), where the moving MLC aperture sweeps the field while the beam stays on.
1.3

Volumetric Modulated Arc Therapy
The idea of IMRT with continuous gantry rotation using the conventional C-arm linear

accelerators was introduced by Yu C. X. [6] in 1995. The technique was termed “intensity
modulated arc therapy (IMAT)” and involved continuous irradiation with gantry rotation. The
early technique applied a limited number of intensity levels (MLC apertures) using gantry arcs
with constant dose rate. Later studies concluded that for a better target coverage and organ-atrisk (OAR) sparing, it was desirable to increase the number of MLC apertures by combining leaf
travel with gantry rotation, and to vary the accelerator dose rate in the process [7, 8].
3

Volumetric modulated arc therapy (VMAT) is the variation of the IMAT with the
variable dose rate and continuous MLC sweeping back and forth through the field. The term
‘VMAT’ was first used by Otto K. [9] who devised an algorithm for the treatment plan
optimization and control points generation with dynamic arcs. The algorithm accounts for the
machine physical delivery constraints in terms of gantry rotation and leaf translation speeds. The
immediate benefit was the reduced delivery time for the same level of modulation. The
variations of the algorithm were adopted by the major equipment vendors and included in their
respective treatment planning systems with specific trade names: SmartArc by Philips Medical
Systems, VMAT by Elekta and RapidArc by Varian Medical Systems. The VMAT has shown
comparable tumor control to the standard IMRT techniques for a range of treatment sites [10].
1.4

Stereotactic Radiosurgery
Stereotactic radiosurgery (SRS) is a single fraction, high-dose modality used for the

treatment of (multiple) small lesions commonly diagnosed in the brain [11, 12]. SRS was first
introduced by a Swedish neurosurgeon Lars Leksell [13] as early as in 1951. The treatment
planning and delivery require stringent spatial margins to deliver an ablative dose to the PTV
while sparing the adjacent critical structures. The early implementations of SRS, therefore
required a rigid frame affixed to the patient head to achieve stereotaxy (the precise knowledge of
the geometrical path to the tumor). Currently, the demonstrated accuracy of the-image guided
patient setup made frameless SRS competitive with and often preferred to the frame-based
approach [14].
SRS treatments are being delivered by the dedicated machines or using the general
purpose linear accelerators equipped with the stereotactic cones or high spatial resolution MLCs.
The use of the gantry based linear accelerators are getting popularity in the clinics [15-17]. The
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treatment planning with the conventional LINACs may involve multiple isocenters placed inside
individual targets or using a common isocenter placed at the center of the mass of distributed
lesions with both coplanar and non-coplanar arcs. The conventional conformal arcs usually treat
a single or a couple of adjacent targets. For multiple, spatially spread targets, such multiisocenter SRS plans take a long time to deliver as it requires a separate full setup for each
isocenter. These days, single-isocenter multiple-target treatments are gaining in popularity.
These plans are more efficient in terms of the delivery time and have shown clinical outcomes
comparable with the legacy techniques [18, 19].
1.5

Patient Specific Quality Assurance (PSQA)
PSQA, also known as a patient-specific end-to-end test, is the process of verifying the

planned and deliverable dose distribution before its actual delivery to the patient. Although
PSQA is most often thought of

in the context of the dose distribution or monitor unit

verification, the scope of the concept is wider, involving plan quality review at the planning
stage, export from the TPS to the delivery device [20, 21], and finally verification of the delivery
and dose distribution through measurements or independent calculations.
The advanced treatment planning techniques (IMRT/VMAT/SRS) generate complex dose
distributions having concave dips and steep dose gradients around the targets. These may give
rise to uncertainties in planning and delivery of such treatments. In treatment planning, the errors
may arise from the uncertainties of the beam modeling parameters in TPS such as MLC
transmission and tongue-and-groove effect [22], penumbra due to collimator or MLC leaves and
MLC leaf ends [23]. These treatments usually involve many small sized MLC apertures,
therefore the errors in the measurements and subsequent TPS beam modeling of small field
output factors and off-axis profiles also reflect in the dose distribution. The delivery issues may
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involve the errors in gantry angle, position and speed of the MLC leaves, isocenter wobble,
accuracy of the couch motions, and the LINAC beam output [2, 23]. The SRS treatments
involve many small non-standard fields (< 3 cm) requiring special attention to the dosimetry of
such fields for beam calibration and modeling in TPS [24-26]. Lack of attention to these details
could lead to serious radiation incidents [27]. Due to the complexities and uncertainties of these
treatments, the major professional organizations in the field (AAPM, ACR and ASTRO)
recommended to perform PSQA prior to the actual treatment delivery [23, 28-36].
The initial plan check and reviews can spot the issues related to the treatment site,
prescription, beam orientations, optimization and plan export. For this purpose, some plan
quality review methods have been devised and currently implemented in the clinics [21, 37]. For
the verification of dose distribution generated by the TPS, PSQA requires the comparison of the
predicted dose against the dose either measured or calculated independently by software other
than the primary TPS. There is an on-going scientific debate on the merits of one method over
the other. Nevertheless these methods (alone or in combination) are being employed in the
clinical practice [2, 23, 38-40]. They are briefly described in the following sections and a brief
comparison of the error sensitivities of some important dosimetry systems is presented in Table
1.1.
1.5.1

Measurement-Based Methods
The measurement-based methods involve the dose measurements at a point, plane (2D)

or volume defined by the detectors (3D). It is typically not possible to measure the dose inside
the patient, therefore, the approved patient plan is projected onto a dosimetry phantom. The
treatment is then delivered to the phantom and the dose distribution is sampled at a point, plane,
or in (quasi) 3D volume, depending on the type of the detector.
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The point dose is typically measured with a small-volume detector in the homogenous
dose region. The absolute measured dose is compared with the dose predicted by the TPS at the
same point or averaged over the detector active volume. This method was sufficient for the dose
verifications in the forward planned treatments [41] but IMRT/VMAT treatment plans need the
measurements at more than one point due to the complex dose distribution with steep dose
gradients around the targets [2]. The common detectors employed for the point dose
measurements are ion chambers (IC), thermoluminescent dosimeters (TLDs), opticallystimulated dosimeters (OSLDs), and semiconductor diodes. It is recommended that the dose
variation across the detector sensitive volume does not exceed ±5% [23]. To obtain absolute
dose, the detector requires some sort of calibration. It can be absolute, as an ADCL calibration of
an ion chamber. However in the context of PSQA it is often more convenient to cross-calibrate
the detector in the phantom against the TPS calculation in some simple reference field
arrangement, such as a 10 × 10 cm2 parallel-opposed fields pair.
Ion chambers (IC) are often the first choice in clinical practice for point dose
measurements. They are largely isotropic and show a linear response that is largely independent
of energy and dose rate (or can be easily corrected for it). The diodes have an advantage over the
IC in having a very small (practically a point) active volume. However, they are prone to
accumulated radiation damage and show dependence on energy, field size, total dose, dose rate
and beam direction. Thus accurate diode dosimetry requires a series of correction factors [2].
The planar dose measurements are performed using 2D dosimeters such as film or
detector arrays. Film dosimeters have unsurpassed spatial resolution, superior to the vast
majority of electronic arrays. However, quality film dosimetry is a laborious process, hardly
suitable for PSQA in a busy modern clinic. Two types of film have been traditionally used.
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Silver halide based radiographic film have become largely obsolete in general, and in radiation
therapy in particular. They are not tissue equivalent, require wet chemical processing and show
energy dependence due to the high-Z materials in the emulsion. On the other hand, radiochromic
film is nearly tissue equivalent (Z ~ 6.7) and has minimal energy and dose rate dependence [42].
However, to obtain reliable results, they require frequent recalibrations and meticulous, laborintensive handling, including individual background scanning and preservation of the film
orientation throughout the scanning cycle. In addition to being inherently off-line dosimeters, the
recommended time-lag between irradiation and readout makes them even less efficient. Thus
film is mostly used for special measurements and research purposes, particularly when high
spatial resolution is the dominant consideration. A more practical alternative to film are 2D
detector arrays which use small detectors (diodes or ICs) arranged in a single active plane.
Initially the detector arrays were developed for individual en face irradiations from the static
IMRT beams [43-45]. Later on, for true composite measurements (at planned gantry angles) of
IMRT or VMAT plans, the 2D arrays were used with specially designed phantoms [46-50].
Usually quasi-3D detector arrays include the detectors arranged within the cylindrical
phantom volume. Two widely used examples are the ArcCHECK (a helical diode array) and the
Delta4 (bi-planar diode arrays). Both of these arrays were used in this study and their detailed
descriptions are given in (section 2.1). These arrays are used for true composite measurements
and are suitable for both static IMRT and VMAT treatments. The dose sampling is more
comprehensive than with a single-plane array, allowing for a better dose distribution comparison
with the predicted dose. In addition, with a single-plane detector a 2D energy fluence distribution
inherently degenerates to 1D when the beam incidence direction is parallel to the active plane.
Like with most diode detectors, the response of 2D and 3D diode detector arrays depends on
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energy, inherent individual diode sensitivity, beam incidence angle, field size, dose, dose rate
and temperature, requiring rigorous and delicate calibration and proper commissioning prior to
clinical use.
The major drawback of direct array measurements is that they are performed in
effectively homogeneous phantoms and thus cannot take into account the real patient
heterogeneous anatomy. One solution is to reconstruct the volumetric dose on a homogenous
phantom based on the measurements (so called measurement-guided dose reconstruction, or
MGDR [51, 52]) and then perturb the TPS dose on the patient dataset based on the ratios of the
TPS and MGDR reconstructed dose on the phantom.
A second concern with direct measurements is that some gantry-couch angle
combinations are off-limits, whether because of the challenges in physical positioning,
limitations on directional corrections, or direct irradiation of the array electronics.
1.5.2

Calculation-Based Methods
As implied in the title, these methods do not involve any measurements. An independent

algorithm performs a 3D dose calculation on the patient CT dataset based on the DICOM RT
PLAN exported from the TPS. This dose distribution is then compared to the original TPS one.
Such methods have been developed and validated based on the Monte Carlo (MC [53-59] ) and
collapsed-cone convolution-superposition algorithms [60, 61]. These methods test the accuracy
of the TPS dose calculations as well as the fidelity of the plan export procedure (if the plan is
harvested downstream of the TPS), but provide no information about physical delivery.
1.5.3

Hybrid Dose Verification Methods
Considering that both purely measurement- and calculation-based methods have their

advantages and disadvantages, efforts have been put forth to come up with hybrid solutions
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based on the input from the TPS, a dosimeter (typically an EPID), and/or the accelerator itself.
Among the EPID-based methods, some use EPID as a dosimeter [62-67] wherein the images are
calibrated to dose and those planar dose distributions are then used to reconstruct the dose in the
patient. Other EPID-based methods acquire images to harvest the MLC aperture shapes
independent of the planned ones [68-70] to feed in an integrated algorithm together with the
accelerator log files to re-compute the dose on the patient dataset. The non-EPID methods use
just the accelerator log files to determine the control points delivered during a pre-treatment run
and then use this information to generate the volumetric dose on the patient dataset using an
integrated dose calculation engine [71-75].
Table 1.1. A brief comparison of error sensitivities of few patient-specific quality assurance systems.

Error sensitivity
Dosimetry
system

ArcCHECK

Delta4

OCTAVIUS
4D
PerFRACTION

1.6

Description
3D, helical array of
1386 cubic n-type
diodes with size 0.8
×0.8×0.03 mm3
3D, biplanar array of
cylindrical 1069 p-type
diodes with 1 mm dia.,
and 0.05 mm height
Planar array of 729
parallel plane cubic ICs
(5 × 5 × 5 mm3) in
octagonal phantom
EPID based (semiempirical)

Method

Gantry Collimator
angle
angle

Set up

MLC
leaf
position

True
composite

0.5°

1°

< 2mm/0.5°

0.5 mm

True
composite

3°

---

<2 mm/1°

0.5 mm

True
composite

2°

2°

0.5°

0.5 mm

Hybrid

---

0.5°

0.2 mm

0.4 mm

Dissertation Overview and Organization
This dissertation describes the validation of advanced techniques for treatment planning

and verification in megavoltage radiotherapy. Majority of this work deals with the rigorous
validation of dose verification methods in clinical settings. The selected PSQA systems include
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at least one from each method, based on measurements, independent calculations or hybrid
techniques. One of the projects deals with the validation of a feasibility tool for the prediction of
dose-volume histogram (DVH) in treatment planning. The feasibility tool also helps to determine
the plan quality at the planning phase making it logically consistent with the PSQA philosophy.
The organization of the dissertation is described briefly below.
Chapter 2 describes the general materials and methods applied in the whole study. This
includes the phantoms, detectors and software packages used for dose assessment and analysis,
supporting the clinical validation of the dose verification systems under investigations.
Chapter 3 deals with the validation of a method for a priori estimation of best feasible
DVH for OAR. This method is validated for head and neck VMAT planning. The method uses
(nearly) first principles to estimate the feasibility DVH specific to the patient dataset and
provides the planner with the dose-volume objectives to feed the TPS optimizer. This results in
an efficient treatment plan optimization to achieve realistic goals. The validation includes the
proof of the concept using the geometric VMAT plans on cylindrical homogenous dataset as well
as the clinical head and neck cases.
Chapter 4 describes an independent commercial GPU-based 3D dose calculation method
for PSQA and its validation for open beams on solid water and a set of IMRT and VMAT plans
using four datasets from AAPM Practice Guideline 5a [76]. This method is independent of
measurements and employs a collapsed-cone convolution-superposition algorithm to calculate
the volumetric dose on a patient dataset. The algorithm is referred to as the Calculator.
Chapters 5 & 6 are devoted to the true composite measurement based PSQA methods.
Chapter 5 describes the comprehensive evaluation of the improved helical diode array,
ArcCHECK (Sun Nuclear Corporation [SNC]) along with its measurement-guided dose
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reconstruction software (3DVH). The device was improved with the reduction of the high Z
materials in the diode die and relocating some components deeper inside the phantom. The
dosimetric response of the device was investigated for the dependence on the gantry angle, field
size, dose, dose repetition rate, dose pulse rate, and the out-of-field scatter (under the MLC
leaves). A mechanism was proposed for the out of field scatter corrections for measurementguided dose reconstructions in 3DVH. The clinical applications include the IMRT and VMAT
plans generated on datasets from TG-244 [76] and TG-119 [31] using three energies (6MV,
10MV flattening filter free,10MVFFF, and 15MV).
Chapter 6 describes the investigation of calibration accuracy of a high-resolution planar
diode array for true composite SRS treatment verifications. The dosimetry system comprises a
2D diode array (SRS MapCHECK) inserted in a cylindrical head phantom (StereoPHAN). The
dosimetric response of the calibrated device was investigated for the dependence on gantry and
couch angles, dose rate and filed size down to 5×5mm 2 MLC fields. All measurements were
compared against either IC or a plastic scintillator detector. The effect of the calibration was
studied by comparing the devices’ calibrated and uncalibrated responses. Furthermore, the
clinical application of the dosimetry system was validated in an end-to-end test against
radiochromic films for single-isocenter multiple-target (SIMT) VMAT based SRS treatment
plans.
Chapter 7 deals with the validation of a hybrid volumetric dose verification method for
single-isocenter multiple-target cranial SRS treatments. The dose reconstruction method takes
input from both the TPS and the LINAC. The input from the machine is in the form of EPID
aperture images in a movie format, and accelerator log files, while DICOM RT files (plan, CT,
structures, and reference dose) are imported from the TPS. The information is fed into an
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integrated dose calculation engine to reconstruct dose on the patient dataset. The dosimetric
validation was performed against radiochromic film.
Chapter 8 details the conclusions and the future work.
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2

2.1
2.1.1

METHODS AND MATERIALS

Three Dimensional Diode Arrays
ArcCHECK
ArcCHECK (Sun Nuclear Corporation, Melbourne, FL) is a qausi-four dimensional diode

array consisting of 1386 n-type silicon diodes arranged in a helical fashion. The size of a single
point diode is 0.8 × 0.8 × 0.03 mm3. The spacing between the diodes is 1 cm along the
circumference and length of the array causing a 5 mm shift between entrance and exit diodes. In
this fashion, the exit diode avoids the shadow of the entrance diode. Further, helical arrangement
increases the detector density in the beam-eye-view (BEV) of the radiation field. The detector
array is placed in a doughnut type poly (methyl methacrylate) (PMMA) cylindrical phantom with
outer diameter of 26.6 cm. The diameter of the helical detector array is 10.4 cm and is placed at a
depth of 2.9 cm in the phantom. The inner cavity hole has a diameter of 15.1 cm. The cavity may
be filled with a PMMA plug having movable inserts for absolute dosimetry. Figure 2.1(a) shows
the AC with plug and IC insert. The location of the diode array is also shown in the insert.
The overall length of the device is 44.3 cm out of which 11.9 cm is taken up by the
electronics. The remaining 32.4 cm is the PMMA phantom. The length of the helical array is 21
cm symmetrical to the axis of the helical array. However the scatter conditions may be different
along the length of the array as the inferior part of the array has more material (additional
PMMA plus electronics) adjacent to it than that of the superior part.
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The AC measurements were collected and processed using SNC Patient software v. 6.6.
The dose is updated after each 50 ms for each diode and a virtual inclinometer is used to
determine the gantry angle. The data are saved in the text format as well as in the proprietary
movie format (.acml) for later processing. This software allows the profile or gamma
comparisons between the AC measurements and TPS dose at the detector locations [77, 78].
2.1.2

3DVH
3DVH (Sun Nuclear Corporation, Melbourne, FL) is a software employed to perform

three dimensional measurement-guided dose reconstruction (MGDR) on phantom or patient data
set based on time-resolved AC measurements. The software uses an algorithm called
ArcCHECK plan dose perturbation (ACPDP) previously described and validated by Nelms et al
[51]. The idea is relatively simple: to perturb the TPS predicted dose based on the ratios of the
MGDR reconstructed and TPS dose on AC phantom. Thus a high spatial resolution dose cloud is
generated from relatively low resolution measurements. The software facilitates the gamma as
well as OAR DVH analysis of dose distributions by gamma or DVH comparisons with ROI
statistics [75, 79].
The AC and 3DVH dosimetry system is intended for true composite measurements for
IMRT/VMAT plan verifications. Although this system was previously characterized [51], the
manufacturer has changed the hardware design of the AC, which resulted in substantial changes
to certain dosimetric parameters. Therefore it had to be subjected to a thorough evaluation in this
work prior to the clinical use.
2.1.3

Delta4
Delta4 (ScandiDos AB, Uppsala, Sweden) consists of a cylindrical PMMA phantom 22

cm in diameter and 40 cm length, cut into four pizza-slice shaped sections as shown in Figure
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2.1 (b). The phantom houses two orthogonal planes having three detector boards. Each detector
board is 10 mm thick with 9.5 mm of PMMA and 0.5 mm thick fiberglass printed circuit board
(PCB) with diodes soldered to the copper conductors. One board is continuous through the
phantom and named the “main board” while the other boards form two wings to ease the
assembly. The main board and the “wings” are placed at +50 degrees and -40 degrees from
vertical respectively thus making an “X” profile at cross-section. This arrangement avoids the
tangential beam entrance for gantry angles of 90° and 270°. The boards can be removed for
calibration purposes.
There are 1069 p-type silicone diodes in total. The diodes are accommodated in PMMA
phantom through milling process resulting in small air cavities around the diodes which are
visible in CT images. The diodes are of cylindrical form having diameter and thickness (height)
of 1 mm and 0.05 mm, respectively. The sensitive volume is approximately 0.0393 mm 3. The
PMMA is milled out near diodes. On each board, the diodes are separated by 5 mm in the central
6 × 6 cm2 region and 10 mm for the remainder of 20×20 cm2 active area.
The device receives a trigger signal from the accelerator before each beam pulse. This
strategy synchronizes the device with the delivery and adds a temporal component to the dose
distribution. After the synchronization, electrometers integrate the charge and download the
signal to the software on the control PC. The device zeros the signal after each pulse which
reduces the background noise and improves the signal-to-noise ratio (SNR).
The device is operated through dedicated software which requires the operational
parameters such as ambient temperature and the phantom orientation. The software imports the
plans, composite dose and dose per beam, calculated on the phantom by TPS. The diode
positions in both of the planes and the overlaying calculated dose are displayed in the software
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for the visual inspections. After the measurements are completed, gamma analysis [80] is
performed with the user-selected criteria. Delta4 was extensively characterized previously and it
was found that the device has field size and dose rate dependence [81, 82]. The software applies
the necessary correction factors while processing the data.
In this work Delta4 is used for the measurements of IMRT/VMAT plans to perform
comparisons against the investigated PSQA techniques in multiple studies.

Figure 2.1. (a) ArcCHECK with plug and IC insert. The insert shows the position of the detector array; (b) Delta 4
with the connector and network hub.

2.2

SRS MapCHECK and StereoPHAN
SRS MapCHECK (SMC, Sun Nuclear Corp, Melbourne, FL) consists of 1013 point (0.48

× 0.48 mm2 cross-section, 0.007 mm3 active volume) diode detectors arranged on two 7.7× 7.7
cm2 printed circuit boards (PCBs). The PCBs are aligned face to face in such a way that the
active volumes (p-n junction) of all diodes are in the same plane. The detectors on the main
board are facing up in the normal horizontal position. The spacing between two detectors on each
board is 3.5 mm. However, the daughter board is shifted 1.75 mm relative the main board in both
x- and y-axes, resulting in an overall inter-detector spacing of 2.47 mm. The buildup and
backscatter to the detectors are provided by 2.2 cm thick Poly methyl methacrylate (PMMA)
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plates. The device can accommodate the maximum repetition rate of 3400 MU/min, which
exceeds typical values for the FFF 6 or 10 MV radiosurgical beams.
StereoPHAN (Sun Nuclear) is specifically designed to accommodate the SMC for the
end-to-end dosimetric testing of the SRS treatment plans. It is a cylindrical PMMA phantom
with a hemisphere on its superior end to mimic the head. The diameter of both cylindrical and
hemispherical parts is 15.24 cm and the total phantom length is 20.87 cm. The phantom has an
inner cavity with dimensions of 17.5 × 8.5 ×8.5 cm3. With appropriate spacers, the cavity
accommodates the SMC as well as other imaging and dosimetric inserts, including those for ion
chambers, radiochromic film, and special detectors (scintillator). Specifically, the film insert
accommodates a square 7.5 × 7.5 cm2 piece of film. There are five embedded titanium fiducials
to assist in aligning the phantom with onboard imaging and subsequent spatial registration of the
film dose distribution. The physical depth of the SMC detector active volumes, ion chamber
center, and film plane inside the StereoPHAN is 7.62 cm. The distance from the superior
spherical end of the phantom to the SMC central detector is the same. When aligned at the
accelerator isocenter, the assembly (SMC inserted in the StereoPHAN) provides a means of true
composite measurements with gantry and couch rotations. For the non-coplanar beams, the
system supports the couch angles up to ± 45°. This limitation stems primarily from the need to
avoid direct irradiation of the array’s electronic by the primary beam.
The dosimetry system is shown in Figure 2.2 and is subjected to comprehensive rigorous
clinical evaluation in this work.
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Figure 2.2. Assembly for the SRS true composite measurements (a); SRS MapCHECK (b); SMC diode array sizing
7.7 × 7.7 cm2.

2.3

Point Dose Measurements
The majority of this work is focused on the validation of dose verification methods. The

dosimetric validation requires comparison of the dose from investigated system with the dose
measured with standard, well-characterized dosimeters such as ion chambers or plastic
scintillation detectors [83]. The detectors used were 0.125 cm 3 Semiflex Model TN31010 ion
chamber (PTW, Freiburg, Germany), 0.06 cm3, Exradin A1SL ion chamber, and W1 plastic
scintillator detector (Standard Imaging, Inc.). Those detectors were used for:
1. Studying the device response dependence on gantry angle, dose, dose rate, field size
and out-of-field scatter.
2. The absolute point dosimetry for the IMRT/VMAT plans in high-dose, low-gradient
regions, using 20 × 20 × 20 cm3 Plastic Water Cube phantom (CIRS Inc., Norfolk,
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VA) for all plans or Thorax Phantom (modified Model 002LFC; CIRS Inc.) for lung
plans only. IMRT/VMAT point dosimetry was performed with ion chambers only. In
every session, the chamber was cross-calibrated in a 10×10 cm2 field against the
expected TPS dose prior to the measurements. The chamber volume was drawn as a
region of interest and the corresponding mean dose for every plan or test field was
used for comparisons. The confidence limit (CL) of the average difference between
the measured and predicted dose was expressed as mean dose ±1.96 times of standard
deviation (D±1.96σ) [31].
2.4

Radiochromic Film Dosimetry
In this work, EBT-eXtended Dose Gafchromic film (EBT-XD, Ashland Inc.,

Bridgewater, NJ) were used for planar dosimetry of SRS treatments. The films came in a sheet
size of 8 × 10 in2 (Lot # 1206160). The EBT-XD film has an optimum dose range of 40 – 4000
cGy, well suited for SRS dose verification. It was also shown that the film has no significant
dependence on energy, dose rate or scanning orientation and has reduced lateral artifact [84-86].
2.4.1

Film Handling and Preparation
The films were handled following a meticulous protocol recommended in the literature

[42, 87]. Gloves were used to avoid moisture and fingerprints, and the films were secured in the
light-tight paper pockets to avoid unnecessary exposure to the environment. The films were
stored well below the temperature limit. Each film was scanned in a marked orientation prior to
irradiation for the background correction.
2.4.2

Film Calibration
The dose calibration curve was obtained in a solid water slab phantom (30 × 30 × 21.5

cm3) using a 6 MV beam. Small film pieces measuring 1.25 × 2 in 2 were placed at the depth of
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maximum dose (1.5 cm). The phantom was set with 100 cm SSD and 10 × 10 cm 2 field defined
on its surface. Backscatter was provided by 20 cm thick slabs. The films were irradiated with
sixteen dose levels ranging from 2 to 40 Gy. The films were labeled with the dose level and
irradiation time.
2.4.3

Film Scanning and Processing
All films (calibration and plans) were scanned 24 hours post-irradiation using a 48 bit

color flatbed document scanner (Epson, Expression 11000XL Epson Seiko Corporation, Nagano,
Japan), in transmission mode and without color correction. Resolution was set at 72 dpi (0.035
cm/pixel). The initial orientation of the films was maintained during pre- and post-exposure
scanning. Red channel dosimetry was performed using RIT v. 6.6 software (Radiologic Imaging
Technology, Inc., Colorado Springs CO). The 48 bit TIFF images were imported into RIT and
background correction was applied using built-in routine.
For the calibration films, a 1 × 1 cm2 region of interest was chosen to sample the optical
density. The calibration curve was generated and saved in RIT.
For the SRS plans, the registration of the films was performed using a pre-defined
geometric template based on the film fiducials. The films were calibrated and the film dose was
further scaled to the match the ion chamber dose at the isocenter.
2.5

Gamma Analysis
Gamma analysis is a tool used to compare the measured and calculated dose distributions.

The method was first proposed by Low et al [80, 88] . The measured and TPS predicted dose
distributions are termed as “evaluated” and “reference”, respectively. The method includes the
user defined criteria on percent dose difference (%∆D) and distance-to-agreement (DTA). DTA
is defined as “the distance between the measurement and closest calculated points having the
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same dose level” The method combines the percent dose difference and DTA in the following
fashion:

𝛤(𝒓 , 𝒓 ) =

(𝒓 ,𝒓 )
∆

−

(𝒓 ,𝒓 )
∆

2.1

Where 𝛤(𝒓 , 𝒓 ) is the gamma calculated for the measured (re) and calculated (rr) points.
The parameters 𝑟(𝒓 , 𝒓 ) and δ(𝒓 , 𝒓 ) are the distance and dose difference between the two
selected points as defined in equations 2.2 & 2.3.
𝑟(𝒓 , 𝒓 ) = |𝑟 − 𝑟 |

2.2

𝛿(𝒓 , 𝒓 ) = 𝐷 (𝑟 ) − 𝐷 (𝑟 )

2.3

Δd and ΔD are the user defined criteria for the DTA and dose difference respectively.
The dose-difference criteria may be defined at the local and global levels. The local
normalization expresses percent ΔD normalized at the local measurement point, whereas the
global normalization uses the single (typically maximum) dose level as the denominator. After
𝛤(𝒓 , 𝒓 ) is calculated for all evaluated points, the metric of interest, (𝒓 ), is defined as 𝛾(𝒓 ) =
𝑚𝑖𝑛[𝛤(𝒓 , 𝒓 )], ∀ 𝒓 . The evaluated point passes the test if 𝛾(𝒓 ) ≤ 1. For meaningful
interpretation of the results, at least one dose distribution (typically reference) must have high
spatial resolution. Many modifications and refinements of the original algorithm have been
proposed in the literature to improve the accuracy and speed of the 𝛾 calculations. In this study,
algorithms implemented in the software associated with the measurement device were used, as
appropriate. For film dosimetry, digital gamma analysis implemented in RIT, based on the study
by Depuydt et al.,[89] was used.
This study includes gamma analyses performed with both local and global
normalizations. The gamma criteria are represented as γ(%ΔD/Δd) where the dose criteria may be
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locally (L) or globally (G) normalized. The following metrics were used in this study: 2%/2mm,
3%/2mm (both local and global) for all IMRT/VMAT plans except SRS treatments. For SRS
dose verifications, 3%/1mm and 2%/2mm with global normalization were used. The dose
threshold of 10% of the maximum was set, with points falling below that threshold excluded
from analysis.
2.6

Treatment Planning and Delivery
The treatment planning system used in this study was Pinnacle (v. 14-16, Philips

Radiation Oncology Systems, Fitchburg, WI). The dose calculations were done using adaptive
convolve algorithm. It is a version of collapsed cone convolution dose calculation engine that
adaptively varies the resolution of the dose grid depending on the curvature of TERMA and dose
distribution, to improve computational speed [61]. The phantoms and devices were scanned on a
16-slice Big Bore scanner (Philips Medical, Cleveland, OH) using the standard clinical
protocols. The datasets were then transferred to the TPS for the placement of isocenter and
subsequent treatment planning and optimization.
All of the measurements were performed with megavoltage (MV) beams from TrueBeam
v 2.0-2.5 linear accelerators (Varian Medical Systems, Palo Alto, CA) equipped with a standard
or high definition (HD) 120 – leaf Millennium multileaf collimator (MLCs).
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3

A METHOD FOR A PRIORI ESTIMATION OF BEST FEASIBLE DVH
FOR ORGANS AT RISK: VALIDATION FOR HEAD AND NECK
VMAT PLANNING1

3.1

Introduction
Radiotherapy treatment plan optimization is an iterative and time consuming task [90]. A

lot of dosimetrist’s time is spent in trial and error efforts to produce an optimal plan. Recently a
controlled inter-institutional study resulted in a noticeable variability in the treatment plan
quality attributed to the inter-planner skills [91]. All other sources of uncertainties such as
structure segmentation, optimization goals and plan quality scoring algorithm were kept constant
throughout the cohort. Therefore, this variability could not be assigned to obvious technical
factors such as delivery modality and specific TPS employed.
Current research efforts are being focused on treatment plan optimization process to
efficiently generate good quality plans in busy clinics. One logical and important approach is to
improve the training of professional planners and incorporate objective metrics by which to
benchmark performance and guide continual improvement. Another approach is to strive towards

1

This chapter is partially reproduced from work published in a peer reviewed journal. The author of this dissertation
is the first author of the published work. See Appendix B for the permissions.
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more effective, computer-aided automation. Plan automation is a popular topic today with
several commercial strategies already available, such as (1) explicitly mimicking the steps taken
by experienced users (AutoPlanning, AP) [37, 92] , (2) using the database of previous good
quality similar plans (knowledge-based planning, KBP) [93-95], and (3) developing plans based
on multi-criteria optimization (MCO) [96-98].
It could be argued that any automation strategy might benefit if the system had a priori
expectations of the ideal achievable results based on each patient’s unique anatomy. Such
knowledge could be used in two main ways: (1) during optimization, to provide superior inputs
(as compared to standard tolerances used across all patients) that might allow the automated
planning to exceed standard goals while avoiding chasing impossible ones, and (2) after
optimization, to help gauge plan quality by comparing achieved results to theoretical but patientspecific limits. The current commercial AP method does not generate patient-specific
optimization goals. It mimics the human actions to intervene the optimization process. In
published MCO approaches, some offer exploration of the de novo generated Pareto surfaces
[99] while others are used to generate a constraint list that performs well as a class solution for
patients with the same tumor type [96]. As for KBP, the common approach among different
methods is to build a database derived from previously-designed good quality plans for generally
similar disease site, and from them predict the achievable objectives using statistical modeling
for any new patient dataset – a machine learning approach. This method was applied to quality
control [100-102] and, more recently, to the design [93, 94, 103] of the plans. One challenge of
KBP is that it requires careful selection of learning plans. To that end, a priori dosimetric
feasibility data could serve as the basis for additional patient-specific benchmarks,
complementing the more basic pass/fail inspections of population-based objectives. Such tools
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could enhance KBP, by helping to select the high quality plans for the learning database and
providing an additional measure of quality control for the output plans. They could also be useful
in other approaches to treatment planning automation as well as for evaluation of traditional
manual plans.
In this study, a Feasibility DVH (FDVH) tool introduced in the PlanIQ software (Sun
Nuclear Corp., Melbourne, FL) is described. The primary purpose of this tool is to estimate the
patient specific best case sparing (lowest possible) DVH for the OARs, given the full coverage
target volumes by the prescribed doses. It is intended as a guide to help generate challenging
patient-specific dose objectives, not as a “predicted DVH” engine. The secondary purpose is to
assess the plan quality by adjusting the plan scoring metrics, components of a composite Plan
Quality Metric (PQM) formalism described previously [37], to the challenges presented by
patient-specific anatomy.
The goal of this study is to describe the algorithm behind the FDVH as implemented in
PlanIQ v. 2.1.2, and to validate its performance across a series of head and neck (HN) cancer
patients.
3.2

Methods

3.2.1

Feasibility Calculation
The FDVH calculation process is broken into three steps: 1) specify target volumes,

prescription doses, and calculation parameters, 2) build the benchmark dose grid, and 3) generate
the FDVH curves.
3.2.1.1

Target doses and calculation parameters
The first input to the FDVH tool is the patient CT dataset with targets and OARs

delineated. The user is required to select the planning target volumes (PTVs) and their respective
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prescription dose levels. Next, the user is prompted to enter a few calculation parameters, some
of which are beam energy, dose grid spatial resolution, and an option to correct for CT-based
density. If the latter option is declined, a water-equivalent volume is assumed.
3.2.1.2

Benchmark dose grid
The benchmark dose (BD) is a fictitious 3D dose grid ensuring 100% coverage of each of

the target volumes with its respective prescription dose. Next, the algorithm estimates the
minimal dose to the voxels outside the targets. The BD is unachievable by design, and is
ultimately used as the basis for the feasibility estimates. The calculation of the BD is a multiphased process, described below and presented in Figure 3.1.
In all equations, the coordinate system is the right-handed IEC couch coordinate system,
with Y increasing into the gantry and Z upward normal to the couch surface.
The algorithm, for each target in the specified layer overlap order, simply paints the
PTVs with the prescribed dose. During this process, target “edge voxels” are also tagged and
stored for the later use. If the OAR overlaps the target then the target “owns” the common voxels
and that will be reflected in the OAR DVH. The output is a simple target coverage grid:

𝐷

[𝑥, 𝑦, 𝑧] =

𝐷[𝑥, 𝑦, 𝑧]

,

,
0,

𝑓𝑜𝑟 𝑣𝑜𝑥𝑒𝑙𝑠 𝑖𝑛𝑠𝑖𝑑𝑒 𝑡𝑎𝑟𝑔𝑒𝑡(𝑠)
𝑓𝑜𝑟 𝑣𝑜𝑥𝑒𝑙𝑠 𝑜𝑢𝑡𝑠𝑖𝑑𝑒 𝑡𝑎𝑟𝑔𝑒𝑡(𝑠)

3. 1

Next, the algorithm starts assigning dose to non-target voxels. The first step uses energyspecific 3D high gradient dose spread (HGDS) function. Critical to this is a library of precalculated, energy-specific high-gradient dose spread functions that cover a range of media
densities relative to water (see examples in Figure 3.1 B,D,F). The inputs to the HGDS function
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are nominal photon energy along with the physical and radiological distances from nearest target
voxel. The HGDS is best conceptualized as capturing the general penumbra effects at a beam
edge, tangential to the target surface. The HGDS function is really a series of multi-dimensional
lookup tables built into the software, generated using a set of observed, reliable dose
distributions. Specifically, a representative library of measurement-guided dose reconstruction
(MGDR) [51] dose grids were built for a number of static beams conforming to small- to
medium-sized targets over a range of depths in water-equivalent media, and for a variety of
LINAC models and nominal energies. In other words, building a library of observed penumbra
gradients was done by extracting data from a strategic set of single-beam dose grids per energy.
These source grids needed to have high spatial resolution, because the lookup tables used for
HGDS have resolution of 1 mm within 20 mm from the target. To achieve best possible
accuracy, we used measurement-based (MGDR) rather than just TPS-calculated dose. From this
library of 3D source dose grids, the dose falloff just outside a covered target surface were
extracted by drawing dose profile lines perpendicular to the beam direction, saving the dose vs.
distance data, and normalizing them to target dose. This was repeated in low (0.25) and high
(2.0) density media relative to water to cover a range of ratios of radiological-to-physical
distances. The practical HGDS function is thus a collection of multi-dimensional numerical
lookup tables rather than a formulaic algorithm. To ensure 100% coverage of each target volume
even under the condition of interpolated dose near the target surface, the HGDS return value is
set to 1.0 for any distance up to half a voxel away from the target surface in all dimensions,
which effectively extends the prescription dose out to a thin rind. This is a conservative
approach, erring on the side of coverage for abutting or overlapping OARs. For each non-target
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voxel, the output is dose assignment equal to the maximum spread value searched over all
neighboring target voxels (𝐷
𝐷

[𝑥, 𝑦, 𝑧] = 𝑚𝑎𝑥

[𝑥, 𝑦, 𝑧]):

,

𝐷

,

[𝑥 , 𝑦 , 𝑧 ] 𝐻𝐺𝐷𝑆[𝐸, 𝑟, 𝑟

]

3. 2

where r and rrad are the physical and radiological distances, respectively, from the non-target
point [x,y,z] to each searched target point [𝑥′, 𝑦′, 𝑧′], and E is the nominal beam energy. The
HGDS is not a convolution, it can only add dose to surrounding voxels but not remove or blur
dose inside the assigned target volumes.
With the best-possible high-gradient portion of the dose spread now determined, the next
step is to account for additional dose outside the targets that will occur due to a combination of
factors, including dose attenuation along beams’ axes, i.e. the percent-depth-dose (PDD) effect,
and also low dose outside the steep portion of the penumbra due to scatter out-of-field. This lowdose spread (LDS) calculations are highly influenced by the target size (compare Figure 3.1 B
and D). Since the total amount of energy needed to raise the target to a certain dose is
proportional to its volume (~r2 for a cylinder) and the area available for fluence delivery is only
the surface (~r), more energy has to cross each surface element along the beamlets’ axes for a
larger target, increasing the dose spread outside the target along the beamlet direction; hence the
“PDD effect”.
Two LDS dose operations are followed in sequence. The first covers “mid-range”
distances away from targets (𝐷

,

) and the second covers “far-range” (𝐷

,

). For 6 MV

x-rays, mid-range has influence up to about 5 cm and far-range up to about 10 cm away from the
target surfaces. Each operation starts with a 2D convolution in axial planes of a signal function
with energy-dependent 2D kernels. This strategy works well for beam setups that are expected to
be nearly coplanar and allows dose gradients at the most superior and inferior edges of targets to
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remain steep, i.e. not influenced by beam PDD effects. The 2D LDS kernels are radially
symmetric and were derived by fitting the dose spread curves to experimentally achieved ones
over a suite of test datasets optimized for VMAT or for IMRT with 7 to 9 coplanar beams. These
kernels are pre-programmed, just like the HGDS lookup tables, and are not at this time exposed
to the user to edit. The convolution signal function for 𝐷
signal function for 𝐷

operation is 𝐷

,

,

operation is 𝐷

, and the

. The final operation reduces dose in very low

,

density regions so that it tapers to zero in air
𝐷

,

𝐷

,

[𝑦][𝑥, 𝑧] = 𝐶𝐹[𝜌

(𝑥, 𝑦, 𝑧)]

𝐷

[𝑦][𝑥, 𝑧] = 𝐶𝐹[𝜌

(𝑥, 𝑦, 𝑧)]

𝐷

𝜌
𝐶𝐹[𝜌

(𝑥, 𝑦, 𝑧)] =

𝜌

,

[𝑦][𝑖, 𝑘] 𝐿𝐷𝑆

[𝑦][𝑖, 𝑘] 𝐿𝐷𝑆

[𝑥 − 𝑖, 𝑧 − 𝑘]

[𝑥 − 𝑖, 𝑧 − 𝑘]

, for relative density < 0.05

3. 3

3. 4

3. 5

1.0, everywhere else

LDSMid[x,z] and LDSFar[x,z] are the aforementioned energy-dependent, radially
symmetric kernels, i.e. LDS[r].
After the parameterization of LDSMid[x,z] and LDSFar[x,z], the final benchmark dose
(𝐵𝐷

) is the maximum value at each point [x,y,z] from the three input grids (Figure 3.1 B,D

and F). Simply put, there are now three equally sized and spaced 3D dose grids capturing
different traits of potential dose-at-distance from target, and the benchmark dose at each voxel
[x,y,z] is assigned the highest value at that location from each grid:
𝐵𝐷

[𝑥, 𝑦, 𝑧] = max [𝐷

[𝑥, 𝑦, 𝑧], 𝐷

,

[𝑦][𝑥, 𝑧], 𝐷
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,

[𝑦][𝑥, 𝑧]]

3. 6

Figure 3.1. Summary of the FDVH process. (a), (c), (e): Benchmark dose (BD) distribution resulting from assigning
uniform doses to the targets (2-cm cylinder, 10-cm cylinder, and realistic HN, respectively). (b), (d), (f):
Corresponding BD profiles (along the arrows) from the border of the target showing high-gradient dose spread
(HGDS) and low-dose (LDS) components separately as solid lines, and the final combination as circles.

3.2.2

Feasibility DVH (FDVH)
FDVH can be calculated for any OAR, and is intended for OARs only, as target coverage

is implied. The first step is simply to compute the OAR’s DVH based on the benchmark dose
grid. This FDVH is assigned feasibility (f) level of zero (FDVH(0)). The f value ranges from zero
(lower bound of achievable under best circumstances, referred to from here on as
“unachievable”) to 1.0 (easily achievable). With FDVH(0) known for an OAR, an arbitrary DVH
coordinate defined by a specific dose (D) and cumulative percent volume (V) can be assessed for
feasibility, using:
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𝐹[(𝐷, 𝑉)] =

0,
𝑓𝑜𝑟 (𝐷, 𝑉)𝑖𝑛𝑠𝑖𝑑𝑒 𝑡ℎ𝑒 𝐹𝐷𝑉𝐻(0)𝑐𝑢𝑟𝑣𝑒
],
𝐶𝐿𝐼[(𝐷, 𝑉), 𝐹𝐷𝑉𝐻(0)] 𝐶2𝐹[(𝐷, 𝑉), 𝐷
𝑒𝑙𝑠𝑒𝑤ℎ𝑒𝑟𝑒

3. 7

where
𝐶𝐿𝐼[(𝐷, 𝑉), 𝐹𝐷𝑉𝐻(0)] = 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑓𝑟𝑜𝑚 𝑝𝑜𝑖𝑛𝑡 (𝐷, 𝑉) 𝑡𝑜 𝐹𝐷𝑉𝐻(0) 𝑐𝑢𝑟𝑣𝑒

3. 8

and

𝐶2𝐹[(𝐷, 𝑉), 𝐷𝑀𝑎𝑥] = max 𝐶2𝐹

, 𝐶2𝐹

,

𝐷

𝐷

, 𝐶2𝐹

,

𝑉

100

3. 9

𝐶𝐿𝐼 is the “closeness index” equal to the distance of the (D,V) coordinate from the
FDVH(0) curve; the distance is unitless with V normalized to the OAR volume and D
normalized to the highest target dose (Dmax). C2F is a “closeness-to-feasibility” function that
converts the closeness index to an 𝐹[(𝐷, 𝑉)] value. The C2F has a minimum (C2Fmin), but can
increase up to value C2Fmax,Dose as D approaches the maximum target dose or to C2Fmax,Vol as V
approaches 100%, respectively.
Using this function, coordinates for an FDVH curve for any specific feasibility value f,
i.e. FDVH(f), can be calculated. First, an array of volumes [Vj: 0 to 100%] of sufficient resolution
is defined. For each sampled volume (Vj), increasing dose values (Di) are sampled, starting at
intersection of Vj and the FDVH(0) curve. When F[(Di,Vj),] returns a value ≥ f, the point (Di,Vj)
is added as a coordinate on the curve FDVH(f) and the process repeats for the next volume point,
Vj+1.
Several FDVH achievability zones are defined and separated by discrete FDVH(f) curves.
Area below the curve FDVH(0) is labeled unachievable in the case of full target coverage. The
region between f=0 and f=0.1 curves is qualitatively called “difficult” (but achievable). The
FDVH(0) and FDVH(0.1) were previously examined in terms of predictive power across a
population of OAR metrics for the highest-quality plans from multi-institutional plan studies for
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the four different disease sites: abdomen, head and neck, lung, and prostate [104]. A statistical
approach was used where the feasibility estimates (i.e. predicted achievability for each
metric/objective) were compared to empirical observations from the highest quality plans pulled
from the library of plans submitted by a large, international group of professional dosimetrists
and physicists. Examining the highest scoring plans was critical, as those were the ones that
achieved both excellent coverage of targets and sparing of critical organs. Quantified in this
study were the following: Positive Predictive Value (PPV) equal to the ratio: (No. of True
Positives)/(No. of True Positives + No. of False Positives), Negative Predictive Value (NPV)
equal to the ratio: (No. of True Negatives)/(No. of True Negatives + No. of False Negatives), and
Accuracy equal to the ratio: (No. of True Positives + No. of True Negatives)/(No. of Total
Results). For each of these three metrics, the ideal value is 1.000. In the current context, True
Positive means that plan does not achieve an OAR DVH below FDVH prediction, and the other
three scenarios are easily derived from that The results from these studies for PPV, NPV, and
Accuracy were 1.000, 0.88 and 0.89, respectively, for FDVH(0) and 0.81, 0.95, and 0.92 for
FDVH(0.1). Given this strong performance, this study is focused on examining the behavior of
FDVH(f) with f -values from 0 to 0.1.
3.2.3
3.2.3.1

Validation Strategy
Geometrical test cases
First, a collection of model geometries were examined as they are helpful for both

illustrating the concepts and testing the basics of the FDVH algorithm. All targets and OARs
were cylinders of equal length (5 cm) but varying diameters (2 - 10 cm). The centers of the
targets were placed at the center of a water-equivalent 22 cm diameter cylindrical phantom with
the OARs arranged as shown in Figure 3.2. In the axial view, sets A,B,D, and E represent large
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(10 cm diameter) and small (2 cm) targets either adjacent to, or 1 cm away from a 3 cm diameter
OAR. Set C consist of a 10 cm diameter target with a 2.3 cm diameter doughnut hole containing
a concentric 2 cm diameter OAR.

Figure 3.2. Geometrical test structures set. All dimensions are in mm. (a), (b): A large (100 mm diameter)
cylindrical target with a 20-mm OAR. (d), (e): A small (20 mm) target with the same OAR. (c): A doughnut target
with an OAR in the middle. The surrounding 22-cm diameter phantom is not shown.

VMAT plans were generated for comparison to FDVH. Plans used 6MV beams from a
TrueBeam linear accelerator with a 120-leaf Millennium MLC (Varian Medical Systems, Palo
Alto, CA) using the collapsed cone convolution (CCC) algorithm in Pinnacle TPS (v. 9.8, Philips
Radiation Oncology Systems, Fitchburg, WI). A single full arc was used for each plan with
gantry angle spacing of 2˚and isotropic 2 mm calculation voxel size. For this and subsequent
tests it is important to underscore the challenge of creating a target coverage in the TPS that
approximates the ideal uniform dose assigned to the targets in PlanIQ. For the OAR, the goal
was to drive the maximum and mean (equivalent uniform dose, or EUD, in planning) doses as
low as possible. It is impossible to have a truly homogeneous target dose in the real plan. The
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main objective for the target was to achieve the near-perfect conformity of the prescription dose
to the portion of its border facing the OAR, while maintaining visually acceptable prescription
isodose conformality elsewhere. Dose homogeneity within the PTV was maintained within
±10%. This 10% number is clearly higher than is normally clinically desirable, but it was chosen
to minimize the OAR dose, since we were looking for the lowest achievable values, and the
target dose homogeneity and OAR sparing exhibit exponential trade-off [105].
To demonstrate the effect of the realistic delivery constraints, we approximated idealized
dose distributions. To that end, for the same geometrical test cases, optimization was run in
Pinnacle for 100 iterations without the Convolution/Superposition dose calculation step. This
resulted in idealized optimized dose clouds calculated with a Pencil Beam algorithm with no
regard to physical delivery constraints [106]. While full DICOM dose export is disabled in the
TPS in this configuration, the DVHs could be extracted via a custom script and qualitatively
compared to the full planning and FDVHs.
3.2.3.2

Clinical head and neck test cases
In the next step, for validation of FDVH predictions on realistic datasets, ten previously

described advanced HN cases were used [37]. Each patient had two targets: a primary PTV
treated to 70 Gy in 35 fractions and an elective bilateral neck clinical target volume (CTV)
simultaneously irradiated to 56 Gy. The OARs selected for this study were each parotid, larynx,
and inferior pharyngeal constrictor (IPC). In two patients the entire larynx was a part of the
target and therefore was excluded from analysis. The same planning strategy was used for the
target coverage and OAR sparing as that of geometrical cases but with two arcs. One OAR at-atime was considered in each plan, thus avoiding competition with others and ensuring the best
possible sparing.
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Two metrics were used to compare the planned and FDVHs: 1) the difference in mean
doses, ΔDmean, and 2) the Dice similarity coefficient (DSC) as defined below.

𝐷𝐶𝑆 = 2

𝐴∩𝐵
A+B

3. 10

where A and B are areas under the planned and FDVH curves, respectively, and A∩B is
the intersection of those areas. The DSC quantitates the similarity between the shapes of the
DVHs and can take values from 0.0 (no overlap between the curves) to 1.0 (identical curves).
The f -level for comparison FDVHs (sampled at 0.01 intervals) was chosen so that the
lower boundary of the 95% confidence interval of the average of the mean planned doses to all
OARs across 10 patients was just above the corresponding average for FDVHs. The DSCs were
then computed for that baseline feasibility level. The data were analyzed for all OARs in
aggregate and for each organ type separately.
To illustrate how the presence of competing objectives changes the achieved DVHs in
relation to the single-OAR FDVHs, the mean doses and DSCs for the same organs as before
were calculated for the previously described Pinnacle auto-planning (AP) test plans [37]. It was
observed that the AP software tends to achieve the lower OAR doses compared to the
corresponding human-driven plans [37, 92] as it attempts to drive the OAR dose lower than
specified by the user, if possible. Thus the AP plans were chosen for comparison. The realistic
plans reflected all optimization objectives routinely employed in our clinic, which are more
stringent than similar objectives from RTOG protocols [107]. Some relevant examples are as
follows. The gross tumor volume (GTV) must be entirely covered by the prescription isodose.
PTV single voxel doses must be within ±5% of the prescription, with at least 95% of the PTV
covered by the prescription dose. Parotid mean dose should not exceed 26 Gy. The mean IPC
dose should not exceed 50 Gy, with the volume-dose percentage indices V 40
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Gy

<65%, V50

Gy

<47%, and V60 Gy <11%. Similarly, the mean larynx dose should be <20 Gy to (dysphonia) or at
least below 41 Gy (aspiration), with the volume-dose indices V35 Gy <79%, V45 Gy <45%, V55 Gy
<32%, and V65 Gy <22%. The other structures included in optimization, as appropriate, are brain
stem, spinal cord, submandibular gland, oral cavity and lips, mandible, superior and middle
pharyngeal constrictors, optics and thyroid.
3.2.3.3

Multi-institutional head and neck cases with OAR overlapping targets
The case of an OAR overlapping (or abutting) a target is interesting considering that

feasibility benchmark dose paints targets with 100% of prescription dose while at clinics
coverage goals are often less (e.g., 95%). To study this effect, the top 10% quality plans were
analyzed from an international, multi-institutional plan study recently completed for the head and
neck case from the MPPG 5.a [76] library of standard TPS commissioning cases. The controlled
plan study followed the general methodology previously employed by Nelms e al. [91] and used
cloud-based data collection and real-time scoring system (ProKnow Systems, Sanford, FL,
USA). In this study, the ideal coverage for a large PTV_5600 volume was set at 95%, while the
mean dose to the contralateral right parotid had a minimal requirement of 30 Gy with an ideal
objective of 24 Gy. The total right parotid volume was 28.2 cc, with 3.4 cc (12.2%) inside the
PTV_5600. The OAR DVHs for the top 10% total score plans (N = 23) of the 238 submitted and
analyzed plans were extracted and compared to the FDVH. The top 10% plans encompassed a
range of x-ray treatment techniques (VMAT, IMRT, helical tomotherapy), TPS vendors, and
LINAC models.
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3.3
3.3.1

Results
Geometrical Test Cases
Figure 3.3 and Figure 3.4 illustrate the most important general concepts of the Feasibility

algorithm. Figure 3.3 demonstrates how the conformal target coverage is paramount for the TPS
and FDVH agreement in the low-dose region. The best sparing for the OAR immediately
adjacent to the target [Figure 3.3(B) and Figure 3.3(D)] could be easily achieved by a vertical
parallel-opposed beam pair. Only the high-gradient (penumbra) dose spread would affect the
OAR DVH. However the target coverage would not be conformal. To achieve tight target dose
conformality, some fluence must enter and exit through the adjacent OAR triggering the low
(PDD) dose spread throughout it. In the left panels of Figure 3.3 the dose conformality is not
strictly enforced, and one can see how the dose distribution near the target-OAR interface is
shaped by the relatively high weight assigned to the vertical beamlets, partially mimicking a
parallel-opposed beam arrangement near the target/OAR interface. As a result, the low-dose
portion of the TPS DVH dips in the “unachievable” area. If the low-dose spread in the
benchmark dose calculation is turned off, the FDVH retracts below the achieved one providing
conceptual proof of the calculations by first principles [Figure 3.3(A)]. Conversely, if the target
dose conformality is enforced [Figure 3.3(D)], the achieved OAR DVH shifts to the right,
towards the FDVH calculated in normal manner, with both low-and high-dose spread, reflecting
additional fluence entering and exiting the OAR.
Figure 3.4 demonstrates that by invoking parameterization on the geometrical targets the
feasibility algorithm takes into account the realistic capabilities of the delivery system. For the
same target coverage, the idealized optimized OAR DVHs dip into the “impossible” zone under
FDVHs with f =0. The effect is present on every graph, but is more pronounced for the larger
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targets, and in particular with the doughnut geometry (Figure 3.4 B). This can be easily
explained by the extra central dose in the full CCC calculation due to the MLC transmission.

Figure 3.3. Two VMAT plans for a 10 cm target with immediately adjacent 3 cm OAR with lower (A,B) and higher
(C,D) level of dose conformality to the target. A: Feasibility DVH curves with f=0 (‘’unachievable”) generated with
and without the low dose spread component. C: The FDVHs at f =0 and 0.1 for a more conformal plan. The dotted
lines in panels A and C are TPS DVHs. The lower panels (B,D) depict the axial dose distributions for the two plans.
The “unachievable” area under the FDVH with f =0 is shaded.

Figure 3.4. Comparison of FDVHs with TPS DVHs for realistic VMAT (“Full”) and idealized optimization
(“Ideal”) dose distributions. Panels A-D correspond to Panels B-E in Figure 3.2, which contain the exact
dimensions. Feasibility OAR DVHs for f =0 and 0.1 are presented along with the TPS-generated target and OAR
DVHs for a full CCC algorithm calculations and idealized Pencil Beam dose at the end of optimization. The
“unachievable” area under the FDVH with f =0 is shaded. The target/OAR arrangements from Figure 3.2 are
illustrated.
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3.3.2

Head and Neck Test Cases
Dose-Volume Histogram metrics results for individually optimized OARS in HN plans

are presented in Table 3.1. The feasibility level f with the lower limit of the 95% CI of the
average ΔDmean closest to zero was 0.05. Thus Table 3.1 uses this f=0.05 value for all FDVH(f).
A good agreement between carefully planned achieved DVHs and FDVHs with the f- value
somewhere between 0.0 and 0.1 was expected from the preliminary data [104].
An example of the achieved DVHs for different individually optimized OARs on one of
the datasets, superimposed on FDVHs with f -values from 0.0 to 0.1 is presented in Figure 3.5.
Table 3.1. Descriptive statistics comparing the achieved and FDVHs (f=0.05) for single-organ optimization plans.
Presented are the DSC and mean dose differences, ΔDmean, with 1SD and 95% confidence intervals.

OAR
All
Parotids
Larynx
IPC

N
38
20
8
10

Ave. DSC
0.961±0.018
0.954±0.021
0.963±0.012
0.972±0.010

DSC 95% CI
0.955 – 0.967
0.944 – 0.964
0.953 – 0.973
0.964 – 0.979
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Ave. ΔDmean (%)

ΔDmean 95% CI (%)

1.8 ± 5.8
-0.5±6.4
5.7±3.3
3.0±3.7

-0.1 – 3.6
-3.5 – 2.5
3.0 – 8.5
0.4 – 5.7

Figure 3.5. Example feasibility DVHs with f from 0.0 to 0.1 and the achieved TPS DVHs for individual OARs from
one dataset (#6). The “unachievable” area under the FDVH with f =0 is shaded.

3.3.3

Comparison of Achieved and FDVHs in Realistic Plans
On average, as expected, in the presence of competing priorities the mean dose for every

OAR is higher for clinically realistic plans compared to the single-organ optimization ones. The
results are shown in Table 3.2 in the same fashion as in Table 3.1, as the average DSC values and
a percentage difference in average ΔDmean from the FDVH (0.05). The lower DSC values
comport with the greater differences in the mean doses
Table 3.2. Descriptive statistics comparing the achieved and FDVHs (f =0.05) for clinically realistic AP plans.
Presented are the DSC and mean dose differences, with 1SD and ranges.

OAR
Parotids
Larynx
IPC

Ave. DSC

DSC Range

0.882±0.087
0.809±0.143
0.844±0.090

0.616 – 0.979
0.564 – 0.994
0.668 – 0.944
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Ave. ΔDmean
(%)
22.4±26.7
54.7±47.9
37.4±27.6

ΔDmean Range (%)
-16.0 – 125.5
1.2 – 154.2
11.9 – 98.5

Comparing Table 3.1 and Table 3.2 one can notice much larger ranges and standard
deviations of values in the latter. This is a reflection of the fundamental difference between the
single-OAR optimization plans and clinical ones with multiple competing objectives. The range
of planning results is illustrated in Figure 3.6. Panel A depicts the rather prevalent one when an
OAR cannot be spared as well as in the single-OAR plan without unacceptable sacrifices in other
objective(s). Panel B shows an achieved parotid DVH that was close to the FDVH, indicating
high priority placed on sparing that organ. Finally, as shown in Panel C, occasionally the
achieved OAR DVH dips noticeably below the FDVH. Every case where that happened has been
carefully examined and inevitably it was found that PTV coverage at the interface with the OAR
in question was sacrificed. This violates the major assumption of the Feasibility algorithm,
namely the complete coverage of the target(s) by the prescription dose(s).
As evident from Table 3.2, the realistic parotid DVHs are on average closer to the
corresponding FDVHs than the IPC or larynx ones. This is understandable, as the parotids’ dose
objectives are generally lower and the parotid mean dose being a high clinical priority. With the
IPC and larynx, the low-dose portion of the DVH is of relatively less importance and is not being
pushed down as hard (Figure 3.6 A). We also expect that with the larynx and IPC being central
structures, as opposed to the laterally situated parotids, it is harder for the optimizer to find a
solution where the fluence at least does not exit through the OAR, raising the low-dose portion
of the DVH.
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Figure 3.6. Examples of the changes in achieved DVH between the single-organ optimization plans and clinically
realistic Auto-Plans (AP), in relation to the “impossible” FDVH (f=0). A: IPC #2. B: Lt. Parotid #6. C: Lt. Parotid
#5.

The case of an overlapping OAR in the multi-institutional study where PTV coverage, as
is common, was specified at 95% is shown in Figure 3.7 (A,B). Here, the achieved right parotid
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DVHs for the top 10% quality plans are plotted along with the FDVH. The achieved DVH
curves venture inside the “impossible” FDVH curve in places, and this is because the PTV_5600
coverage goal was allowing 5% (37.2 cc) of the total target volume (744.4 cc) to fall under 56
Gy without penalty. The experience planners concluded that sacrificing some target coverage in
favor of the parotid sparing in this case was rewarded by a higher overall score. A useful
observation can be made that if an achieved DVH falls inside the FDV, it indicates that the target
coverage was likely compromised. As shown in Figure 3.7, when the PTV coverage is enforced
at 100% (Panel C vs. B), the OAR DVH is fairly close to the FDVH (Panel A).

Figure 3.7. Achieved right parotid DVHs for the top 10% quality plans from a controlled plan study, along with the
FDVH and a DVH from a plan with 100% PTV_5600 coverage. B: PTV_5600 coverage by the 56 Gy isodose line
for the best study plan. Note how PTV coverage is sacrificed. C: Isodose coverage corresponding to the dashed
DVH curve, for the plan covering 100% of PTV_5600.
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3.4
3.4.1

Discussion
Study Strengths and Weaknesses
To the best of our knowledge, the approach described here is unique as a whole and has

never been implemented before. However, while the method is different, the results are largely
determined by the same physics principles, and certain elements of the described algorithm by
necessity overlap with the previous body of work on KBP [93-95, 101, 108-113]. In particular,
the geometry of the OAR in relation to the target is the major driver of the achievable OAR
DVH. To that effect, Petit et al [114] used a subset of previous plans with less favorable
PTV/OAR configuration to find the minimum achievable OAR dose for a new patient. Different
mathematical frameworks were proposed to correlate minimum achievable dose to a voxel with
the distance from that voxel to the target surface [108, 115-118], sometimes coupled with the
attempts to identify additional descriptors of the target/OAR geometrical relationship through
principal component analysis [93, 115, 117, 119].
In the entire body of KBP work, partially cited above, the dose/geometry relationship is
always determined from the set of existing treatments plans. This is where our Feasibility
approach fundamentally diverges from KBP. Feasibility is independent of the treatment planning
technique and prior experience - no learning database of similar treatment plans is necessary.
Hence one of the strengths of the method lies in its simplicity and minimal, if any,
commissioning effort. Tailoring the parameters of the method to accommodate a specific
machine type or technique could produce slight improvements in the feasibility analyses, but
would also introduce variation and thus remove the ability to be used as a benchmark against
which to compare achievements of a various TPS or delivery system.
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By the same token this simplicity leads to limitations. Most importantly it approximates
the lowest possible boundary of the OAR DVH, but not necessarily its actual shape in the
presence of competing objectives of multiple OAR sparing, target dose coverage [120, 121] and
homogeneity [105, 122].In particular, Tol et al [105] noted a strong (exponential) tradeoff
between OAR sparing and target dose homogeneity. These tradeoffs are implicitly built in the
KBP learning approach [102], assuming a uniform planning protocol [122]. Such realistic
delivery tradeoff information is not available to the Feasibility algorithm that assumes that the
target is just uniformly painted with the prescription dose. Similarly, the algorithm effectively
deals with one OAR at a time and is agnostic to fluence redistribution necessary to fulfill
multiple competing objectives. This is why the Feasibility algorithm is a much stronger predictor
of the unachievable (lower) DVH boundary than of the likely achievable DVH.
In addition, the Feasibility method is better suited for OARs close to the target. As the
distance between the OAR and the target increases, specific beam arrangements, unknown to the
algorithm, exert more influence on the OAR DVH. This can be understood by comparing for
example the rectum with the femoral head in prostate cancer treatment. While the dose to the
rectum at first approximation is largely independent of the IMRT beam angles, the femoral heads
can be almost completely protected from both entrance and exit fluence, depending on the beam
configuration. Thus the beam-agnostic Feasibility prediction becomes unreliable.
The DVH curves often differ most form the corresponding FDVHs at the point of
transition from the high-to low-gradient portion of the curve (Figure 3.4 C). It can be attributed
to a simplistic mathematical form of piecewise constructing the final dose spread from the highand low-gradient portions (the higher of the two, see Eq. (3.6) and Figure 3.1). In the future a
more sophisticated function could be used to describe the transition region.
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Finally, the method is well-suited for approximating the general shape of the bestpossible OAR DVH; however, because it enforces 100% coverage whereas real-world plans
often sacrifice coverage near OARs, there can be deviations (actual vs. FDVH) in the curves as
they approach the high dose region. This characteristic is easily internalized by the learned
treatment planner, though, and the actual DVH dipping below the FDVH curve becomes a useful
indicator of sacrificed coverage. This phenomenon is illustrated by the multi-institutional plan
study where the top 10% scoring plans had OAR DVHs (for the right parotid, which overlapped
the PTV_5600 target) that dipped inside the FDVH curve because target coverage was driven
only to 95%, leaving 5% of the target to be under-dosed without penalty.
The benchmark dose algorithm is currently designed for coplanar (or nearly-coplanar)
beams, stemming from the cylindrical form of integration (summation) in convolution Eqs. (3.3)
and (3.4). Furthermore, it was honed and deployed for common photon delivery techniques
(coplanar VMAT or IMRT with 7+ beams) and LINAC hardware. One disease site (HN) was
explored here. It has a moderate amount of density heterogeneity and for the purposes of this
study is comparable to most body sites, but dose to (or near) lung volumes should be evaluated
separately.
3.4.2
3.4.2.1

Current and Potential Applications
Plan review
In the PlanIQ software, the user can set up plan quality algorithms that are relevant

dosimetric metrics and corresponding scoring functions for each target and OAR. The output is
a composite plan quality metric (PQM) [37, 91]. If desired, the FDVH can be used in the current
software to normalize any individual metric score based on the best possible sparing for the
specific patient, rather than the generic OAR objective. This way the plan quality score can be
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adjusted for any metric where the standard clinical objective is fundamentally unachievable. This
essentially allows grading on a curve in the cases of difficult patient anatomy. In authors’
experience, occasionally it was demonstrated outright that the OAR dosimetric objectives could
not be achieved without compromising PTV coverage and appropriate clinical adjustments were
made. In addition to straightforward plan evaluation, this method could be useful in the
assessment and commissioning of KBP and other auto-planning methods in the future, by
helping grade existing plans in terms of quality, to determine which ones are candidates to be
added to the knowledge base.
3.4.2.2

Plan optimization
Another possible application is based on the multiple observations that feeding the

optimizer challenging objectives specific to the patient anatomy improves plan quality [95, 102].
Thus, it hypothesized that FDVH data (curves in the range of f=0 to 0.1) derived prior to
optimization would provide patient-specific planning objectives that are challenging yet realitybased. The optimization solution in this case should be automatically Pareto-optimal [123]. That
is, for a given level of target dose coverage and homogeneity, the OAR DVH curves will be
driven as close as possible to, but never below, the corresponding FDVH. Hence no individual
region of interest objective function can be further improved without sacrificing at least one
other. Other groups are currently pursuing this application of the Feasibility algorithm to plan
optimization, with promising preliminary results [124, 125]. This study only endeavors to
describe and validate the method of generating the FDVHs.
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3.5

Conclusions
A novel method (Feasibility DVH, or FDVH) for a priori estimation of the lower

achievable boundary of the OAR DVHs in inverse treatment planning was introduced and
validated on a series of HN VMAT plans. The algorithm does not require a database of prior
plans but rather derives the FDVH from nearly first principles, assuming that the targets are
uniformly covered with the prescription doses. It is easily parameterized based on a short list of
model geometrical datasets. The method is agnostic to the planning technique and beam
arrangement, requiring only the regions of interest, the energy, and, optionally, the CT dataset as
inputs. But this simplicity is also the cause of the algorithm’s limitations. It is designed to
approximate the lowest possible OAR DVH based on that OAR’s geometrical relationship to the
target, but not the likely achievable one for the class of plans in the presence of realistic
competing objectives. The method is best suited for the parallel OARs close to the target and is
currently implemented for (nearly) coplanar beam arrangements. It is useful for plan quality
assessment and can potentially be used to supplement and augment automated planning
techniques.
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4

VALIDATION OF A GPU-BASED 3D DOSE CALCULATOR FOR
MODULATED BEAMS2

4.1

Introduction
This chapter describes a pure calculation-based PSQA method and its clinical validation

for the inverse planned treatments (IMRT/VMAT). After the treatment plan is reviewed with the
physician, one of the next necessary steps is to perform dosimetric PSQA described in section
1.5. Historically, patient specific IMRT QA was performed by projecting the treatment plan on a
phantom containing a dosimeter and comparing the measured sample of the 3D dose distribution
with calculations [2]. As the inversely-planned techniques matured and became the mainstay of
radiotherapy, alternative dose verification techniques started to be actively explored. Those
included electronic portal imaging device (EPID)-based dosimetry [67], calculation-based
reconstruction from the accelerator log files [75, 126], including harvesting aperture shapes (but
not fluence) from the EPID [69], or just a straightforward recalculation by an independent dose
engine [74, 127]. Each method has its advantages and disadvantages, and none is capable of
catching every possible mode of failure [128] including catastrophic events.

2

This chapter is partially reproduced from work published in a peer reviewed journal. The author of this dissertation
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In this study, a fast and independent 3D dose calculator is examined and validated as an
additional tool that potentially could be incorporated in the IMRT/VMAT QA process. This
calculator is the dose engine used in the commercial products (Sun Nuclear Corp., Melbourne,
FL) for purely calculational (DoseCHECK) or empirically-guided (PerFRACTION) dose
reconstruction. For the former, all of the input is from TPS in the DICOM format (RT Plan, CT
dataset) through R&V system. In the latter, the aperture shapes recorded by the EPID during
beam delivery are used to generate the MLC control points. Simultaneously, corresponding
monitor unit and angle progressions are harvested from the accelerator log files for dose
calculation. A common step to both the calculational and the semi-empirical approaches is dose
calculation by a Superposition/Convolution (S/C) technique. Obviously, the accuracy of the dose
calculation engine employed in these products is of paramount importance for their clinical
performance and deserves a thorough investigation.
4.2

Methods

4.2.1
4.2.1.1

Calculator Description
Dose calculation algorithm
The approach was originally developed and described in detail by Jacques et al [129]. It

is a variant of a S/C style dose calculation [130, 131] adapted for fast execution on the graphics
processing unit (GPU) card(s). As with all implementations of S/C methods, the calculation
consists of three steps: fluence calculation, total energy released per unit mass (TERMA)
calculation, and, finally, superposition.
The fluence calculation simulates radiation transport within the LINAC treatment head.
There are separate sources used to model primary, extra focal (scatter), and electron
contamination radiation. The primary and extrafocal sources each have their own spectrum and
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arbitrary radial intensity profile. Jaws and MLC characteristics, including properties such as
MLC tongue-and-groove thickness and MLC leaf end curvature, are accounted for explicitly.
In the next step, fluence is transported through the patient to compute primary energy
released in the volume (TERMA). The material composition of the patient volume is determined
using the CT dataset along with a user-provided CT-to-relative electron density (ED) conversion
table. From relative electron density, other material properties are computed by interpolation
among nine predefined materials, one of which is water. The TERMA calculation uses energydependent (16 bins) mass attenuation coefficients for the appropriate material [131], while
electron density is used to attenuate the primary fluence through the patient along the
heterogeneity-corrected ray-trace path. TERMA is calculated every 2° for VMAT plans.
Finally, the superposition step spreads the TERMA by the energy deposition kernel to
determine the final dose at each point [132]. The kernel is derived from high resolution (1 mm,
1°) Monte Carlo (MC) simulations in the water phantom. A cumulative-cumulative kernel is
used to minimize voxelization effects [130]. The energy deposition kernel scales with electron
density, which differentiates the superposition approach from the traditional convolution [129].
The kernel’s angular dependence is discretized using a collapsed cone approximation [133] and
both kernel tilting and beam hardening are accounted for. The superposition calculation for
VMAT is performed every 5°, which still allows for acceptable accuracy of the overall
calculation [129] . As TERMA calculations are substantially faster than superposition
calculations, using a high TERMA but low superposition angular resolutions increases the speed
of VMAT calculations [129].
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4.2.1.2

Input data
The Calculator comes preconfigured with standard beam models for each machine class.

For example, the energy spectra/beam profiles for the TrueBeam LINAC used in this work
(Varian Medical Systems, Palo Alto, CA) are based on average measurements for 5 machines of
the same class. The same is true for the majority of relative output factors (S cp). However, for
the small fields (≤ 4 cm) the output factors from Kerns et al [134] were used. On the user end, it
is required to supply the local CT number-to-ED conversion table and the absolute output per
monitor unit under the reference conditions. For patient-specific data, a set of DICOM CT and
corresponding DICOM RT Plan and DICOM RT Structure objects are required. The structures
determine the extent of the dose reporting volume. Also, if the density override information is
present in the Structure object, it is used in dose calculations.
4.2.2

Validation
The main goal of this study is independent validation of the algorithm described above.

To cover a reasonably wide range of energies and different beam types, three photon energies
were examined: conventional 6 MV and 15 MV, and 10 MV flattening filter free (10 MVFFF).
The validation was performed in a deliberate fashion, gradually increasing the complexity of the
tests in terms of radiation fields (from basic open beams to IMRT/VMAT), analysis
dimensionality (from point doses to 2D to 3D dose sampling) and dataset heterogeneity (from
homogeneous phantoms to thoracic CTs).The strategy included a number of steps similar to
commissioning of a primary TPS [76] albeit abbreviated:
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1. Dose distributions for simple square fields were compared on the water phantom
between the Calculator and the primary TPS (Pinnacle v. 9.8);
2. Central axis percentage depth doses (PDD) were compared on a lung-simulating
slab phantom between Pinnacle, the Calculator, and Monte Carlo (MC)
simulations;
3. IMRT/VMAT plans generated on the AAPM Practice Guideline 5a [76] datasets
were recalculated on the phantoms. Point doses were measured with an ion
chamber in the phantoms and compared to the doses predicted by the Calculator;
4. The Calculator dose distributions for selected plans on a homogeneous cylindrical
phantom were compared against a biplanar diode array (Delta 4) measurements for
a limited number of points (the diodes’ locations);
5. The 3D Calculator dose on the patients’ CTs was compared to the 3D
measurement-guided dose reconstruction on the same datasets;
6. Finally, all calculated 3D patient dose distributions were compared between the
Calculator and the primary TPS, as would ultimately be done in the clinic.
4.2.2.1

Basic beams on the water phantom
The dose distributions on the synthetic CT phantom of unit density were compared to the

primary TPS for a series of open square fields (5×5, 10×10, and 20×20 cm 2) and a 3×3 cm2
MLC-defined aperture in the middle of a 10×10 cm2 jaw opening. The Pinnacle Collapsed Cone
Convolution [61, 135] beam model in our system generally agrees with water scans for basic
fields to within 1%, and thus the TPS was used as the reference to facilitate easy full 3D dose
comparison. Also, it is useful to compare the basic beam data with Pinnacle, as ultimately the
modulated dose distributions are compared to it as well. The absolute point dose under the TPS
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reference conditions, as generated by the Calculator, was found to be within 0.2% of the
expected (input) dose, thus satisfying the Guideline 5a [76] recommendations. To achieve similar
agreement in Pinnacle, the calculation mode had to be switched to the homogeneous water
phantom. Otherwise, a synthetic CT phantom of unit density is treated in Pinnacle as being
slightly different from water, due to the CT to material assignment method [136]. After proper
reference dose was confirmed, the Pinnacle and Calculator dose grids (2 mm voxel size) were
loaded in 3DVH software v. 3.3 (Sun Nuclear Corp) and compared using gamma analysis using
2% (global normalization) dose-error and 2 mm distance to agreement criteria, with low-dose
cut-off at 10% of the maximum (2%G/2mm/10%).
4.2.2.2

Slab inhomogeneities
The calculator has two modes for handling significant inhomogeneities (e.g. lung),

requiring two separate beam models. The basic S/C approach was described above.
Alternatively, an additional correction known as Heterogeneity-Compensated Superposition
(HCS) [137] can be applied. It relies on the patient density near the material interfaces being
modified (filtered) in a position and direction sensitive manner, allowing the dose to be changed
compared to the standard S/C approach. Application of this correction approximately doubles the
calculation time.
Depth-dose curves were extracted from Pinnacle, standard Calculator, HCS Calculator,
and Monte Carlo (MC) calculations for 2×2, 5×5 and 10×10 cm 2 fields on a wide slab phantom
consisting of 5 cm of water, followed by 5 cm of lung (0.3 g/cm 3), and 20 cm of water. All PDDs
were normalized beyond their respective dmax, at a 2 to 3 cm depth, depending on the beam
energy.
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Monte Carlo calculations were performed with PRIMO, a radiotherapy graphical
interface to PENELOPE code [138]. Manufacturer-provided IAEA-compliant phase space files
for the TrueBeam accelerator [139] were used in lieu of modeling the accelerator head above the
movable jaws. The current version of those files provides a phase space on a horizontal plane 27
cm downstream from the source. The number of histories was sufficient to achieve 1% statistical
uncertainty (two standard deviations) at the dose level above 50% of the maximum in the
phantom. An in-house script was written to convert PRIMO ASCII dose files into DICOM RTcompliant dose objects. The PRIMO simulations were validated against Pinnacle for the 10×10
cm2 fields on the water phantom, at the 2%/2mm level.
4.2.2.3

IMRT/VMAT planning and delivery
All measurements were done on a TrueBeam v 2.0 linear accelerator equipped with a

120-leaf Millennium MLC (Varian Medical Systems).
The IMRT and VMAT plans were developed based on the Guideline 5a Report library of
test plans [76]. They included four realistic plans from the available downloadable datasets:
Anal, Head and Neck (H&N), Abdomen and Lung. The concept behind these Guideline 5a cases
is to provide challenging but clinically relevant goals, with large targets and tight constraints,
resulting in highly modulated plans pushing the accuracy limits of the TPS calculation
algorithms.
Both VMAT (Pinnacle SmartArc [140, 141] ) and static gantry, segmented IMRT
(Pinnacle Direct Machine Parameters Optimization [142]) plans were created for each case.
Optimization was done for the 6 MV beams, and other energies were simply recalculated for the
same control points (CP). The H&N and Anal VMAT plans used two arcs, while the remaining
plans used one. The VMAT plans were calculated with 2° angular CP increment. The IMRT
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plans used seven to nine equidistant gantry angles. Three out of four plans (except the
Abdomen), had targets too large to be encompassed for conventional IMRT with a single set of
the MLC carriage positions, due to the limitations of the maximum leaf extension. They were
instead planned with the “wide-field” IMRT technique, where the leaves are allowed to nearly
close inside the treatment field, not necessarily under the X jaws, but those leaf abutment points
move across the field from segment to segment to avoid excessive exposure at any one location
in the patient. In all cases, a uniform 2.5 mm dose grid resolution was used for both the TPS and
the Calculator.
4.2.2.4

The Calculator vs. point dose measurements
For the three out of four cases (excluding the Lung), the plans were projected on the

homogeneous 20×20×20 cm3 Plastic Water Cube phantom (CIRS Inc., Norfolk, VA). Point
doses in the high-dose, low-gradient regions were measured with a 0.125 cm 3 Model TN31010
(PTW, Freiburg, Germany) ion chamber (IC). The chamber was cross-calibrated in a 10×10 cm 2
field against the expected primary TPS dose prior to every measurement session. The chamber
volume was drawn as a region of interest and the corresponding mean dose was used for
comparisons.
Unlike the previous three plans, the Lung plan was recalculated on a heterogeneous
anthropomorphic Thorax Phantom (modified Model 002LFC, CIRS Inc.) [143], with the
isocenter paced at the middle of the spherical target. The phantom is based on a Plastic Water
cylinder with an approximately elliptical cross-section. The overall dimensions are 30 cm × 30
cm × 20 cm. The phantom contains two cylindrical “lungs” made out of epoxy resin 0.21 g/cm 3
in

density. The right lung can accommodate a 4 cm diameter spherical Plastic Water target. The

target and a number of other locations in the phantom accept an A1SL 0.06 cm 3 IC (Standard
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Imaging Inc., Middleton, WI). The IC measurements were performed at two points: in the target
sphere and in the “mediastinum”, the latter representing a point well within the homogeneous
portion of the phantom.
4.2.2.5

The Calculator vs. biplanar diode array
In the next step, the Calculator dose distributions were compared to the Delta 4

(ScandiDos AB, Uppsala, Sweden) measurements, sampling the dose volume with two
orthogonal detector planes. The daily correction factor was determined by irradiating two
parallel-opposed 10×10 cm2 fields and minimizing the difference with the primary TPS in the
central portion of the irradiated area. Gamma analysis with 3%G/2mm/10% criteria was used as
the primary metric here and later in this study. Results with 2%G/2mm criteria are also presented
for comparison, as warranted. Gamma analysis was performed using the Delta 4 software, with
the Calculator DICOM RT dose grid loaded as reference dose.
4.2.2.6

The Calculator vs. 3D MGDR on patient CT
Following the measurements with the ArcCHECK (AC) dosimeter (Sun Nuclear Corp.),

measurement-guided dose reconstruction on the patients’ datasets was performed, using the ACbased planned dose perturbation (ACPDP) method [51, 143-145]. The AC measurements and the
primary TPS (Pinnacle) dose grid were used as the required ACPDP inputs. The ACPDP dose
was loaded as the reference in 3DVH software [51], and the Calculator dose as the comparison.
Both Pinnacle and the Calculator used the CT number-to-density conversion tables derived from
the same phantom scan. However, the physical density values were specified for Pinnacle and
electron density for the Calculator. The ACPDP method generates a 3D dose grid on a patient
dataset. However, it has no knowledge of the (variable) density of the patient and relies on the
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primary TPS to account for inhomogeneities. For the test plans excluding the Lung dataset, the
density variations do not pose a problem beyond possible minor discrepancies. However, with
the large low density heterogeneities, there is no guarantee that the different dose calculation
algorithms would agree. Therefore the Lung case was excluded from the ACPDP analysis and
was investigated separately as described in the following sections.
The same 3%G/2mm gamma analysis criteria were used, supplemented by 2%G/2mm
data. Since the discrepancies in the buildup region are expected, and are effectively ignored in
the traditional phantom measurements by the virtue of the active volume placement at depth, the
analyzed volumes here and in the next section were filtered to exclude the outermost 7 mm of the
body on the CT datasets.
4.2.2.7

The Calculator vs. TPS on the patient CT (No Lung)
The 3D Calculator doses on the patients’ datasets were directly compared to the

corresponding Pinnacle dose distributions using the same methodology as described above. This
configuration represents the intended use of the Calculator. The Lung case is not included in this
comparison, to isolate differences in accounting for heterogeneities.
4.2.2.8

The Calculator vs. TPS (Lung)
Additional comparisons were made for the Lung plan to better understand the

differences, and their practical significance, between the two versions of the Calculator
heterogeneity corrections. Unlike with the previous three datasets, special tests were done for the
Lung plan. In addition to comparisons on the patient dataset, the plans were recalculated on the
Thorax phantom with Pinnacle, no-HCS, and HCS versions of the Calculator. The phantom
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provides clear-cut interfaces and uniform low-density regions, which were expected to
emphasize the differences between various algorithms.
Comparisons with MC were also performed. Unfortunately, it is not practical to
recalculate segmented beams with PRIMO. Instead, a simple 5-beam coplanar plan was created
which could be calculated on the Thorax phantom with identical parameters with every S/C
algorithm and MC. All beams were equally weighted and the MLC apertures surrounded the 4
cm diameter spherical target with a 0.7 cm margin. The relative MC calculations were
normalized to the isocenter dose measured with an IC. The resulting dose grids were compared
in 3DVH software.
4.3
4.3.1

Results
Basic Beams on the Water Phantom
For all beams and energies the average γ(2%G/2mm) agreement beyond d max was 99.3 ±

1.3% (1 SD). The only plans having <100% agreement were the 20×20 cm 2 fields for 10 MVFFF
and 15 MV (96.7 and 97.9%, respectively) and the MLC-defined 3×3 cm 2 15 MV field. To
emphasize the areas of disagreement for the 20×20 cm2 fields , the error maps in Figure 4.1 are
based on the more sensitive gamma analysis with local (L) dose-error normalization,
γ(2%L/2mm). It is clear that for the larger fields the beam profiles disagree somewhat,
particularly with increasing depth. For the 10 MVFFF beam, the Calculator profile and Pinnacle
straddled the experimental curve, although the Calculator was closer. On the other hand,
Pinnacle showed better agreement with the measurement for 15 MV. The disagreement for the
MLC-defined 3×3 cm2 15 MV field inside the 10×10 cm2 jaw opening is due entirely to the 2.9%
difference in computed outputs for a partially obscured distributed secondary source (all
comparisons were done in absolute dose mode). Pinnacle and Calculator calculation results
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straddled our experimental output value, with Pinnacle being 0.7% high and the Calculator 2.2%
low, both reasonable values. The Pinnacle dose matched exactly the median of measured values
from Kerns et al [134]. Scaling the Calculator dose accordingly lead to a 100% agreement at the
2%L/2mm level beyond the dmax.

Figure 4.1. Gamma analysis (2%L/2mm) error maps (inserts) between Pinnacle and SNC Calculator, and normalized
cross-plane profiles at 20 cm depth for 10 MVFFF (a) and 15 MV (b) 20×20 cm2 fields. Ion chamber profiles are
also included for comparison. Red and Blue pixels are where the Calculator dose is above and below TPS
respectively.

4.3.2

Slab Inhomogeneities
The central axis PDDs on the lung slab phantom for a small (2×2 cm 2) field are shown in

Figure 4.2. For the 15 MV beam (Figure 4.2A) one can see the difference in lung dose between
Pinnacle, Non-HCS Calculator, and HCS-corrected Calculator. The HCS correction improved
agreement with Pinnacle and MC in the simple geometry, as reported previously [137]. For the
lower energies (Figure 4.2 B and C), the difference between Pinnacle and the standard Calculator
mode in the inhomogeneity was minimal (< 1.3% and 0.7% of D max for 10 MVFFF and 6 MV,
respectively), and both were sufficiently close to MC. Therefore the effect of the HCS correction
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was not further studied for those energies. The larger fields (not shown) exhibited the same
trends but to a smaller degree.

Figure 4.2. Central axis PDDs on the lung slab phantom for the 2 × 2 cm2 filed: 15 MV (a), 10 MVFFF (b), and
6MV (c).

4.3.3

The Calculator vs. Point Dose Measurements
For the point doses in the homogeneous phantoms or portions thereof (e.g. excluding the

target location in the Thoracic phantom), the mean Calculator vs. the IC difference was -0.3 ±
0.8% (1SD). The range was from -2.0 to 1.0%. For the plans based on the Guideline 5a Lung
case as delivered to the Thorax phantom, the 15MV IMRT and VMAT plans showed 2.8 and
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4.0% difference from the IC in the target, respectively. Pinnacle doses at the same point were
within 1.4% of the IC. With the HCS correction applied, the disagreement was reduced to -0.7%
and 1.6% for the 15 MV IMRT and VMAT plans, respectively, while the change in the
homogeneous portion of the phantom was minimal. The findings for the Lung plans with both
lower energies were unremarkable at both measurement points in the Thorax phantom.
4.3.4

The Calculator vs. Biplanar Diode Array
The average γ(3%G/2mm) and γ(2%G/2mm) passing rates of the Calculator against the

Delta4 measurements were 98.9 ± 2.1% and 96.1 ± 6.4% respectively. The Calculator produced
γ(3%G/2mm) agreement rates with the Delta4 measurements above 95% in all the studied cases
but two, and all were above 90% (Figure 4.3). Both lower passing rates are associated with the
6MV Anal case plans (94.8% for VMAT and 91.4% for IMRT).
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Figure 4.3. Frequency distribution of the γ-analysis passing rates comparing the Calculator to the Delta4 for all
Guideline 5a test cases and energies. N = 24.

4.3.5

The Calculator vs. 3D MGDR (No Lung)
In the next step, the agreement between the measurement-guided dose reconstruction on

the patient datasets using the ACPDP method, and the Calculator followed the same trend as the
direct comparison on the homogeneous phantom (compare Figure 4.4 and Figure 4.3). The
Guideline 5a Lung plans were excluded from the comparison. The average γ(3%G/2mm) and
γ(2%G/2mm) passing rate were 98.2 ± 2.0%. and 93.8 ± 5.7%, respectively. The only test case
falling below the γ(3%G/2mm) 95% agreement level (91.8%) was again the 6MV IMRT Anal
plan. To clearly demonstrate the predominant areas of failure, representative transverse and
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coronal cross-sections for that plan are shown in Figure 4.5 A and D, with the highlighted pixels
representing the areas of 2%G/2mm analysis failure. The failing pixels are largely concentrated
in the lower dose areas peripheral to, or in between the targets. The rest of the ACPDP doses for
both VMAT and IMRT plans agreed with the Calculator for 96.4% of the points or better
(3%G/2mm).

Figure 4.4. Frequency distribution of the γ-analysis passing rates comparing the Calculator to the ACPDP
measurement-guided dose reconstruction on the patient datasets for Guideline 5a test cases excluding the Lung (all
energies). N = 18.
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Figure 4.5. Graphical representation of the γ(2%G/2mm) comparison for the 6X Anal IMRT plan between the
Calculator and ACPDP (left column) and Pinnacle vs. ACPDP (right column). The highlighted pixels where the
gamma analysis fails are overlaid on the dose map. The targets are also shown. The transverse cuts (A,B) are taken
superiorly to demonstrate the areas of failure between the irradiated nodal chains. The coronal cuts (C,D) are 2 cm
posterior to the midline, where both the primary and secondary targets are prominently present.

4.3.6

The Calculator vs. Primary TPS on the Patient CT (No Lung)
The mean γ(3%G/2mm) and γ(2%G/2mm) passing rates comparing the Calculator to

Pinnacle were 99.0 ± 1.0% and 97.5 ± 2.4%, respectively. The corresponding ranges are 96.3 to
100% and 91.6 to 99.7%, respectively. The frequency distributions are shown in Figure 4.6. The
three instances with the γ(2%G/2mm) passing rates below 95% are all associated with higher
energies on the H&N dataset, which is unlikely to be seen in practice. Of note, the patterns of
γ(2%G/2mm) analysis failure against ACPDP for the 6MV IMRT Anal plan are visually similar
between the Calculator and ACPDP (Figure 4.5). Not surprisingly the 2%G/2mm gamma passing
rate between the Calculator and TPS is 99.1%.
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Figure 4.6. Frequency distribution of the γ-analysis passing rates comparing the Calculator to Pinnacle on the patient
datasets for Guideline 5a test cases excluding the Lung (all energies). N = 18.

4.3.7

The Calculator vs. Primary TPS (Lung)
The agreement level between the Calculator and Pinnacle for the Lung plan is energy-,

calculation mode-, and dataset-dependent, which necessitates a more detailed discussion. As can
be seen in Table 4.1, passing rates on the Guideline 5a Lung dataset decrease as the beam energy
increases, which is particularly clear with the 2% dose-error threshold. The HCS correction
applied to the 15MV plans did not lead to an improvement. The data for the same plans
recalculated on the Thorax phantom are presented in Table 4.2. Unlike with the original dataset,
the improvement in agreement with Pinnacle due to the HCS correction is substantial. However
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that by itself does not prove that the HCS correction leads to more accurate results. A
comparison with a definitive standard, such as an MC calculation, is necessary. Such analysis
was performed for a 5-beam 15 MV 3D plan. Pinnacle and the Calculator were in agreement by
the γ(3%G/2mm) analyses for 98.5% (no HCS) and 97.6% (with HCS) of the voxels. Subsequent
comparisons with MC are presented in

Table 4.3.

The Calculator without the HCS correction showed the best overall agreement

with MC by gamma analysis, as well as the target dose-volume histogram (DVH) agreement as
shown in Figure 4.7. On the other hand, the Pinnacle lung DVHs were the closest to MC.
Table 4.1. Gamma analysis passing rates comparing the Calculator to Pinnacle on the Guideline 5a Lung dataset.

Energy/Plan
6MV-VMAT
6MV-IMRT
10MVFFF-VMAT
10MVFFF-IMRT
15MV-VMAT
15MV-IMRT

γ-Analysis passing rate (%)
Non-HCS
HCS
2%G/2mm 3%G/2mm
2%G/2mm 3%G/2mm
99.4
98.6
93.9
94.2
82.9
89.9

100.0
99.8
98.9
98.6
93.4
96.3
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82.8
89.0

92.4
95.5

Figure 4.7. Representation of the gamma (2%G/2mm) comparisons on the transverse cut through the isocenter for
MC vs. Pinnacle (A), Calculator with no HCS (B), and Calculator with HCS correction (C). Blue pixels correspond
to the evaluated dose being below MC and red vice versa. The corresponding DVHs are presented in the right
panels. Solid lines represent MC and dashed the corresponding comparison calculations.
Table 4.2. Gamma analysis passing rates comparing the Calculator to Pinnacle for the same plans as in
but recalculated on the Thoracic phantom.
Energy/Plan
6MV-VMAT
6MV-IMRT
10MVFFF-VMAT
10MVFFF-IMRT
15MV-VMAT
15MV-IMRT

γ-Analysis passing rate (%)
Non-HCS
HCS
2%G/2mm
3%G/2mm
2%G/2mm
3%G/2mm
99.6
100.0
98.8
99.8
92.0
98.6
90.0
97.7
76.4
86.1
90.8
97.2
81.9
89.6
90.9
95.8
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Table 4.3. Gamma analysis passing rates comparing MC to Pinnacle and the Calculator (with and without the HCS
correction) for the 15 MV 3D plan on the Thoracic phantom.
MC vs. Pinnacle
2%G/2mm 3%G/2mm
87.1
92.1

4.4

γ-Analysis passing rate (%)
MC vs. Calculator (No HCS)
2%G/2mm
3%G/2mm
95.7
97.4

MC vs. Calculator (HCS)
2%G/2mm
3%G/2mm
92.1
94.9

Discussion
The calculator was put through a series of tests representing a subset of those required for

commissioning of a primary TPS dose engine [1, 76]. The mean IC point dose error in the
homogeneous phantoms is well below the 1.5% expectation [31, 76].

According to the

forthcoming recommendation on IMRT QA criteria, 95% of the points on a homogeneous
phantom passing the 3%G/2mm/10% gamma analysis should constitute the tolerance limit, with
the action limit set at 90% (private communication). While no compelling data exist to suggest
that 3%/2mm criteria hold an advantage in sensitivity/specificity over 3%/3mm, reducing the
distance-to-agreement tolerance to 2 mm appears intuitive, given that recommended distancetype tolerances in TG-142 [146] for IMRT machines are 1 to 2 mm.
Comparisons between the Calculator and direct measurements by the diode array
indicated that the Calculator performed at the accuracy level that could be expected for routine
patient-specific QA from a primary TPS. Similar results were seen for the volumetric
comparisons on the Guideline 5a patient datasets (excluding the Lung) with measurement-guided
dose reconstruction. In both series of experiments only some Anal plans exhibited less than 95%
(but above 90%) passing rates at the 3%G/2mm level. This is one of the most challenging plan
classes, featuring large bifurcating targets that require a rather high number of segments, thus
challenging the dose engine model accuracy under the MLC leaves and in the penumbra. As
such, these types of cases often exhibit the largest dosimetric discrepancies regardless of the dose
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calculation algorithm. The 6MV Anal IMRT plan’s pattern of pixels failing the more stringent
2%G/2mm gamma analysis against ACPDP (Figure 4.5) is similar between the Calculator and
TPS. The most challenging are the low dose areas outside and in particular in between the
targets, indicating imperfect dose calculations at the voxels spending a relatively large proportion
of time under the closed MLC leaves. A qualitatively similar pattern of failure is observed with
the Delta4, increasing the likelihood that the observed errors are real rather than a measurement
artifact, as a 2% dose-error threshold is pushing the accuracy of diode arrays.

Overall,

considering a generic beam model used in the Calculator, the demonstrated level of agreement
on the homogeneous or mildly inhomogeneous datasets should be considered satisfactory.
The situation is more complicated in the thoracic region. The slab geometry model
indicates that for the lower energies (6 and 10 MV), the difference between Pinnacle and the
Calculator PDDs at the tissue/lung interfaces is minimal and both are close to MC. However the
differences were noticed for 15 MV, with the HCS-corrected Calculator PDD being closer to
Pinnacle and MC than the uncorrected data. But that did not translate into a better overall
agreement between Pinnacle and the Calculator on the Guideline 5a Lung dataset for modulated
plans (93-96% for γ(3%G/2mm)). The plans were then projected on the Thorax phantom, which
contains better defined, sharp interfaces between 0.21g/cm3 and ~1 g/cm3 densities. In that
configuration, the HCS-corrected Calculator showed substantial improvement in agreement with
Pinnacle for the modulated plans (Table 4.2). While Pinnacle was widely tested in lung, it cannot
be considered the standard and in fact has been shown to be rather inaccurate in certain situations
[143]. Unfortunately, we did not have the ability to recalculate the modulated plans with MC.
However a five-field 15 MV 3D plan was compared with MC on the Thorax phantom. The best
overall agreement with MC in this case was observed for the standard (no HCS) Calculator dose.
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The nature of the HCS correction – changing the CT dataset densities - is non-physical. It was
optimized for slab inhomogeneities but does not improve accuracy in all situations. We therefore
cannot recommend its routine use without further investigation. On balance, this is largely an
academic point. The correction makes the most difference for the SBRT-type lung treatments,
the precise situation where the use of energies above 10 MV should be rather limited.
There is no guidance document yet on IMRT dose distribution verification by
independent calculation, with or without some empirical input. In the meantime, it seems
reasonable to apply the forthcoming experimental verification criteria in most situations.
However there are additional uncertainties related to calculating dose in lung, and appropriate
criteria need to be developed, perhaps such as the varying action limits based on the algorithm
similarity and case complexity established for secondary checks in non-IMRT radiotherapy [41].
Finally, we must point out that subtle dose differences could stem from the way the
different algorithms calculate or report dose to different tissue types. For example, both Pinnacle
and the Calculator determine the tissue type from their CT to density conversion tables, using the
mass and electron densities, respectively. This tissue assignment is then used to look up the
appropriate mass energy absorption coefficient for TERMA calculations. The Pinnacle
assignment table does not include water, while in the Calculator CT voxels corresponding to
approximately unit density would resolve to water. This difference in dose reporting could
potentially lead to up to ~1% error even on an ideal unit-density phantom, and is hard to control
for a patient CT dataset.
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4.5

Conclusions
We benchmarked a fast GPU-based independent S/C dose engine that produces 3D dose

distributions on the patient CT datasets for comparison with the TPS IMRT/VMAT calculations.
Comparisons with the ion chamber, diode array measurements, and measurement-guided 3D
dose reconstruction

for challenging datasets reveal the accuracy level expected in routine

patient-specific testing (≥95% γ(3%G/2mm) passing rates in most cases). Direct comparison
with the Pinnacle TPS on the realistic CT datasets showed similar agreement. The alternative
additional heterogeneity correction can change the dose noticeably in some situations with the
higher energy beam (15 MV). However this correction does not always result in the more
accurate dose calculation and should be used with caution.
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5

VALIDATION OF AN IMPROVED HELICAL DIODE ARRAY AND DOSE

RECONSTRUCTION SOFTWARE USING TG244 DATASETS AND STRINGENT
DOSE COMPARISON CRITERIA3

5.1

Introduction
This chapter focuses on true composite measurement based dosimetry system. These

systems have recently been recommended by TG 218 [23] for PSQA. In this study, a quasi-3D
helical diode array, ArcCHECK (AC) and its associated measurement-guided dose
reconstruction software (3DVH) was validated for VMAT/IMRT dose verifications. The basic
details of AC and 3DVH are presented in section 2.1 and are briefly introduced here.
The AC is a diode array dosimeter used primarily for quality assurance of IMRT/VMAT
treatments. It can be employed by itself to compare measured and reference dose at the detectors’
locations [78, 147-151] or in conjunction with 3DVH software (Sun Nuclear) that uses a ACbased planned dose perturbation (ACPDP) algorithm to perform volumetric measurement-guided
dose reconstruction (MGDR) on a phantom or patient dataset [51, 143-145, 152]. While the

3

This chapter is partially reproduced from work published in a peer reviewed journal. The author of this dissertation
is the first author of the published work. See Appendix B for the permissions.
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dosimeter and associated software have been characterized and employed rather extensively [51,
78, 79, 148-150, 153, 154], two recent developments necessitated revisiting the subject.
First, there have been several design changes in the AC hardware since the original
calibration factors [148] and 3DVH beam models [51] were validated. These changes were
implemented to improve device performance and regulatory compliance, but it was suspected
that some of the changes could influence the dosimeter response characteristics, which would
naturally change the volumetric dose reconstruction with 3DVH. The reconstruction procedure
was optimized based on the original AC design. It is good practice to repeat the basic
characterization of the array, to rule out (or mitigate if necessary) any unexpected effects and
verify the intended improvements. In addition, while the practical use of the AC with 10 MV
flattening filter free beam has been reported [155], the comprehensive evaluation has not.
Second, in departure from the previous school of thought [2], the AAPM TG-244 Report
on medical physics practice guidelines for commissioning of dose calculations [76]allows the use
of electronic dosimetry arrays as a primary commissioning tool for evaluating IMRT/VMAT
dose distributions, provided that dose measurement or reconstruction is performed with adequate
spatial resolution. Furthermore, TG-244 makes challenging, patient-based cases (image sets,
structure sets, and detailed list of dosimetric objectives) available for download to be used for
commissioning of the IMRT/VMAT systems. It would be useful for the clinical physics
community to have a benchmark of the level of dosimetric agreement achievable with the AC
and 3DVH for these cases. Unlike the previously reported TG-119 datasets [31], the TG-244
ones are more clinically relevant and include fairly large target volumes, which are known to be
challenging for the TPS calculation accuracy. Finally, TG-244 suggests more stringent dose
comparison metrics be employed in addition to the ubiquitous [2, 156]3% (global dose-error
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normalization), 3 mm distance to agreement gamma passing rates that were used in the TG-119
report [31], but since then have been largely proven to be neither sensitive nor specific [157162].
5.2
5.2.1

Methods
General
All measurements were performed with conventional (6X and 15X) and Flattening Filter

Free 10X (10XFFF) beams from a TrueBeam v 2.0 linear accelerator equipped with a 120-leaf
Millennium multi-leaf collimator (MLC) from Varian Medical Systems, Palo Alto, CA. The
treatment planning system (TPS) was Pinnacle v. 9.8 (Philips Radiation Oncology Systems,
Fitchburg, WI).
The AC features an array of 1386 point detectors that form a 10.4 cm radius cylindrical
active surface inside a doughnut-shaped PMMA phantom. The phantom has an outer diameter of
26.6 cm and a 15 cm diameter inner hole that can be plugged with a PMMA cylinder [148]. All
tests in this work were performed with the plug inserted, as this is the configuration necessary for
3D dose reconstruction [51]. The phantom was represented in the TPS by a cylinder with a
uniform relative density of 1.15, which was shown previously to provide adequate agreement
between the ion chamber measurements and TPS calculations [148].
ArcCHECK measurement data were collected using SNC Patient software v. 6.6 (Sun
Nuclear Corp). Statistical analyses were performed with GraphPad Prism software package (v. 6,
GraphPad Software, La Jolla, CA).
5.2.2

ArcCHECK Hardware Changes
The original AC is designated by the manufacturer as Version 1, while the redesigned

one, subject of the current investigation, is Version 2. Version 2 began shipping in 2014, in part
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to meet the European Union hazardous substances mandate [163]. One difference between the
“old” (v.1) and “new” (v.2) AC hardware is a redesign of the readout electronics. An on-board
buffer memory in combination with a more robust interface and connection cable ensures better
reliability of 50 ms updates recording. The new electrometers are more sensitive and also more
stable with respect to zero drift, both features particularly advantageous for longer and/or low
dose rate measurements.
The second major change – the one that directly affects the dosimeter response – was a
reduction in the overall amount of high atomic number materials, particularly lead, used in diode
and printed circuit board manufacturing. Also, wherever possible, metal conductors were placed
farther away from the sensitive volumes. Since the energy dependence of the diode is largely
determined by the surroundings of the die [164], the impact on detector response had to be
thoroughly investigated.
5.2.3

Basic Dosimeter Properties
A full dosimetric characterization of the new AC was performed, as warranted by

significant design changes. However, for brevity we will only elaborate here on those tests that
have not been performed before either at all or for certain energies, or produced results
substantially different from the v. 1 AC.
5.2.3.1

Dosimetric tests with no substantial new findings
The tests in this category included: a classic relative calibration test (the 180° “detector

flip”) [44, 78]; and diode sensitivity as a function of position in transverse and longitudinal
directions tests and diode sensitivity as a function of field size test. In all cases the device
performed within specifications and/or substantially equivalent to the previous version [147, 148,
165]. However, for the completeness these tests are described here.
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5.2.3.2

Detector “flip” test
A classic relative calibration test is the “detector flip” [78]. A wide (30 × 22 cm2) 6X

full arc was delivered once with the device in its normal position (electronics away from the
gantry) and once with it rotated 180° (electronics towards the gantry). Since the beam aperture
length was limited to 22 cm to avoid irradiation of the electronics, the most superior and inferior
diode “circles” partially lie in the penumbra and were excluded from evaluation. The dosedifference was tabulated between the two orientations for the remaining 1254 diodes.
5.2.3.3

Transverse profiles
This test addresses potential residual variation of the diodes’ response relative to the

normal entrance point detector, compared to the ion chamber, as the point of interest moves
around the circumference of the array. Strictly speaking, this test verifies the combination of the
angular and position-specific field size corrections. However, should the need be, the (small)
field size correction effect can be easily isolated based on the previous experiment. A wide (30 ×
22 cm2) single vertical field was used. Ion chamber readings were taken in the isocenter plane
every 30 mm of the AC X coordinate. They were averaged left to right, normalized at the
entrance, and compared to the corresponding relative average, corrected AC diode doses. The
TPS point doses were also included for comparison. All three energies were tested. Similar
measurements were also performed for a series of smaller fields, from 5×5 to 20×20 cm 2. The
primary goal of those experiments was to test the accuracy of the AC exit to entrance dose ratio
vs. the IC, which is crucial for accurate MGDR.
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5.2.3.4

Longitudinal profiles
Similarly, as the incidence angle of the ray changes with the diode’s position shifted

away from the isocenter along the Y direction (along the couch), the sensitivity could be
potentially affected. This was tested with the 6X beam in two configurations. The first test was
performed with the field wide open in the Y direction (10×25 cm 2). The second version included
smaller (5×4 cm2) fields moving in 1 cm increments along the Y direction, formed by the
asymmetric jaws. The fields were centered on the AC diodes, with the appropriate divergence
correction for the top (10.4 cm above the isocenter) and bottom (10.4 cm below) longitudinal
strings of diode positions. The Y position dependence for the exit side diodes was never
reported before, but the exit dose is as important for accurate 3DVH reconstruction as the
entrance. In either case, the dummy shell was first aligned on the lasers at the isocenter. Equal
monitor units were delivered with the couch translated along the Y direction in 1 cm increments
and the IC readings were recorded. This procedure was performed for the top and bottom diode
positions. Then the AC, aligned at the isocenter, was irradiated either in a single shot by the large
field (test 1), or sequentially by the small fields (test 2). The corrected diode doses were
extracted, normalized at the central axis, and compared to the corresponding relative IC readings.
The average readings of two diodes closest to the centerline were used. Since in theory the ion
chamber was surrounded by extra PMMA compared to the most superior diodes (towards Y =
+10 cm), additional scattering material was placed next to the superior end of the AC for an
additional measurement.
5.2.3.5

Field size dependence
The field size dependence of the diode response was evaluated against an ion chamber

(IC) for 6X, 15X and 10XFFF beams. Here and elsewhere in this work the IC readings were
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corrected for recombination with the two-voltage technique [166]. The detectors are positioned
along the array circumference in 1 cm intervals, measured on the 10.4 cm radius circle. This axis
is defined in the software as X, with Y oriented along the long axis of the cylinder. The topmost
detectors are located ±5 mm from the central axis and the bottom ones ±325 mm. The field size
dependence varies with the diode AC X position with respect to the beam because of the
changing scatter conditions. The IC (0.053 cm3 A1SL, Standard Imaging Inc., Middleton, WI)
was positioned in an AC-mimicking PMMA dummy shell drilled to center the chamber at the
diodes’ sensitive volume depth [148]. The average ratio of the AC dose to the IC reading was
recorded for varying filed sizes at the AC X positions of ±5 mm (top), ±325 mm (bottom), and
±155 mm (lateral). Asymmetric accelerator X jaws were used to define the necessary field sizes
for the off-axis lateral position. The AC dose was reported after the corrections [148]were
applied, so ideally the ratio normalized to the 10×10 cm 2 field should be 1.0. The equivalent
square field size varied from ~29 to 4 cm. It is assumed that from 4 × 4 cm 2 to the “very small”
(~1.5 cm for 6 MV) fields the relative sensitivity of the diode does not change, and the 4 cm
correction is applied for smaller fields. Similarly, the correction curves flatten out above the 20
cm and the constant value is assumed above that field size.
5.2.3.6

Dose and dose rate dependencies
The AC diodes are potentially subject to a variety of sensitivity changes related to both

the accumulated dose and dose rate, as described below.
5.2.3.6.1

Low MU linearity

With the central plug in place, the AC exit dose is about ¼ of the entrance one. Therefore
the dose linearity has to be studied separately for different diode positions. The relative AC
response for the entrance and exit diodes in a 10×10 cm2 6X beam was studied in the 1-100 MU
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range against the ion chamber. Because of the known long-lived trap population effect [167],
these measurements were performed with two SNC Patient software settings. At first the default
parameters were used, whereby the beam-on recognition was turned on and 10 measurement
updates (every 50 ms) were collected after the beam-off flag. In the subsequent measurement
series, effectively all the updates were collected, whether the beam was on or off.
5.2.3.6.2

Dose per pulse

Diode sensitivity variation with dose per pulse (DPP) was measured against the IC by
varying the source-to-detector distance (SDD). Within the studied SDD range from 74.6 to 119.6
cm, the dose per pulse changed from approximately 2×10 -4 to 5×10-4 Gy for the 6X beam and
from 2×10-3 to 6×10-3 Gy for 10XFFF. The AC or the dummy shell with the IC were irradiated
by a vertical beam and the readings were taken at the entrance (average of X = ±5 mm for the
AC). The normalized ratios of AC dose to IC reading were recorded.
5.2.3.6.3

Repetition rate

The accelerator repetition rate (MU/min) dependence was studied less frequently than
dose per pulse one. However, such dependence for the AC diodes does exist [148] and was
hypothesized by Jursinic [167] to be attributable to the capture of excess minority carriers by
charge traps. The slow reopening of these traps should occur on the hundreds of milliseconds to
seconds time scale to serve as the physical basis for the repetition rate dependence. The
repetition rate was varied from 5 to 600 MU/min for the 6X beam and from 400 to 2400 Mu/min
for 10XFFF, extending the repetition rate range compared to the previous reports [147, 148]. The
diode doses were divided by the corresponding IC readings, and normalized at 400 MU/min, a
common repetition rate setting for both x-ray energies.
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5.2.3.7

Out-of-field sensitivity
Being not water-equivalent, diode detectors have energy dependence, and one of the

manifestations of this fact is a variation in sensitivity with the distance from the aperture edge
outside the direct beam, due to the energy spectrum changes. The change in sensitivity to
scattered low-energy photons is the largest difference between the two AC designs that is
apparent to the end user. To quantify the changes, the diode-loaded AC (v.1 and then v.2) and
the dummy AC shell with the ion chamber were aligned at the isocenter and then slightly rotated
to place the sensitive volume at the central axis. A series of the MLC apertures were designed.
They varied from 0.5 to 3 cm in width and were positioned such that the measurement point was
either 1 or 2 cm outside the field. The AC diode and the IC readings were normalized to their
respective open 10×10 cm2 fields values, and the AC/IC ratios were plotted for the 6X and 15X
beams.
5.2.4

Three-Dimensional Dose Reconstruction

5.2.4.1

3DVH software changes

5.2.4.1.1

Background

3DVH software uses time-resolved dose information from the AC to generate high
density 3D dose grids. Necessary to this process is a library of beam models, each of which is
unique for specific LINAC/energy/MLC combinations. These models are essential to create a
high density, high resolution dose grids for each sub-beam, that can then be perturbed to fit the
corresponding measurements at the entry and exit surfaces [51]. The model library was
developed based on measurements from the AC v.1. The AC data acquisition software currently
does not include an explicit correction for the diode out-of-field (OOF) over-response. Therefore
this over-response was implicitly accounted for in the volumetric reconstruction model, to ensure
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favorable comparison with the independent IC measurements inside the volume. Consequently,
if/when the OOF sensitivity changes with new hardware designs, the method’s original
compensation for over-response is no longer optimized and would lead to erroneous results.
While it is theoretically possible to create different model versions that are specific to each new
AC hardware configuration, this would be prohibitive from the product maintenance standpoint.
Instead, the strategy was to keep the existing, universal library of beam models and provide a
simple correction mechanism to tune it for a particular AC version. A correction factor can now
be assigned by the user for each distinct combination of the AC hardware version (identified by
serial number) and 3DVH beam model. This correction factor is a single, relative value that
essentially quantifies the difference in response to the OOF radiation between the new original
AC designs. The default correction of 1.0 means “no change” but for any other value, a special
correction takes place during the reconstruction of each time-resolved sub-beam’s absolute dose.
Taking the current AC design change as an example, the beam model that compensated for the
original over-response now overcompensates. Left uncorrected, ACPDP dose would be
systematically low even though the measurement data are technically more accurate. The
purpose of the correction is simply to dampen the compensation and “add back” small amounts
of dose, but only in the areas of each sub-beam that are under an MLC leaf and/or jaw.
5.2.4.1.2

Correction method

The straightforward solution would be to split the 3D dose into primary (i.e.
transmission) and scatter components for every reconstructed sub-beam, then correct only the
scatter component. We implemented this method at first, only to realize that it caused a marked
increase in the dose reconstruction time. Therefore, we implemented a simplified and fast
method. This approach creates a single 2D correction mask for each reconstructed sub-beam,
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where the mask is in a beam’s-eye-view (BEV) sense perpendicular to the beam axis, following
divergent lines from the source. The correction mask is constant over all depths but tapered to
unity at the curved entry and exit surfaces of the diode array. The dose reconstruction time using
the simplified method was, on average, within 10% of the original (i.e. uncorrected) calculation
time. The dose correction factor for any point (x,y,z) in the beam coordinate system for a
modulated sub-beam is summarized by the equations below.
𝐷𝑜𝑠𝑒

(𝑥, 𝑦, 𝑧)

,

= 𝐷𝑜𝑠𝑒

(𝑥, 𝑦, 𝑧) ∗ 𝐶𝑜𝑚𝑝𝑜𝑠𝑖𝑡𝑒 𝑂𝑂𝐹 𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 (𝑥, 𝑦)

,

(5.1)

where x and y are the ray position coordinates in BEV and z is the orthogonal (depth)
coordinate. The last term in Eq.

(5.1) is defined as

𝐶𝑜𝑚𝑝𝑜𝑠𝑖𝑡𝑒 𝑂𝑂𝐹 𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 (𝑥, 𝑦) =

∫
∫

[𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝐹𝑙𝑢𝑒𝑛𝑐𝑒 (𝑥, 𝑦, 𝑀𝑈) 𝑑𝑀𝑈]
[𝑈𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝐹𝑙𝑢𝑒𝑛𝑐𝑒 (𝑥, 𝑦, 𝑀𝑈) 𝑑𝑀𝑈]
(5.2)

The MU parameter represents the dynamic progression for modulated beams derived
from the meterset progression in the DICOM RT Plan. Integration (summation) is performed
from start to end of each sub-beam. Uncorrected Fluence for any x, y point is a measure of
“exposure” to the beam, or cumulative time a point spends inside an open aperture (1.0
contribution) relative to being under an MLC leaf (contribution equals MLC transmission
fraction). This value is then corrected:
𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝐹𝑙𝑢𝑒𝑛𝑐𝑒 (𝑥, 𝑦, 𝑀𝑈)
= 𝑈𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝐹𝑙𝑢𝑒𝑛𝑐𝑒 (𝑥, 𝑦, 𝑀𝑈) + 𝑂𝑂𝐹 𝐴𝑑𝑗𝑢𝑠𝑡𝑚𝑒𝑛𝑡 (𝑥, 𝑦, 𝑀𝑈)
(5.3)
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In turn,
𝑂𝑂𝐹 𝐴𝑑𝑗𝑢𝑠𝑡𝑚𝑒𝑛𝑡 (𝑥, 𝑦, 𝑀𝑈)
=

(𝑁𝑜𝑚𝑖𝑛𝑎𝑙 𝑂𝑂𝐹𝐶𝐹 − 1.0) ∗ 𝐸𝐷𝐹,
for regions under collimation
0.0,
for directly irradiated regions, i. e. inside the momentary aperture
(5.4)

where Nominal OOFCF is the Nominal Out of Field Correction Factor (specified by the
user on the software setup tab) and EDF is the Energy Dependence Factor, a small fraction
derived from the PDP model parameters. The EDF increases with energy but is always a small
number, on the order of 0.01 to 0.025. This factor is introduced so that the user-defined Nominal
OOFCF stays effectively the same across all energies, for the ease-of-use.
5.2.4.2

ACPDP comparisons with direct measurements

5.2.4.2.1

Test plans

IMRT and VMAT plans were selected based on the TG-244 Report recommendations
[76]. They included two well-known plans from the TG-119 suite [31] (C-shape and Mock Head
and Neck (H&N), optimized on the 20×20×20 cm3 Plastic Water (PW) Cube phantom from
CIRS Inc., Norfolk, VA), and three more realistic plans from the downloadable datasets in the
TG-244 library: Anal, H&N, and Abdomen. The concept behind the TG-244 cases is to provide
challenging but clinically relevant goals, with large targets and tight constraints, resulting in
highly modulated plans pushing the accuracy limits of the TPS calculation algorithms. These
datasets were previously used for large, inter-institutional plan studies similar to the pilot study
described by Nelms et al [91].
All plans were optimized based on 6X beams and for the purpose of this work simply
recalculated for other energies [76]. All plans were created with both VMAT (Pinnacle
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SmartArc) and step-and-shoot IMRT (Pinnacle Direct Machine Parameters Optimization)
techniques. The TG-244 H&N and Anal VMAT plans used two arcs and the rest one. The
VMAT plans were calculated with 2° angular control points (CP) increment. The IMRT plans
used seven to nine equidistant gantry angles. Two of the plans (TG-244 H&N and Anal) had
targets too large to be encompassed for conventional IMRT with a single set of Varian MLC
carriage positions, due to the limitations of the MLC leaf extension. They were instead planned
with the “wide-field” IMRT technique, where the leaves are allowed to nearly close inside the
treatment field, not necessarily under the X jaws, but those leaf abutment points move across the
field from segment to segment, to avoid excessive exposure at any one location in the patient. In
all cases, uniform 2.5 mm dose grid resolution was used.
5.2.4.2.2

ACPDP point dose comparisons

Point doses in the high-dose, low-gradient regions were measured in the PW Cube
phantom with a 0.125 cm3 Model TN31010 ion chamber (PTW, Freiburg, Germany). The
chamber was cross-calibrated in a 10×10 cm2 field against the expected TPS dose prior to every
measurement session. The chamber volume was drawn as a region of interest and the
corresponding mean dose was used for comparisons. The confidence limit (CL) of the average
difference between the measured and reconstructed dose was expressed as mean ±1.96 standard
deviation [31, 168]. Note that this confidence limit is different (larger) than the traditional
statistical confidence interval.
5.2.4.2.3

ACPDP dose distribution comparisons with a biplanar array

The ACPDP volumetric dose was directly compared to the applicable measurement
planes of a previously validated biplanar dosimeter [81, 82, 169-171]. Excellent agreement
between ACPDP reconstructed dose (based on the original AC design) and Delta 4 (ScandiDos
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AB, Uppsala, Sweden) measurements was demonstrated earlier [145]. Note that the Delta 4
calibration formalism includes an adequate empirical software correction for the diode response
variation outside the beam aperture [82]. It is however a second-order correction for the
cumulative dose measurements.
The AC phantom with the plug was centered on the lasers. The daily correction factor
was determined by comparing measured and calculated doses in the central portion of the
parallel-opposed 10×10 cm2 field pair, at the mid-range repetition rate [148, 167]. Threedimensional ACPDP dose reconstruction was performed with a prototype version of 3DVH
software incorporating OOF corrections as described above. The cylindrical Delta 4 phantom
represented the “patient” dataset used for dose reconstruction [145]. The reconstructed dose grid
was saved in DICOM RT Dose format and imported into the Delta4 software as reference dose.
After the treatment was delivered to the Delta4 in a usual fashion, the reconstructed dose was
compared to direct measurement using built-in gamma analysis tools [80]. Both 3%/2mm and
2%/2mm criteria combinations were used, with global (e.g. 3%G) and local (e.g. 3%L) doseerror normalization. Low dose analysis threshold was 10% of the maximum. For conciseness,
only the results with 2% dose-error criteria are presented in detail when comparing the AC to the
Delta4.
5.2.4.2.4

Comparisons with the TPS

One of the goals of this study, in addition to validating the modified ACPDP hardware
and software, is to estimate the range of achievable gamma analysis results on a phantom for the
TG-244 datasets, which unlike TG-119 [31] have not been extensively studied so far. To that
end, we present the data for both the direct AC to TPS comparison and the comparison between
the 3D ACPDP and TPS dose grids. In this case, the results of gamma analysis with 3%G/2mm
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are also included, as this seems to be the emerging criteria combination for patient-specific
IMRT QA.

Following the TG-119 methodology, the 95% one-sided confidence CL is

established for the gamma analysis passing as 100% - (mean passing rate) - 1.96*(standard
deviation) [31].
5.3

Results and Discussion

5.3.1
5.3.1.1

Basic Dosimeter Properties
Flip test
The mean difference between the AC diode readings (normal and flipped) was 0.1% ±

0.1% (1SD) ranging from -0.2% to 0.4%. This is fairly close to the reported average of -0.3% ±
0.2% for the older AC version. The results show the accuracy of the relative calibration of the
array.
5.3.1.2

Axial profiles
Figure 5.1 shows the relative dose of AC versus ion chamber measurements and TPS

calculations for two field sizes (10 × 10 cm2 and 30 × 30 cm2). The percent dose differences
from IC were -1.0%, -0.9% and 2.1% for the 6X, 15X and 10XFFF beams respectively. The
only noteworthy variations were observed for the two 10XFFF points located laterally away
from the isocenter (2.1% and 1.7% at X = 125 and 155 mm respectively). For all energies and
field sizes, the AC exit to entrance dose ratio does not exceed from IC by more than 0.5%.
5.3.1.3

Longitudinal profile
The ratios of AC to IC as a function of the Y position (cylindrical axis of AC) are

presented in Figure 5.2. For the entrance diodes the relative diode dose agrees to IC within 1%
and 0.6% for large and small fields respectively. The additional scatter material a t the superior
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edge of the phantom does not affect the results (0.1% change). However, for the exit diodes there
is a bias of the AC under-responding at the superior and inferior ends of the phantom. Without
adding the scatter material the under-response is ~3% at the superior end which reduces to 2%
with the addition of material to that end (shown in the bottom panel of Figure 5.2). With the
small fields, the AC agrees with the IC within 1% indicating the error in the large field due to the
partial loss of the scatter at the superior end of the phantom. At the inferior, the effect is also
present but is partially mitigated by the materials in the electronics compartment. Since the
primary intended use of the AC is for the IMRT/VMAT measurements, the results with the small
fields are more indicative of the expected device performance in practice.
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Figure 5.1. The comparison of axial profiles measured by ArcCHECK and ion chamber and calculated by TPS at the
AC diode locations for the field size of 30 × 30 cm2 and all investigated energies.
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Figure 5.2. The sensitivity profiles along cylindrical axis of the AC (Y-profile) for both entrance (a) and exit (b)
diodes with large and small fields (2 × 2 cm2).

5.3.1.4

Field size dependence
Across all three positions, the AC/IC ratio normalized to the 10×10 cm 2 field was in the

range of 0.992 -1.003, 0.992 – 1.008, and 0.991 – 1.008 for the 6X, 15X, and 10XFFF beams ,
respectively. Thus the raw field size dependency that can reach 5% or more in magnitude [148]
is compensated to within less than 1% of the IC measurement by the software correction factors.
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5.3.1.5

Dose and dose rate dependencies

5.3.1.5.1

Low MU linearity

The results are presented in Figure 5.3. The deviation from the straight line for the 2 MU
setting (entrance diode) is -2.8%, somewhat larger than the -0.9% error reported by Li et al [165]
for the comparable data point with the AC v.1. Since for the same MU setting the exit dose is
about ¼ of the corresponding entrance one, the apparent non-linearity of response is more
pronounced for the exit diodes. Extending the integration time (modified vs. default settings
curves in Figure 5.3) reduces the maximum non-linearity by approximately one-half, consistent
with the notion that shorter integration time prevents all the charge trapped in the long-lived
centers from being collected.
The residual non-linearity is likely associated with the intrinsic diode properties [167]
rather than the readout electronics, since similar effects were reproduced with this type of diode
connected to a variety of electrometers in different devices. It was also verified by the ion
chamber measurements at the different depths in a phantom that the observed effect is not caused
by the possible initial beam instability during short exposures. The investigated version of AC
(v.2) has a more robust background and zero drift suppression that its predecessor, and therefore
the modified settings with long integration times were used for subsequent data collection.
Longer integration times should become the default for the AC v.2. Current findings agree with
the AC specifications of <0.5% integration non-linearity from 6 to 30 cGy total dose [172].
However it must be noted that for the 6X beam the exit dose with the plug is approximately 0.3
cGy/MU and thus the specifications do not address dose linearity for segments with less than
~20 MU, which are quite common with standard fractionation. The results in Figure 5.3 provide
the non-linearity estimates down to 1 MU.
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Figure 5.3. Low MU non-linearity. AC exit and entrance doses are normalized to the ion chamber and shown as a
function of MU. The default software settings limit the number of updates after the beam is turned off, while the
modified settings do not.

5.3.1.5.2

Dose per pulse

Within the studied SDD range from 74.6 to 119.6 cm, the AC/IC ratio varied smoothly
from 1.012 to 0.992, and from 1.001 to 0.995 for the 6X and 10X FFF beams, respectively. The
ratios were normalized to 1.000 at the calibration SDD of 89.6 cm. The overall change in
response of ~2% for the 6X beam is substantially smaller than reported by Chaswal et al [147].
Their 7% variation for the same SDD range, based on the inverse-square dose estimates, appears
excessive compared to the previous reports studying similar diodes [43, 44, 165]. We believe
that the methodology of direct comparison with recombination-corrected IC employed in this
work is a well-established standard for these types of measurements and provides a more realistic
estimate of the SDD dependence, in line with the previous findings. With the 10XFFF dose per
pulse being approximately an order of magnitude higher than 6X, the large percentage of the
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charge traps remain populated regardless of the SDD within the studied limits, and there was
little change in diode sensitivity.
5.3.1.5.3

Repetition rate

The AC response relative to the IC as a function of repetition rate is presented Figure 5.4.
Normalized at 400 MU/min, the curve is relatively smooth, with two different energies used for
the low and high end of the repetition rate range. For the lowest (5 MU/min) repetition rate the
AC/IC ratio was 0.978, which is reasonably close to the previously reported value of 0.986
[148]. The difference did not exceed 1% for the 100 – 600 MU/min range with the 6X beam and
the entire 400 – 2400 MU/min range with the 10XFFF beam.

Figure 5.4. Repetition rate dependence for the 6X and 10XFFF beams. The AC/IC ratio is normalized at 400
MU/min.
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5.3.1.6

Out-of-field sensitivity
Normalized ratios of the AC to IC readings outside the field are presented in Figure 5.5 A

and B. Since the amount of scattered radiation reaching the point of measurement increases with
the field size and decreases with the distance to the field edge, it is natural that the relative
sensitivity of the diode would generally increase as shown in Figure 5.5. With the exception of
one data point, the ratio of AC to IC stays fairly flat for the given hardware version, namely
within 1%. It is clear from Figure 5.5 that the AC v.2 has substantially lower over-response
outside the field, which is consistent with the reduction in the amount of high-Z materials present
in the newer design. In comparison with the previous work [147], we believe that directly
referencing the ion chamber provides a more realistic over-response estimate than their TPSbased analysis. The out of field response was also reported in 2013, presumably for the v. 1 of
the AC, by Li et al [165]. The differences in the geometry preclude detailed comparisons of the
results, but under the most similar conditions, our factor for the AC v. 1 appears to be about 10%
higher.
The OOF sensitivity change is a second-order effect which has limited practical
consequences when the dosimeter is used to directly compare the diode dose to the TPS.
However it becomes important when the apparent AC dose profiles are used to determine the
dose-spread kernel parameters for internal calculations during volumetric dose reconstruction.
The results above clearly support the need for the additional correction factor in the 3D dosereconstruction software.
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Figure 5.5. Ratios of readings at the points 1 and 2 cm outside the field as a function of the aperture width. Panels A
and B show the AC to IC ratios for the old (v.1) and new (v.2) versions of the ArcCHECK. In panel C the ratios of
the v.1 to v.2 AC readings are presented.
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5.3.2
5.3.2.1

Three-Dimensional Dose Reconstruction
Selection of the over-response correction factor in the software
The ratio of the old to new AC diode over-response from Figure 5.5 varied from 1.0 to

1.17 between all geometries and the two extreme energies (6X and 15X). In the search of the
simplest practical solution, we elected to use the highest value (1.17) as the starting point, the
rationale being that the points with the largest amount of scatter are likely to have the highest
OOF absolute dose and thus have the most influence on the final results. This value was further
refined by varying the correction factor to maximize the 2%L/2mm gamma analysis agreement
rate and minimize the median dose deviation for one dataset (TG-119 C-shape) between the
ACPDP on the Delta4 phantom and direct Delta4 measurements. This was done for both 6X
plans, VMAT and IMRT. As one can see in Figure 5.6, the median dose difference is minimized
around the OOFCF of 1.17, while the passing rates nearly plateau. Since the maximum measured
value was 1.17, it was logical not to exceed that value.
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Figure 5.6. Gamma analysis passing rates (2%L/2mm, A) and median dose-differences (B) for 6X IMRT and
VMAT plans, comparing ACPDP with the Delta4 as a function of user-selectable out-of-field correction factor
(OOCF).
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5.3.2.2

ACPDP comparisons with direct measurements

5.3.2.2.1

Point dose comparisons

The average difference for all plans and energies between the ACPDP dose reconstructed
on the PW Cube and the ion chamber measurement in the high dose low gradient regions was
0.0±1.4% (95% CL -2.7 to 2.7%). The distribution passed the D’Agostino & Pearson omnibus
normality test and the mean was not statistically significantly different from 0 (t-test p = 1.0).
For practical implementation of the modified software with the wider user base, whereby
an independent array dosimeter may not be readily available, similar ion chamber measurements
are likely to be the primary means of establishing the correction factor. They can be performed in
either an arbitrary phantom, as was done here, or with the standard single-hole PMMA plug in
the AC phantom, or with the optional Multi-Plug that provides a variety of possible chamber
locations throughout the reconstruction volume [152].
5.3.2.2.2

Comparisons with a biplanar array

The detailed results are presented in Table 5.1. The overall mean agreement rate at the
most stringent level of 2%L/2 mm gamma analysis is 96.7±3.7% (1SD), which appears
somewhat lower than reported with the previous AC/3DVH version (98.2 ± 1.6%) [145].
However, a closer look reveals that for the plans common to both investigations (TG-119 Cshape and H&N), the mean agreement rate for all energies and techniques is 98.3±0.8%,
essentially unchanged from the previous report. Likewise, the TG-244 Abdomen plan passing
rate is 98.5±1.6%. The lower agreement rates, that pull down the average, are associated only
with the larger targets (TG-244 H&N and Anal plans), particularly with the 10XFFF beam. The
worst agreement at the 2%L/2mm level is observed for the TG-244 H&N plans with 10XFFF.
With both VMAT and IMRT, the median dose difference between the ACPDP and Delta 4 in

99

those cases is 1.3%, the largest in the population. On the other hand, the median dose difference
averaged across all plans and energies is 0.0 ± 0.6%, with the 95% CL from -1.2% to 1.2% and
the distribution passing the normality test. In conjunction with the IC data presented above, this
confirms the choice of a single value for the over-response correction described in the previous
section.
Relaxing the criteria to 3%L/2mm results in the average γ analysis agreement rate
between the ACPDP and Delta4 of 98.3 ± 2.2%, with only 4 data points below 95%, and none
below 92%.
The modification to 3DVH software was definitely necessary. Without it, the average
ACPDP vs. Delta4 2%L/2mm and 2% G/2mm agreement rates would have been unacceptable:
73 and 78%, respectively, with a bias of ACPDP dose being too low.
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Table 5.1. Gamma analysis passing rates and median dose-differences for 3D ACPDP on the Delta4 phantom vs.
Delta4 directly measured dose.
Dataset

ABDOMEN-TG 244

H&N-TG 244

ANAL-TG 244

Cshape-TG 119

H&N-TG 119

Energy/Technique

6X-VMAT
6X-IMRT

ACPDP vs. Delta4 γ passing rate (%)
Local
2%/2mm
3%/2mm
100.0
100.0
98.2
99.8

Global
2%/2mm
3%/2mm
100.0
100.0
100.0
100.0

Median
ΔD (%)
0.2
0.3

15X-VMAT

100.0

100.0

100.0

100.0

-0.1

15X-IMRT

99.1

99.2

99.8

100.0

0.0

10XFFF-VMAT

95.9

99.2

96.6

100.0

-0.9

10XFFF-IMRT

97.5

99.2

99.2

100.0

-0.5

6X-VMAT

96.2

98.9

98.3

100.0

0.4

6X-WFIMRT

96.0

98.4

97.9

99.5

0.3

15X-VMAT

98.7

99.3

99.6

100.0

-0.1

15X-WFIMRT

99.2

99.7

99.9

100.0

-0.1

10XFFF-VMAT

84.4

92.2

92.7

97.9

1.3

10XFFF-WFIMRT

87.8

93.8

94.4

99.6

1.3

6X-VMAT

99.1

99.4

100.0

100.0

-0.1

6X-WFIMRT

94.7

96.1

97.1

98.8

-0.1

15X-VMAT

98.0

98.5

99.0

99.7

-0.6

15X-WFIMRT

91.8

93.5

96.8

99.3

-0.8

10XFFF-VMAT

93.3

96.7

98.5

99.7

0.7

10XFFF-WFIMRT

91.1

93.3

96.7

99.6

0.7

6X-VMAT

98.0

98.7

99.5

100.0

-0.1

6X-IMRT

98.4

99.2

99.4

100.0

0.4

15X-VMAT

98.9

99.4

99.8

100.0

-0.3

15X-IMRT

99.1

100.0

99.2

100.0

0.6

10XFFF-VMAT

97.3

98.6

99.0

100.0

-0.7

10XFFF-IMRT

99.8

100.0

100.0

100.0

-0.5

6X-VMAT

97.5

99.2

99.4

99.8

-0.4

6X-IMRT

97.3

99.2

99.7

99.8

0.5

15X-VMAT

98.2

98.6

99.2

99.8

-0.3

15X-IMRT

98.6

99.8

99.8

100.0

0.4

10XFFF-VMAT

97.7

98.8

98.8

99.7

-0.4

10XFFF-IMRT
Average
SD
Min
Max

99.2
96.7
3.7
84.4
100.0

99.5
98.3
2.2
92.2
100.0

100.0
98.7
1.8
92.7
100.0

100.0
99.8
0.4
97.9
100.0

0.0
0.0
0.6
-0.9
1.3

101

5.3.2.2.3

Comparisons with the TPS

As a point of reference, the average difference between the TPS and IC was 0.6±0.9%
(95% CL -1.2 to 2.4%). The distribution did not pass the normality test (p = 0.01) and the mean
value is statistically significantly different from 0.0 (t-test p = 0.001). Despite this slight bias, the
mean value is comfortably below 1.5% reported or recommended for the high dose regions by
the relevant task groups [31, 76].
The results of the direct AC to TPS comparison, and the comparison between the 3D
ACPDP and TPS dose grids are presented in Table 5.2 and Table 5.3, respectively. Following
the TG-119 confidence limit methodology, for the 3%G/2mm criteria, in 95% of the cases one
should expect at least 96.3% of the points to pass with the AC and 96.9% with the ACPDP. This
is above the proposed 95% investigative threshold, let alone the 90% actionable one. Moreover,
the 90% pass action threshold should be exceeded or attained at the 95% confidence level even
with the more stringent 2%G/2mm criteria, for both the AC and ACPDP. Therefore it is expected
that the well-commissioned TPS, in conjunction with the new ArcCHECK hardware and
software, should consistently produce gamma analysis results acceptable by the emerging
standard, whether for the basic AC measurements or for 3D ACPDP on a homogeneous
cylindrical phantom. At the same time, the analyses with the more sensitive local dose-error
criteria show reduced agreement, particularly with the larger targets from the TG-244 datasets
requiring wide-field IMRT. While the average 2%L/2mm ACPDP vs. TPS passing rate is
respectable 91%, the two lowest values are 75.5 and 78.2%, for the 6X and 15X Anal wide-field
IMRT plans, respectively. These types of plans contain complex bifurcating targets separated by
large low-dose volumes and are known to be problematic in terms of dosimetric agreement,
particularly in the low-dose areas when the local dose-error normalization is used. This is clearly
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illustrated in Figure 5.7, where gamma analysis failures, save a few errand pixels, are confined to
the areas outside the targets. Wide-field IMRT introduces an additional challenge of modeling
the leakage through the static, narrow gaps between the nearly abutting MLC leaves inside the
field. Thus the TG-244 plans serve as a useful stress test. While the ACPDP results obviously
based on the AC measurements, the former shows a slightly better agreement with the TPS than
the latter (Table 5.3 vs. Table 5.2), both in terms of the average gamma passing rates and average
median dose-difference across the plan population. This is consistent with the notion that the AC
has an inherently challenging geometry for comparison with the TPS. Given the peripheral
detector location, the AC measured dose is typically considerably lower than the central one.
The 10% low dose cutoff threshold becomes perhaps 5% or so in a global sense, making it more
difficult to achieve agreement with the TPS, exceedingly so with the local dose-error
normalization. The sign of the average median dose deviation (AC>TPS) suggests that further
reducing the AC dose-response non-linearity with low MU would not improve the results, since
it would increase the reported dose, if anything.
Overall, the comparison results, whether with another array dosimeter or the TPS,
underscore the ultimate dilemma one faces with the intensity modulated dose distribution
measurements: the expected accuracy of the measurement tool (~2%) is comparable to the
desired uncertainty in the measured quantity (2-3% in dose), instead of being an order of
magnitude smaller, as dictated by metrology. A relatively small systematic measurement error of
say 0.5% can easily have a noticeable effect.
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Table 5.2. Gamma analysis passing rates and median dose-differences: ArcCHECK vs. TPS.
Dataset

Energy/Technique

ABDOMEN-TG 244

6X-VMAT

H&N-TG 244

ANAL-TG 244

Cshape-TG 119

H&N-TG 119

ArcCHECK vs. TPS γ passing rate (%)
Local
Global
2%/2mm 3%/2mm 2%/2mm
3%/2mm
93.7
96.6
99.8
100.0

Median ΔD
(%)
1.1

6X-IMRT

86.3

92.3

97.9

99.4

1.5

15X-VMAT

94.8

97.6

99.8

100.0

1.1

15X-IMRT

89.2

94.3

98.0

99.4

1.1

10XFFF-VMAT

98.0

99.2

100.0

100.0

-0.2

10XFFF-IMRT

92.0

95.3

97.1

98.8

-0.6

6X-VMAT

86.2

89.2

98.5

100.0

1.3

6X-WFIMRT

78.3

85.5

95.4

98.9

2.3

15X-VMAT

92.0

94.2

99.8

99.9

1.4

15X-WFIMRT

81.8

88.7

95.8

99.0

2.3

10XFFF-VMAT

92.1

95.9

98.4

99.3

-1.0

10XFFF-WFIMRT

90.4

94.2

97.3

99.3

0.1

6X-VMAT

80.8

85.5

97.5

99.9

2.6

6X-WFIMRT

73.4

79.0

92.1

98.0

2.9

15X-VMAT

88.5

91.6

97.4

99.2

1.9

15X-WFIMRT

83.1

88.7

94.5

98.6

2.3

10XFFF-VMAT

92.1

95.4

98.9

99.6

-0.5

10XFFF-WFIMRT

91.8

94.7

98.1

99.5

0.7

6X-VMAT

80.6

84.4

93.4

97.5

2.6

6X-IMRT

85.4

90.1

90.4

95.3

2.4

15X-VMAT

86.3

89.9

95.4

98.6

1.7

15X-IMRT

86.5

90.7

92.1

95.6

0.8

10XFFF-VMAT

91.2

94.6

98.4

99.7

-0.3

10XFFF-IMRT

90.2

93.3

95.2

97.2

-0.3

6X-VMAT

86.0

91.5

94.2

98.4

2.0

6X-IMRT

89.0

94.5

94.1

98.4

1.0

15X-VMAT

90.6

92.5

94.4

97.3

1.0

15X-IMRT

92.5

95.6

95.4

98.1

0.5

10XFFF-VMAT

91.2

93.0

95.3

97.4

-0.5

10XFFF-IMRT

88.8

94.3

94.0

97.8

-1.1

Average

88.1

92.1

96.3

98.7

1.0

SD

5.3

4.4

2.6

1.2

1.2

Min

73.4

79.0

90.4

95.3

-1.1

Max

98.0

99.2

100.0

100.0

2.9
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Table 5.3. Gamma analysis passing rates and median dose-differences: ACPDP vs. TPS (on the 22 cm diameter
Delta4 PMMA phantom).
Dataset

Energy/Technique

ABDOMEN-TG 244

6X-VMAT

H&N-TG 244

ANAL-TG 244

Cshape-TG 119

H&N-TG 119

ACPDP vs. TPS γ passing rate (%)
Local
Global
2%/2mm 3%/2mm 2%/2mm
3%/2mm
97.5
98.6
99.7
100.0

Median ΔD
(%)
0.6

6X-IMRT

94.7

97.4

99.6

99.9

1.1

15X-VMAT

97.9

99.3

99.1

99.9

-0.3

15X-IMRT

95.0

97.2

98.4

99.7

0.2

10XFFF-VMAT

98.3

99.1

99.8

100.0

-0.6

10XFFF-IMRT
6X-VMAT

91.1
90.2

94.7
93.2

98.9
98.1

99.9
99.9

-1.1
0.7

6X-WFIMRT

83.7

91.7

93.4

99.5

1.0

15X-VMAT

92.2

94.7

98.7

100.0

1.0

15X-WFIMRT

85.2

89.7

95.8

99.4

1.6

10XFFF-VMAT

90.3

96.2

95.9

99.5

-1.6

10XFFF-WFIMRT

91.8

96.8

97.1

99.7

-0.9

6X-VMAT

82.7

85.4

93.3

99.3

2.5

6X-WFIMRT

75.5

79.9

84.1

93.2

3.1

15X-VMAT

87.3

89.9

96.5

99.8

2.3

15X-WFIMRT

78.2

83.4

87.1

94.9

2.9

10XFFF-VMAT

95.2

97.1

99.5

99.9

-0.5

10XFFF-WFIMRT

92.6

95.2

98.3

99.6

0.5

6X-VMAT

87

89.3

96.7

99.1

2.3

6X-IMRT

89.6

92.9

97.5

99.3

1.5

15X-VMAT

91.3

93.0

98.8

99.7

1.6

15X-IMRT

89.3

92.3

95.9

98.5

0.9

10XFFF-VMAT

93.5

95.2

98.5

99.7

0.4

10XFFF-IMRT

93.2

95.2

98.6

99.7

0.5

6X-VMAT

94.8

96.6

99.2

99.9

1.3

6X-IMRT

95.8

98.6

98.9

99.9

0.3

15X-VMAT

94.6

96.4

98.9

99.8

0.9

15X-IMRT

93.6

97.2

97.7

99.5

0.8

10XFFF-VMAT

95.3

96.6

98.6

99.7

0.1

10XFFF-IMRT

93.4

96.7

98.9

99.9

-0.7

Average

91.0

94.0

97.1

99.3

0.7

SD

5.5

4.7

3.6

1.5

1.2

Min

75.5

79.9

84.1

93.2

-1.6

Max

98.3

99.3

99.8

100.0

3.1
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Figure 5.7. A coronal cross section for a wide-field IMRT anal plan. The color coding over the dose-intensity map
indicates the areas in the low-dose region that fail 3% L/2 mm gamma analysis (ACPDP vs. TPS).

5.4

Conclusions
We comprehensively characterized the redesigned ArcCHECK helical dosimeter and

dose reconstruction software. Previously unreported response non-linearity with low MU settings
has been quantified. Increasing the integration period compared to the current default setting is
recommended to minimize the effect. While most AC parameters did not change appreciably
compared to the previous versions, the out-of-field diode response did. The over-response to
scattered out-of-field radiation has decreased by as much as 17% due to the reduction of the
amount of high-Z materials in the immediate vicinity of the diodes. While objectively an
improvement in the measurement accuracy, this change made the device incompatible with the
existing 3D dose reconstruction software, which had to be redesigned to accommodate this and
possible future changes. During the dose reconstruction software commissioning process, the
user has to establish a single, energy-independent, correction factor appropriate for the
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ArcCHECK hardware and software versions. After the application of such factor in this work,
the accuracy of measurement-guided dose reconstruction was restored to the previously reported
level. In the process, we demonstrate with the challenging TG-244 commissioning datasets that
ACPDP vs. Pinnacle TPS gamma-analysis passing rates on a homogeneous phantom can be
expected to exceed 96% and 90% at the 95% confidence level, for the 3%G/2mm/10% and
2%G/2mm/10%, respectively. The local dose-error normalization leads to wider variation in
passing rates, with the larger targets presenting a challenge, as expected. Such TG-244 datasets
provide a useful stress test for both the dosimeters and the TPS. They expand the availability of
publicly available, standardized commissioning/verification cases, which are more clinically
relevant and in some respects more probative than those from TG-119 .
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6

A TWO DIMENSIONAL DETECTOR ARRAY FOR DOSE VERIFICATIONS OF
SRS TREATMENTS4

6.1

Introduction
Stereotactic radiosurgery (SRS) is a single fraction high dose technique used for the

treatment of multiple small lesions deemed to be surgically inoperable. The small brain lesions
are distributed at large distances with varying sizes. The SRS treatment planning involves the
multiple coplanar and non-coplanar conformal arcs with single or multiple isocenters using
conventional or robotic linear accelerators. Recent developments include the VMAT planning
with single isocenter. The latter is efficient in delivery and has shown a comparable tumor
control [14, 18, 173]. The SRS treatment planning is carried out with small spatial margins
around the small sized PTVs with a purpose to achieve steep dose fall off and spare the healthy
brain tissue. These requirements generate the complex plans having multiple small MLC
apertures distributed over the whole MLC bank and treating single or multiple lesions
simultaneously. The single isocentric VMAT technique adds more complexity with the leaves
dynamically forming the shapes with gantry rotations.

4

This work is submitted in a peer-reviewed journal for publication.
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The pre-treatment QA for the SRS plans faces challenges due to the complex nature of
the plan in terms of the delivery [30, 32]. For the true composite methods, high spatial detector
density is required to measure the small fields and account for the steep dose gradients. These
devices are further required to accommodate the non-coplanar deliveries involved in such
treatments. Recently, small array of liquid filled ion chamber detectors (2.5 mm spatial
resolution) was investigated for the SRS treatment verifications [174]. The independent dose
calculation algorithms offer alternatives with high spatial dose resolution. However, these
methods lack in accounting the delivery issues encountered with the finite leaf motion and gantry
rotation. These methods are also required to pay special attention in beam modeling for the small
fields. The recent developments involve the use of EPIDs for the plan dosimetry [175] or hybrid
methods taking input from both treatment planning system and the machine [176], gel dosimeters
[177] and radiochromic films [178-180].
The aim of this study is to characterize a denser two dimensional diode detector array for
the pre-treatment QA of SRS treatments based on the true composite measurements. The diode
array is SRS MapCHECK (SMC) and developed by Sun Nucealr Corporation. The diode arrays
generally exhibit the dependence on the incident beam direction [43, 46, 181], beam repetition
rate and field size. This study details the parametric as well as clinical investigations of SMC
installed in the StereoPHAN for true composite SRS measurements.
6.2
6.2.1

Methods
SRS MapCHECK and StereoPHAN
SRS MapCHECK (SMC) consists of 1013 point detectors (SunPoint2) arranged

on 7.7× 7.7 cm2 sized two printed circuit boards (PCBs) aligned face to face in such a way that
the active area of all diodes is in the same plane. The detectors on the main board are facing up.
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The diodes on the daughter board are shifted 1.75 mm, relative to a diode on main board, in both
x- and y-axes resulting in an inter-detector spacing of 2.47 mm. Such arrangement produces at
least 5 diodes in a 5 mm core. On the same board, however, the spacing between two detectors is
3.5 mm. The active area of each diode is 0.48 × 0.48 mm 2 with active volume of 0.007 mm3. The
buildup and backscatter to the detectors are provided with 2.2 cm of Poly (methyl methacrylate)
(PMMA). The total length of the device is 320 mm. The device can accommodate the maximum
dose rate of 3400 MU/min accommodating thus the flattening filter free beams at both 6 and 10
MV energies. The SMC is supplied with two additional buildup spacers with thickness of 2 cm
each to install SMC in StereoPHAN.
StereoPHAN is designed for the end-to-end testing of the SRS treatment plan verification
with the SMC. It is a cylindrical PMMA phantom with a hemisphere on its superior end to mimic
the head. The diameter of both cylindrical and hemispherical parts is equal to 15.24 cm with the
total length of 20.87 cm. The phantom has an inner cavity with dimensions of 17.5 × 8.5 ×8.5
cm3. The cavity accommodates the SMC as well as other dosimetric or imaging inserts, including
those for an ion chamber (0.125 cm3 Semiflex, PTW – Freiburg, Germany) and radiochromic
film. The film insert can accommodate 7.5 × 7.5 cm 2 square film pieces. There are five Titanium
fiducials embedded the film insert to assist in aligning the phantom with onboard cone-beam CT
(CBCT), maintaining the film orientation and subsequent registration. The physical depth of the
SMC detector board, ion chamber center and film plane inside the StereoPHAN is 7.62 cm.
Further, the depth from the superior spherical end of the phantom to the geometric center
(isocenter) of the SMC detector array remains the same. When aligned on room lasers, the
assembly (SMC inserted in the StereoPHAN) provides a means of true composite measurements.
For the non-coplanar beams measurements, the couch can be rotated by up to ± 45 0.
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Figure 6.1. (a) SRS MaoCHECK with StereoPHAN, (b) SRS MaoCHECK and, (c) SMC diode array.

6.2.2

Data Collection and Processing Software
SNC Patient software collects and processes the SMC data. This software is modified to

include SMC in addition to the ArcCHECK and MapCHECK devices. The device is connected
with the computer using an 8 – pin cable and SNC Power/Data Interface 3.0.
When properly connected, the software recognizes the device and initiates the
background measurements for 30 seconds. During measurements, the data are continuously
collected and updated each 50ms when above-background radiation can be detected. The
software can process composite as well as beam by beam measurements of the plans with
multiple beams or arcs. The software allows the profile comparison of measured and calculated
dose distributions along with the gamma analysis at user defined criteria.
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6.2.3

Basic Detector Properties

6.2.3.1

General
Two linear accelerators were used for the investigation of basic detector properties. Most

of the parametric tests were performed with 6 MV and 6FFF MV beams from TrueBeam v. 2.5
(Varian Medical Systems, Palo Alto, CA) linear accelerator equipped with standard Millennium
120-leaf MLC. Pinnacle v. 16.0 (Philips Radiation Oncology Systems, Fitchburg, WI) and
Mosaiq R&V systems were used. The calibration verifications for angular, repetition rate and
dose linearity were performed against the 0.125 cm3 Semiflex ion chamber (PTW – Freiburg,
Germany). The ion chamber measurements were acquired in the StereoPHAN. The angular
dependence was further studied against water equivalent, W1 plastic scintillator detector (W1PSD) [83, 182]. The field size dependence and end-to-end measurements were performed on
TrueBeam linear accelerator equipped with HD Millennium 120-leaf MLC. The field size effect
was verified against the W1- PSD.
6.2.3.2

Detector calibration

6.2.3.2.1

Relative array calibration

The relative array calibration (response equalization) accounts for the differences in
relative sensitivity of the diodes. It generally follows the standard wide-field procedure of
sequential irradiations in a conventional (flattened) beam with array shifts and rotations [183,
184]. However the procedure is somewhat different from the previously described original
MapCHECK calibration [43, 44]. Because of the two PCB with detectors facing in opposite
directions, the sequence is repeated with the array facing towards and away from the beam (“AP
and PA” calibrations). This calibration is performed in the manufacturer-supplied PMMA slab
phantom. Also, for the optimal measurement accuracy with FFF beams, two additional
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measurements in the StereoPHAN are required: AP and PA 5×5cm 2 fields. In addition to
response equalization, the measurements in the parallel-opposed fields help with scaling the
angular response function described later.
6.2.3.2.2

Absolute dose calibration

The absolute calibration is applied to the master (central) diode. We prefer to derive the
known calibration dose value from the TPS calculation at the diode location, in an open field, as
this eliminates the theoretical complexities of using an ion chamber calibrated to water in
PMMA[185], as well as minimizes the influence of the phantom material density selection in the
TPS.
6.2.3.3

Detector flip test
The effectiveness of the relative calibration is typically verified by a 180° rotation test.

To that end, two identical exposures in a vertical wide field (10×10 cm 2) were delivered with the
SMC electronics facing either the foot or the head of the couch. Percent dose differences for each
detector between the standard and rotation orientations were recorded.
6.2.3.4

Angular dependence
Angular dependence is a well-known phenomenon for the diode arrays of this type and

must be corrected for in composite-type measurements [46]. The difference in response of
nearby diodes on the two PCBs facing towards or away from the beam is appreciable and
changes as a function of the beam incidence angle. This change serves as the basis for the
incidence angle approximation. The previously measured angular response function, which
should be for the most part relatively smooth, is scaled based on the AP and PA wide-field
calibration measurements. The angular correction efficacy with gantry rotation was verified in
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the transverse (couch at 0°) and sagittal (couch at 90°) planes, as well as for the various
combinations of couch and gantry angles
6.2.3.4.1

Transverse angular dependence

For the transverse plane angular dependence at CAX, the field size was set to 5 × 5 cm2
and the gantry was rotated in the 10˚ increments, which were progressively reduced to 2˚ and 1˚
as the beam direction came closer to the array plane. The SMC response was compared to the ion
chamber for both energies. The same SMC data were also verified against W1-PSD for the
6MVFFF beam.
6.2.3.4.2

Angular dependence in azimuthal plane

For sagittal plane angular dependence at CAX, measurements, the couch was placed at
90˚ and the gantry rotated in 30˚ increments. The incidence angles where the beam could directly
irradiate the electronics were avoided. The SMC results were evaluated against the W1-PSD.
6.2.3.4.3

Couch and gantry angle combinations

For the combined couch and gantry rotations, the couch angular positions were 0, ±10,
±30, ±50, ±70 and ±90°. At each couch position the gantry was rotated in 30˚ intervals. The data
were again compared to the W1-PSD.
6.2.3.4.4

Angular dependence at off-axis detector locations

In addition to the diode at the CAX, four different off-axis locations of the SMC array
were selected for the angular verifications with a range of gantry and couch rotation
combinations. The couch rotation selected, for these investigations were 0 °, 10°, 30°, 50°, 70° and
90°. The selected points were P0(0,0), P1(31.5,21), P2(10.5, 31.5), P3(-10.5,10.5) and P4(21,31.5)/P4(-21,21). The point coordinates are in mm. The P4(-21,31.5) was used for couch at 0 °
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and 10° rotations. For the remaining couch rotations, point P4(-21,21) was used to avoid placing
the detector in the penumbra region. At least 25 measurements were performed with the
combinations of gantry and couch angles at each point. The SMC response was verified against
the W1-PSD placed inside the StereoPHAN at different off-axis positions. The field size was
8×8 cm2. The measurements were performed for both energies.
6.2.3.5

Repetition rate dependence
The accelerator repetition rate (MU/min) dependence was previously reported for various

Sun Nuclear devices [44, 148, 167] and is corrected for in the SMC software. The correction is
applied based on the measured pulse rate during the collection cycle (50 ms). Its efficiency was
investigated for repetition rates ranging from 10 to 600 MU/min for conventional and 400 to1400
MU/min for FFF 6MV beams. Field size was 5 × 5 cm2 and 100 MU were delivered at each
repetition rate. The data were normalized to the ion chamber readings, which in turn showed
negligible collection efficiency difference (by two-voltage technique) across the range of
repetition rates.

The SMC readings were processed with and without the repetition rate

correction applied.
6.2.3.6

Field size dependence
Diode sensitivity dependence on field size is also a well-known phenomenon that needs

to be accounted for to obtain accurate dosimetric results. The diodes are known to deviate from
water-equivalent detectors for large [186] and very small [187] field sizes. While the former is of
little concern in the context of SRS, the latter is important. The SMC software estimates the
equivalent field size based on the number of diodes registering above-the-background signal and
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applies an energy-specific correction factor measured with radiochromic film for the field sizes
down to 5×5 mm2.
This correction scheme was verified against the W1-PSD detector for square MLCdefined fields ranging from 5 to 40 mm on a side. The scintillator was inserted in a specially
designed rectangular solid water phantom and centered in the radiation field such that its long
axis was parallel to the beam central axis (e.g. 1 mm detector cross-section). The buildup
thickness was chosen so that the effective point of measurement (the middle of the 3 mm length)
was at the same water-equivalent depth as the central SMC diode in StereoPHAN. The SMC was
also used outside of the StereoPHAN, while maintaining the same water-equivalent buildup and
backscatter. The angular corrections were disabled in the control software. For the very small
fields the system cannot determine the beam incidence angle and reverts to the average
correction, which would have distorted these measurements. The data were processed with and
without the field size correction, to demonstrate its magnitude.
6.2.3.7

Cross-beam profiles
The measurements were performed at selected diode locations along the IEC X x-axis of

the SMC device for both energies. The verifications were done against the W1- PSD. The
measurements were performed at the locations having coordinates (0,0), (±10.5, 0), (±21, 0),
and (±31.5, 0) for the field sizes 3 × 3 cm2, 5 × 5 cm2 , 8 × 8 cm2 and 10 × 10 cm2. The SMC
data were processed with all corrections applied.
6.2.4

Clinical Applications (SRS Plan Dosimetry)
The device is intended to be used for the pre-treatment true composite SRS

measurements. The clinical tests involved the dosimetric comparison of SMC measurements
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(with StereoPHAN) against radiochromic film for three SRS treatment plans at each energy. The
dosimetric comparison included the gamma and target peak dose analyses.
6.2.4.1

CT simulation
The StereoPHAN and SMC assembly was scanned on a 16 – slice Big Bore scanner

(Philips Medical, Cleveland, OH) according to our standard SRS protocol (sequential scans with
1.25 mm slice thickness). Four CT datasets were acquired with phantom installed with SMC in
coronal orientation, the film insert placed at coronal and sagittal orientations and lastly the ion
chamber (PTW Semiflex, 0.125 cc) insert placed at the center of the phantom.
6.2.4.2

Treatment planning
The device is intended to be used for the pre-treatment true composite (e.g. with planned

gantry and table angles) SRS measurements. The tests involved the dosimetric comparison of
the SMC measurements against the radiochromic film for three SRS treatment plans for each
energy. The StereoPHAN was scanned on a 16-slice CT scanner (Philips Medical, Cleveland,
OH) according to our standard SRS protocol (sequential scans with 1.25 mm slice thickness).
Four CT datasets were acquired with different inserts to facilitate accurate placement with onboard kilovoltage imaging.
Treatment plans were developed using Pinnacle v. 16.0 (Philips Radiation Oncology
Systems, Fitchburg, WI). The isocenter was placed based on the phantom marks and film
fiducials visible on the CT scans. Three multiple-target plans were created, each with three
spherical targets bisected by the coronal plane and situated within the active area of the array.
Each plan had targets of different sizes placed at the different locations. The target diameters
ranged from 0.5 to 1.3 cm. An example is shown in Figure 6.2 (a) highlighting the arrangement
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of the targets around the isocenter. Figure 6.2 (b) shows the targets in the same plane with the
film image fused with the SMC array image. The plans were optimized without the OAR
constraints for both energies (6 MV and 6FFF MV) using single isocenter VMAT technique. The
details of the plans and targets are given in Table 6.1. In addition to the three targets, a 2 cm
diameter spherical structure was drawn at the isocenter and was included in the optimization to
achieve a low gradient 18 Gy dose region across the 0.125 cc chamber. This allowed us to more
accurately convert film density to dose by applying an ion chamber-derived scaling factor in
addition to the calibration curve.

Figure 6.2. The arrangement of spherical targets(a) on the SMC array, and (b) on the film insert. The insert shows a
SMC array image fused with the film image showing the fiducials.
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The VMAT optimization employed two full coplanar and two partial (130˚ or 90˚) noncoplanar arcs with couch angles from ±20° to ±40° detailed in Table 6.1. Each target was
planned to receive 24 Gy. All plans were calculated with 2˚ control point increment and a 2 mm
isotropic dose grid resolution using adaptive convolve algorithm.
Table 6.1. Description of plans with target arrangements.
Plan

6.2.4.3

1

Target max.
dimensions (cm)
1.0, 1.3, 0.5

Target
Distance
isocenter (cm)
2.7, 3.0, 3.3

from

Max field size,
X × Y (cm2)
7.5 × 8.0

Couch
Angles
±300

2

0.7, 1.0, 1.2

3.2, 2.8, 3.1

8.2 × 7.8

±200

3

0.6, 1.0, 0.8

2.5, 2.4, 3.0

7.1 × 7.3

±400

Delivery of the Plans
All plans were delivered on a TrueBeam accelerator with a HD Millennium MLC and a

six-degrees-of-freedom (6DOF) couch. Each plan was delivered to the StereoPHAN three times
with different detectors in place: the Semiflex ion chamber at the center, the SMC, and the film,
with the latter two in the coronal plane. Before each measurement, the phantom was first leveled
with a digital level and then aligned in three dimensions by cone-beam CT with the help of the
6DOF couch.
6.2.4.3.1

Plan measurements on SMC

All six plans were delivered on the phantom with SMC in coronal orientation. The
measurements were collected in composite mode (all arcs) and processed by applying all
corrections. The measurements were saved in text and movie formats (.smcm) for the later use
and analysis. The manufacturer provided a tool to convert the dose file from text format to the
SunCOM file format to be used in the RIT for comparison against film.
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6.2.4.3.2

Ion chamber measurements

A small volume ion chamber (Semiflex 0.125 cm 3) was used to measure point dose at
isocenter in a uniform dose region (at the center of the 2 cm spherical structure). Before the plan
measurements, the ion chamber in the StereoPHAN was cross-calibrated against the TPS
calculated dose in a parallel-opposed pair of 10 × 10 cm 2 fields.
6.2.4.3.3

Film measurements

Extended range Gafchromic film (EBT – XD, Ashland Inc., Bridgewater, NJ) was used
for the dosimetry of SRS plans. The EBT-XD film has an optimum dose range of 0.4-40 Gy and
has no significant dependence on energy, dose rate [85] and scanning orientation [84, 86].
Absolute dose calibration was performed in a solid water slab phantom (30 × 30 × 21.5
cm2) using 6 MV beam from linear accelerator. Small film pieces cut to 1.25 × 2 in 2 were placed
at the depth of maximum dose (1.5 cm). The phantom was set up at 100 cm SSD and 10 × 10
cm2 field defined on its surface. Backscatter was provided by 20 cm thick slabs. The films were
irradiated with dose levels ranging 2-40 Gy.
For the measurements of the plans, 7.5 × 7.5 cm2 film pieces were prepared and preirradiation background scanning was performed. Opaque templates sized to fit the calibration or
measurement films were used to reproduce the film positions during scanning. The films were
scanned using 48 bit color flatbed document scanner (Expression 11000 XL, Epson Seiko
Corporation, Nagano, Japan) after 24 h of the exposure, in transmission mode and without
applying any color correction. The pixel resolution was 72 dpi (0.35 mm/pixel). Both calibration
and measurement films cuts were scanned in the same orientation with respect to the original
sheet they came from.
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Film processing followed a meticulous protocol paramount for accurate dosimetry [42,
87, 179]. Film were handled with gloves to avoid moisture and fingerprints, and were stored in
light-tight envelopes to avoid unnecessary exposure to the environment. The films were stored
well below the temperature limit.
6.2.4.3.4

Film processing

Red channel dosimetry was performed using RIT software v. 6.6 (Radiological Imaging
Technologies, Cololrado Springs, CO). The individual background correction map, followed by
the calibration curve were applied to each film. The absolute dose was further scaled to match
the ion chamber dose at the isocenter. For scaling purposes, the film dose was averaged over 18
central pixels (~ 6.5 mm) in the craniocaudal direction, approximately equivalent to the length of
the ion chamber active volume. The calibrated film images were saved for analysis.
6.2.4.4

Dose comparison
The corresponding planar dose distributions from SMC and film were imported into RIT

as a reference and target dose images, respectively. A template based registration was performed
based on the fiducials’ imprints on the film. The SMC and film measured doses were compared
using three techniques. First, the gamma analysis was performed with multiple criteria (3%/1mm,
3%/2mm, 2%/1mm and 2%/2mm) with global dose error normalization and low dose threshold
set at 10% of maximum dose. Second, the dose-difference comparison was performed between
the film and SMC measurements in the peak-dose/low gradient region near the center of each
target. The dose was averaged over 5 pixels (1.75 mm). Finally, the spatial alignment of the
SMC and film measured dose profiles was evaluated for each target. The in-plane and crossplane (IEC Y and X) profiles were sampled through the center of each target on every film. The
profile center was defined as the middle of the full width at half-maximum interval. For a few
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cases, the targets were too close to each other precluding the centering at the 50% dose levels,
and they were aligned based on the 60% level. In total 14 cross-plane and 18 in-plane profiles
were examined.
6.3

Results

6.3.1

Detector “Flip Test”
For the wide field irradiation, the average percent dose errors between the normal and

flipped SMC response for all diodes was 0.01% ± 0.1% (range -0.31% to 0.4%) and -0.01% ±
0.17% (range -0.93% to 0.91%) for 6 MV and 6FFF MV beams respectively.
6.3.2
6.3.2.1

Angular Response
Transverse angular response
Figure 6.3 shows the percent deviations of SMC response (corrected and uncorrected)

dependence on transverse gantry angle in comparison to the ion chamber. The graphs shows the
agreement between SMC corrected response and IC within 2% for all gantry angles until the
beam incidence direction approaches the detector plane (±90˚ ± 5˚) where the deviations of up to
-9% were encountered for both energies (Figure 6.3 (b & c)). The overall average percent
differences for the corrected response were -1.13%±2.3% (1SD) and -1.21%±3% (1SD) for 6MV
and 6MVFFF respectively. If all gantry angles within ±5˚ of the detector plane were excluded
then the average response would be 0.01%±0.6% (1SD) and 0.2%±0.7% (1SD) for 6MV and
6MVFFF, respectively. The uncorrected response naturally shows larger deviations for a range
of gantry angles (red lines in Figure 6.3a). The experiment was also performed against
scintillator detector for one energy (6FFF) resulting in the response similar to the SMC response
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versus the ion chamber. The chamber and the scintillator thus could be used interchangeably in
the context of these measurements.

Figure 6.3. The angular response of the SMC against the gantry angles in the axial plane; (a) The percent errors from
the IC for the un-corrected and corrected SMC response for the whole sampling; (b) percent errors for the gantry
close to the detector plane in clock wise rotation for 6 X beam energy; (c) percent errors for the gantry close to the
detector plane in counter-clock wise rotation.

6.3.2.2

Azimuthal angular response
The azimuthal response characteristics are presented in Figure 6.4. The device shows an

excellent agreement within 1% for both energies against scintillator detector. The average errors
were 0.00%±0.7% and -0.1%±0.5% for 6MV and 6MVFFF respectively.

123

Figure 6.4: SMC response in azimuthal plane for both energies. The insert sketch represents the solid angle from (60
– 120) degrees for which the measurements were not performed.

6.3.2.3

Angular response with gantry and couch rotation combinations for diode at
central and off-axis locations
The angular dependence of SMC was investigated for a range of combinations of gantry

and couch angles. Figure 6.5 shows the heat map of percent errors for uncorrected and corrected
central diode response against PSD for 6 MV. The uncorrected measurement data show
deviations as large as 8% at either large gantry angles and/or couch angles. The corrected
response however, agrees with the W1 scintillator detector within -1% for all gantry and couch
angles except for gantry at ±90˚ where the device was found under-responding (~3%). A similar
behavior was observed for the 6FFF energy.
Figure 6.6 shows the corrected response of the SMC off-axis diodes against PSD. The
upper row shows the percent error heat map for the 6 MV and lower row shows the data for 6
MVFFF energies respectively. The data is presented for all the sampled points.
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Table 6.2 lists the descriptive statistics for the percent errors of both investigations (diode
at CAX and off-axis locations) for both energies. The data showed an agreement within or close
to 2% for almost all of the sampled points.

Figure 6.5. SMC response against scintillator detector at different combinations of gantry and couch orientations at 6
MV.
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Figure 6.6. Percent errors for SMC off – axis diodes angular response against W1. Upper row shows the data for 6
MV and lower row shows the data for 6FFF MV beams. The vertical axis presents the gantry angle and horizontal
axis describes the couch angle.
Table 6.2. Descriptive statistics of percent dose errors of diode located at central axis and off-axis locations versus
W1 scintillator detector for all combinations of gantry and couch rotations. The data presented is for the corrected
diode response.
Central diode (whole data)
Minimum

6X

6FFF

6X

6FFF

-3.45%

-1.77%

-2.10%

-1.60%

Maximum

1.22%

0.96%

1.60%

2.06%

Mean

-0.42%

-0.27%

-0.0003%

-0.12%

SD

0.96%

0.57%

0.60%

0.54%

-0.62% to -0.23%

-0.39% to -0.15%

-0.11%to0.11%

-0.22% to -0.03%

95%CI

6.3.3

Off-Axis diodes (whole data)

Repetition Rate Dependence
The dose rate dependence is presented in Figure 6.7. The open and filled symbols present

the uncorrected and corrected SMC relative sensitivity normalized to the IC at a common
repetition rate of 400 MU/min. For 6 MV the corrected SMC values varies from 0.975 at 10

126

MU/min to 1.003 at 600 MU/min for 6 MV. For 6MVFFF, the relative sensitivity normalized to
IC remains very close to 1 (max. deviation of -0.4% at 1000 MU/min).

Figure 6.7. Dose rate dependence of corrected and uncorrected SMC response against ion chamber for both energies

6.3.4

Field Size Dependence
Figure 6.8 presents the output factors (OF) of SMC diode at CAX against the scintillator

detector for all investigated MLC apertures (0.5 – 4) cm. The response was normalized over the
4 cm field size. The uncorrected SMC OFs shows deviations (SMC – W1)% as large as 10.2%
at 0.5 cm aperture for 6 MV which reduced to 3.2% after the SMC response was corrected. For 6
MVFFF beam, it reduced from 8.1% to 1.3% for the same field size (0.5cm). The corresponding
range of the percent errors were -0.9% to 3.2% and -1.7% to 1.3% for 6 MV and 6 MVFFF
respectively. The largest deviations of the corrected SMC OFs for 6MVFFF were found at 1 cm
field (-1.7%). Similar results were obtained when SMC was flipped (daughter board’s diodes
facing up). The largest percent errors of (2.4% range: -1.3% to 2.4%) were noticed again for 5
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mm MLC aperture for 6 MV, and (-2.4% range: -2.4% to 0.6%) for 1 cm aperture for 6 MVFFF
respectively.

Figure 6.8. Dependence of field size on SMC response. (a) 6MV and (b) 6FFF MV.

6.3.5

Cross-Beam Profiles
The cross profiles are presented in Figure 6.9 (a&b) for both energies. An excellent

agreement between the fully corrected SMC response and the scintillator detector (W1) was
observed for both energies. For the whole data, the percent errors did not exceed 1% for all field
sizes.
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Figure 6.9. Cross profiles for SMC versus the W1 scintillator detector.

6.3.6
6.3.6.1

Clinical Applications
Plan comparison and gamma analysis
Table 6.3 shows the results of the gamma passing rates for SMC against film

measurements. Figure 6.10 shows the gamma maps obtained with the stringent criteria of
3%/1mm (global normalization with 10% low dose threshold) and the isodose overlay for two
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different plans. Figure 6.10 (a & b) shows the plan 6X_P1 with passing rate of 97.57% while
Figure 6.10 (c&d) details the 6X_P3 plan with passing rate of 99.82%. The pixels failing the
gamma are shown in red.
Table 6.3. Results for gamma analysis for SMC vs. film measurements.
Passing rates (%) for SMC vs. Film
Plan
3%G/1mm 3%G/2mm
2%G/1mm 2%G/2mm
6X_P1
97.57
99
95.88
98.07
6X_P2
97.98
99.08
95.5
97.98
6X_P3
99.82
99.89
98.57
99.47
6XFFF_P1
99.51
100
97.5
99.21
6XFFF_P2
99.12
99.47
97.08
98.66
6XFFF_P3
99.58
99.82
98.51
99.64
Average
98.93
99.54
97.17
98.84
S.D
0.93
0.43
1.29
0.71
95%CI 97.95-99.91
99.09-99.99
95.82-98.53 98.09-99.59
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Figure 6.10. Gamma maps and isodose overlay SMC measured vs. film at 3%/1mm criteria for the plans generated
at 6 MV. (a&b): 6X_P1 and (c&d): 6X_P3.

6.3.6.2

Peak dose comparison and geometric accuracy
The peak target dose comparison was performed between the SMC and film

measurements for every target. The profiles were extracted from the center of each target and
dose was sampled by taking the average of 5 pixels (1.75 mm). Most of the SMC peak target
doses were found within 2% of the film measurements. The overall average percent dose error
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was -1.06%±1.82% (Range: -4.2% to 2.7%) with 95% CI of -1.97% to -0.15%. The peak dose
data passed the D'Agostino & Pearson normality test (p-value 0.829). The differences in the
centroids of the SMC and film profiles for all of the investigated targets were found below 1 mm.
The data for the percent peak dose differences and the difference in the locations of the profiles
are listed in Table 6.4.
Figure 6.11 presents the example profile overlays (vertical) of two small targets: 0.6 cm
(a) and 1.2 cm (b). The dotted red line shows the profile for the film whereas the SMC profile is
given in green solid line. An example of the best- and worst-case agreement is presented.
Table 6.4. Descriptive statistics of the percent dose differences and the difference in profile centroid locations for
small targets.
%ΔD
No of Targets
Minimum
Mean
S.D
Maximum
95%CI

18
-4.2
-1.06
1.82
2.7
-1.97% to -0.15%

Difference in the centroids (SMC-Film) mm
Horizontal Profile
Vertical Profile
14
-0.46
0.06
0.26
0.39
-0.09 to 0.21

18
-0.16
0.014
0.12
0.24
-0.04 to 0.07

Figure 6.11. Profile comparison through the centers of the targets between the SMC and film measured dose for two
targets; (a) the vertical profile of P3_6X 0.6 cm target (T1) and (b) the vertical profile of P2_6X 1.2 cm target (T3).
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6.4

Discussion
Overall, the basic characterization tests indicated that the device performed within

specifications and with sufficient accuracy. The 180° array rotation test resulted in an average
error close to 0%, demonstrating successful diode response equalization. The repetition rate
correction brings the response variation with MU/min to less than 1% at worst, in the range
relevant to radiosurgery. In the study of the field size dependence, the SMC readings tend to
over-respond, compared to the scintillator, for the smallest measured field (5mm) and underrespond between 10-40 mm. Overall, the agreement is reasonable. With the exception of the 5
mm field at 6MV (3.2% error) the difference from the scintillator is within 2.4% or better.
Results with opposite beam orientations with respect to diodes are within 0.8 percentage points
from each other. The corrected axial angular response did not deviate from the two isotropic
dosimeters by more than 2% for the wide range of gantry angles, except for the narrow angular
intervals when the beam direction is (nearly) parallel to the array plane. This is typical for all
arrays and has relatively small effect on the composite measurements [46, 188]. The purely
azimuthal dependence did not exceed 1%. To conclude the open filed measurements, for a large
number of combinations of gantry and couch rotations the mean deviation from a small waterequivalent detector did not exceed 0.4%, with the 95% confidence interval within 0.6% of zero at
worst.
During the end-to-end testing with multiple-target single-isocenter noncoplanar VMAT plans,
fairly high gamma-analysis passing rates between the SMC and radiochromic film dose
distributions were observed with both 3%/1mm and 2%/1mm criteria combinations, particularly
taking into account the gafchromic film accuracy estimated at 2-3%. For the intended
applications of the array it was important to keep the distance to agreement criteria low, at 1 mm.
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The peak (target) dose-error distribution cannot be statistically distinguished from normal.
However, there appears to be a small bias of the mean, with SMC under-responding by 1.1±1.8%
(1SD). The precise cause of this bias was not ascertained, but we noticed that both the field size
dependence and angular dependence at near-parallel incidence errors in most cases have the
same sign. Finally, of paramount importance in SRS, the film and SMC peak dose profiles show
submillimeter distance to agreement for every target in every plan. This is consistent with the
notion that a grid of point detectors with 2.5 mm spacing is sufficient, in terms of Nyquist
sampling, to faithfully represent dose gradients encountered in megavoltage radiotherapy [189,
190].
In terms of the array’s utility for clinical SRS dosimetry, it can be characterized as a
sufficiently accurate and convenient tool for commissioning an SRS beam, including
simultaneous multi-target treatments. During the commissioning, the artificial targets can be
fairly easily moved around to coincide with the active area. Patient-specific end-to-end testing
recommended for SRS treatments[191] can be logistically more challenging for single-isocenter
multiple-target plans. To sample all the targets, multiple measurements at different array angular
orientations might be necessary. In addition, some targets could be farther away from the
isocenter than the extent of the active area. Finally, some beam directions such as vertex cannot
be sampled due to direct irradiation of the device electronics. As an alternative,
supplementing/replacing direct measurements with semi-empirical 3D dose reconstruction could
be considered for such cases.[192].
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6.5

Conclusions

The SRS MapCHECK diode array in the StereoPHAN phantom has sufficient dosimetric
accuracy and spatial resolution to be a useful tool for SRS commissioning and quality assurance,
including single-isocenter multiple-met modulated plans. The limitations of the device for some
cases might be the size of the active area and inability to sample certain beams at their planned
angles. A hybrid technique allowing to overcome some of the limitations is discussed in the next
chapter.
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7

A HYBRID VOLUMETRIC DOSE VERIFICATION METHOD FOR SINGLEISOCENTER MULTIPLE-TARGET CRANIAL SRS5

7.1

Introduction
This chapter is devoted to the PSQA method based on a hybrid or semi-empirical

technique. It is considered hybrid as it combines data from the TPS with some measurements
performed during pre-treatment delivery, to reconstruct volumetric dose in patient dataset.
Although the method can be applied to any treatment, in this study it was validated for singleisocenter VMAT based SRS treatments of multiple small brain tumors.
Brain metastases are a common oncological diagnosis [12] and intracranial stereotactic
radiosurgery (SRS) has evolved as an important modality of treatment/palliation for that disease
[11, 193]. It was demonstrated that even with multiple metastases the SRS treatment could
provide reasonable local control [194, 195], and a multiinstitutional observational study
suggested that clinical outcomes for patients with 5 to 10 individual metastases treated by SRS
alone may be non-inferior to those with 2 to 4 targets [196, 197]. While conceptually
straightforward in principle, multi-target SRS poses logistical challenges. As the number of

5
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treated metastases increases, the traditional SRS paradigm of one isocenter per lesion leads to
prohibitively long treatment times and had to be revisited with the goal of simultaneously
treating multiple targets. Interestingly, while dynamic conformal arcs were the mainstay of
LINAC-based radiosurgery for years, the feasibility of single-isocenter multiple-target (SIMT)
approach was first demonstrated with a relatively new volumetric modulated arc therapy
(VMAT) technique [18, 19]. The most recent commercial implementation (HyperArc, Varian
Medical Systems) offers refinements in terms of planning automation and collision prevention
[198]. Alternatively, Huang et al. [199]

proposed a concept of single isocenter dynamic

conformal arcs (SIDCA), whereby each lesion is treated by a dedicated group of dynamic
conformal arcs but all groups share the same isocenter positioned between all targets. This
allows for more efficient dynamic arc treatment, as only one isocenter setup is necessary, and the
couch angles and arc directions can be optimized for fastest delivery. A version of SIDCA is
commercially implemented in Automatic Brain Metastases Planning Element software by
BrainLab [200, 201]. It creates a series of dynamic arcs and each lesion can be covered by all or
some of them, depending on the relative position, to minimize normal tissue irradiation. Both
techniques by necessity produce treatment plans containing complex MLC apertures, and it is
prudent to perform patient-specific end-to-end test prior to commencing the treatment [32]. The
number of small, off-center targets poses a unique challenge to dosimetry devices commonly
used for such tests. The approach should possess high spatial resolution as the lesions could be of
the order of 1 cm or less in size. At the same time, the targets could be fairly wide spread, which
negates the advantages of dedicated “stereotactic” detector arrays with small detector pitch, that
typically have a relatively small active area under the assumption that the lesion would be
located at isocenter [202]. Moreover, the targets randomly placed in three dimensions naturally
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call for a 3D verification approach. The only true 3D dosimeters with high spatial resolution are
radiochromic gels/polymers [203, 204], one of which was successfully used for VMAT-based
SIMT validation [177]. However volumetric radiochromic dosimetry is sufficiently cumbersome
at this point to prevent its use for routine patient-specific quality assurance [23]. Therefore, a
more practical method is needed that combines some high spatial resolution measurements with
3D dose reconstruction over a volume of an adult head. One such approach, which we validate in
this study, is a hybrid technique whereby information collected from the accelerator electronic
portal imaging device (EPID) and delivery log files is supplied as input to the independent dose
calculation algorithm that reconstructs the expected deliverable dose distribution on the patient
CT dataset [69].
7.2
7.2.1

Methods
System Description
The method evaluated in this study is a part of PerFRACTION (PF) software suite (Sun

Nuclear Corp, Melbourne, FL) that provides a number of options for pre- and on-treatment
patient-specific dosimetric analysis.

We focused on the pre-treatment patient-specific QA

(called Fraction 0) and chose the input configuration that, in our opinion, provided the most
advantageous balance between the empirical and calculation portions of the analysis. The
software runs on a central dedicated Windows server and all routine user interactions occur
through a web browser-based interface. At the heart of the method is the graphics processing
unit-accelerated superposition/convolution dose calculation algorithm described and validated
previously [129, 205]. The beam model can be customized by the vendor to fit the user’s data,
although a generic model for the accelerator class configuration proved sufficient in this work.
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The system is compatible with contemporary Varian and Elekta LINACs. The
verification process starts with transferring the patient CT and finalized Plan, Structure, and
Dose DICOM RT objects from the treatment planning system to PF. This establishes a new
patient/plan in the system. The same plan is transferred to the record-and-verify (R&V) system
and is then delivered to the EPID operating in a cine mode. The compressed (MPEG) EPID
movies, one per beam, are stored after the delivery in a specified network directory that is
monitored by PF, automatically transferred to the PF server, and associated with the individual
beam(s) found in the RT Plan object. The accelerator log files are processed in the exact same
fashion. The EPID image frames are then synchronized to the log files in order to determine the
exact duration of time when each EPID frame was acquired. This is achieved by first creating a
series of predicted images based on the projection of the RT Plan fluence to the plane of the
EPID. The predicted images of every segment (or multitude of segments) are then compared to
the measured frames to find the maximum similarity. The measured frame with maximum
similarity is considered to be acquired during the same segments as the best matching predicted
image.
With the synchronization process completed, the frames are then analyzed to determine
the location of each MLC during that time period. An edge detection algorithm is used to find the
MLC edges on EPID frames. From this information, an internal RT Plan is devised, with the
control points (CP) created by amalgamation of the EPID movies and log files. Specifically, the
time-resolved multi-leaf collimator (MLC) apertures are derived from the EPID files,
independent of the accelerator logs. The positions of the rest of the accelerator axes per CP
(fractional monitor units (MU), gantry angle, etc.) are determined from the delivery log files. In
addition to MLC positions, if radiation is detected on regions of the EPID which were supposed
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to be covered by the jaws, corrected jaw positions are incorporated into the internal RT Plan so
that such unexpected radiation is properly accounted for in the final dose calculation. With CP
point information thus complete, the dose calculation is triggered. The PF calculation voxel size
is the larger of the TPS or the minimum set in PF, which was 2.5 mm in this work. This voxel
size was set to obtain a reasonable compromise between the calculation speed and accuracy and
the dose distribution is not distinguishable from the one calculated with a 2 mm voxel [32] at the
1% dose-difference/1 mm distance to agreement level. The resulting semi-empirical dose
distribution can be compared to the planned one by standard gamma analysis [80] and dosevolume histogram evaluation.
7.2.2
7.2.2.1

Planning and Delivery
The phantom
A MultiPlug (Sun Nuclear) phantom is a 15.1 cm diameter Poly (methyl methacrylate)

(PMMA) cylinder, further encased in a PMMA shell with 26.6 cm outer diameter (Figure 7.1).
The phantom has interchangeable inserts to accommodate either an ion chamber (in this case,
0.06 cm3 A1SL, Standard Imaging, Middleton, WI) or a 13.2 x 16.5 cm2 piece of radiochromic
film. The film insert has small sharp points at five locations to imprint fiducial marks on the film.
Those were augmented by small amounts of Barium paste to provide high-contrast but lowartifact fiducials for eventual cone-beam CT (CBCT) alignment on a linear accelerator. The plug
with the film insert can be freely rotated in the shell around the cylinder axis. The phantom was
scanned on a 16-slice Big Bore scanner (Philips Medical, Cleveland, OH) according to our
standard SRS protocol (sequential scans with 1.25 mm slice thickness), with four different film
plane orientations: coronal, sagittal, and

±45º obliques. The plane angular positions were
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established directly with a digital level. These scans served as the baseline datasets for CBCT
alignment of the phantom with the film holder in different orientations.
7.2.2.2

Treatment planning
The datasets were transferred to the TPS (Pinnacle v. 14.0) and the isocenter was placed

based on the known locations of the film fiducials visible on CT scans. The next step was
devising regions of interest (ROI) for planning. Six plans of two types were created. The first
three plans in Table 7.1 contain only three spherical target ROIs each, with the goal of creating
conformal plans without additional constraints. Each target is intersected in the middle by at least
one film plane. Plans 4-6 are rooted in real patient datasets. The patient RT Structure DICOM
objects were processed to make transfer to the phantom CT possible. The organs-at-risk (OAR)
had to be moved some to ensure that they were positioned within the cylinder. The targets were
also nudged to intersect with at least one film plane each. An example arrangement can be seen
in Figure 7.1A, which shows the targets (red) above, below, and intersecting the coronal plane.
Two to four planes were measured per plan. Overall, 17 films intersecting 27 targets were
analyzed. In addition to those, each plan contained a 2 cm diameter spherical structure (green in
Figure 7.1A) drawn at the isocenter and planned to achieve uniform 18 Gy dose for
normalization purposes.
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Table 7.1. The plans, target sizes and positions, and film plane orientations. The maximum filed sizes (jaws) for
each plan are also presented.
Plan

No. of
Targets

Targets max
dimensions, cm

Target center
distance from
isocenter, cm

Max. field
size (X × Y),
cm2

Measurement planes
orientation

1

3

1.3, 1.2, 2.1

3.6, 5.0, 5.5

10.1 × 12.0

Cor.,Obl.45º,Obl.135º

2

3

1.1, 1.2, 2.4

5.8, 5.9, 6.2

12.7 × 15.0

Cor.,Sag.,Obl.135º

3

3

1.3, 1.2, 2.9

5.5, 4.5, 4.7

11.1 × 13.0

Obl.45º,Obl.135º

4

3

2.2, 1.1, 0.8

4.3, 3.6, 5.4

11.3 × 10.5

Obl.45º,Obl.135º

5

5

2.2, 1.1, 0.8, 3.6, 2.3

4.3, 3.6, 5.4, 4.7, 4.0

10.9 × 12.5

Cor.,Obl.45º,Ob1.135º

6

10

2.2, 1.1, 0.8, 3.6, 2.3,
1.4, 1.4, 0.9, 1.2, 1.1

4.3, 3.6, 5.4, 4.7,
4.0, 4.0, 5.1, 6.3,
3.4, 6.3

12.2 × 12.5

Cor.,Sag.,Obl.45º,
Obl.135º

Figure 7.1. A CT-based coronal plane cut through the center of the assembled phantom. The inner cylinder, the outer
shell and the film rectangle in the middle (coronal orientation) can all be appreciated. An example of ROI
arrangement is presented, with multiple targets (red), normal structures (blue) and a central 2 cm target sphere
(green) for ion chamber normalization, the latter common to all plans. B: A photograph of the Multi-Plug with the
partially inserted film holder and ion chamber. Note that for the actual measurements the ion chamber insert
replaced film at the isocenter.

VMAT optimization employed two full coplanar and two partial (164º rotation) noncoplanar (± 25º table rotation) arcs. The flat caudal edge of the phantom precluded the use of
vertex beams common in SRS, which however should not affect the generality of the tests. All
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plans used a 6 MV flattening filter free beam with the maximum repetition rate of 1400 MU/min
and were calculated with 2º CP increment and a 2 mm isotropic dose grid resolution. The
prescriptions followed RTOG 0320 protocol [206], depending on the target size: 24 Gy to the
planning target volume (PTV) < 2 cm, 18 Gy to the PTV between 2.1-3 cm, and 15 Gy to the
3.1- 4 cm PTV. Plans 4-6 also employed common OAR objectives from the same protocol.
7.2.2.3

Beam delivery
All experiments were performed on a TrueBeam v.2.5 linear accelerator (Varian Medical

Systems, Palo Alto, CA) equipped with a standard 120-leaf Millennium MLC, a 6 degree of
freedom (6DOF) couch, and an aS1000 EPID. The EPID pixel size is 0.39 mm, which translates
into 0.26 mm effective size at isocenter when the EPID is positioned 150 cm from the source.
Prior to measurements the alignment of mechanical, MV, and kV isocenters of the accelerator
were verified by two methods. First, the built-in IsoCal verification routine [207] was employed.
It demonstrated the maximum MV isocenter deviation of 0.42 mm (with no couch rotation) and
negligible translational and angular misalignment of the kV and MV imagers. Second, an
independent MLC-based Winston-Lutz test with 12 angular combinations covering the full range
of accelerator motions confirmed the maximum treatment isocenter deviation of 0.41 mm.
The plan information was transferred to the accelerator through Mosaiq v. 2.4 (Elekta
Impac, Sunnyvale, CA) R&V system. Before delivery, the phantom was first leveled and then
aligned in 3D by CBCT to the film fiducials in the desired plane orientation with the help of the
6DOF couch.
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7.2.3

Dose Comparison
The core of this work is dosimetric comparisons between PF reconstructed dose and film

measurements. The strategy was to convert the relative dose measured by calibrated film to
absolute by normalization to the ion chamber dose at isocenter. To that end, the ion chamber
reading in the MultiPlug phantom was collected under the standard conditions (parallel-opposed
horizontal 10×10 cm2 fields) and converted to dose by comparison with Pinnacle point dose in
the same geometry. Subsequently, an ion chamber measurement was performed for each plan
and the resulting dose at isocenter was used to scale dose for the films belonging to that plan.
7.2.4

Film Measurements
Film handling, calibration, and scanning did not differ from the methods described in the

previous chapter. The film fiducials marks were aligned to the pre-defined geometric template,
and the dose after application of the calibration curve was further scaled to match the ion
chamber dose at the isocenter. The film dose was averaged for scaling over 13 central pixels in
the craniocaudal direction, corresponding approximately to the chamber active volume length.
There is no direct interface for importing dose in arbitrary plane from PF to RIT. Instead,
volumetric dose was exported from PF as a DICOM RT Dose file and then imported to Pinnacle
using a custom script. After that, planar doses in required orientations could be extracted from
Pinnacle on a 1 mm grid using the built-in IMRT QA tool and imported into RIT. Three types of
tests were performed using RIT. First, an overall dose comparison was done using gamma
analysis with 3% (global dose-difference normalization), 1mm distance to agreement, and 10%
low dose cutoff threshold criteria. The RIT digital gamma analysis routine modeled after
Depuydt et al [89] was used. For completeness, the same analysis was performed for Pinnacle.
Second, the point doses in the low-gradient region near the center of each target were extracted
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from the film dose profiles (averaged over 3 pixels, or about 1 mm) and compared to PF. The
distribution of dose-differences was tested for normality by D'Agostino & Pearson test
implemented in GraphPad Prism statistical package (v. 7.0, GraphPad Software, La Jolla, CA).
Finally, paramount to radiosurgical applications, the alignment of measured and reconstructed
profiles at the 50% level (dose centroid) was evaluated. Horizontal and vertical profiles were
drawn in RIT through the center of each target on every film image. The vertical profile always
corresponded to the craniocaudal direction. The horizontal profile anatomical direction varied
with film orientation, anywhere from anteroposterior to lateral, and the results were segregated
accordingly. The metric was, in most cases, the difference in the coordinates of the mid-points
between the 50% level dose profile points. In a few instances where the targets were too close to
each other to produce clearly isolated dose peaks on the film, the 65% profile points were used to
calculate the dose centroid.
7.3
7.3.1

Results
Gamma Analysis
The gamma analysis results (3%G/1mm) are detailed in Table 7.2. Excellent agreement is

observed for PF, with the lowest passing rate of 96.1%. Pinnacle results are also solid, although
for two films the passing rate slipped just below 90%. The 95% confidence intervals were 98.799.8% for PF and 95.2-98.4% for Pinnacle, indicating that both systems can be considered in
agreement with experiment by current standards [205]. It is therefore not surprising that
volumetric gamma analysis comparison between the two algorithms demonstrated 100%
agreement for all plans at the 3%/1mm level.
Figure 7.2 illustrates the patterns of gamma analysis failures for the films with the lower
passing rates. While some minor discrepancies in the target areas are present, the majority of the
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disagreement for both PF and Pinnacle, which is already quite small in absolute terms, is
confined to the low- or intermediate-dose regions. The latter are sometimes prominent when a
film plane glances the target and some of the peripheral target dose is still evident on the film. In
that case, there is a high dose gradient in the direction perpendicular to the film, leading to
dosimetric discrepancies due to residual geometric misalignments. Those errors are not
accounted for in the distance-to-agreement since the gamma analysis is performed in two
dimensions (the film plane).
Table 7.2. Planar gamma analysis passing rates for PF and Pinnacle vs. film.
Plan
1

No. of
Targets
3

2

3

3

3

4

3

5

5

6

10

Planes
Cor.
Obl.45º
Obl.135º
Cor.
Sag.
Obl.135º
Obl.45º
Obl.135º
Obl.45º
Obl.135º
Cor.
Obl.45º
Obl.135º
Cor.
Sag.
Obl.45º
Obl.135º
Ave
SD

PF vs. Film
3%/1mm
2%/2mm
100
99.9
96.1
94.4
99.1
99.6
100
97.7
99.4
99.2
99.8
99.8
100
99.9
99.9
99.9
100
99.9
100
100
99.4
99.0
99.7
99.6
97.3
95.8
98.3
96.4
99.6
99.7
99.3
98.6
99.4
99.3
99.2
98.8
1.1

1.7
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Pinnacle vs. film
3%/1mm
2%/2mm
97.7
97.6
89.4
87.0
99.0
96.4
98.1
90.7
95.7
96.3
99.3
98.5
98.3
95.6
99.2
99.4
97.1
98.1
99.4
99.6
89.9
91.9
98.6
96.8
94.5
93.2
94.3
89.4
99.0
98.9
97.5
95.7
98.4
96.6
96.8
95.4
3.1

3.7

Figure 7.2. Gamma maps and isodose overlays for PF vs. film. (a&b): Oblique 45º plane from Plan 1, (c&d):
Oblique 135º plane from Plan 5, and (e&f): Oblique 45º plane from Plan 6.
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7.3.2

Profile and Peak Target Dose Comparison
The comparison of the profiles extracted through the center of the targets were performed

at RIT. An example is presented in Figure 7.3 and Figure 7.4 showing the comparison of profiles
for PF and Pinnacle vs. film for two targets (1.1 cm and 0.8 cm).

Figure 7.3. Comparison of a horizontal dose profile through the center of a target (size 1.1 cm).
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Figure 7.4. Comparison of a vertical dose profile through the center of a target (size 0.8 cm).

Further, the results of such dose profiles alignment are presented in Figure 7.3 and Figure
7.4. Within the range of accelerator motions employed in the plans, submillimeter average
displacements between the reconstructed and planned dose distribution centroids can be inferred.
Table 7.3. Displacement between PF and film dose profiles centers in different anatomical directions.
Direction

Craniocaudal

Anteroposterior

Lt-Rt

Obl. 45º

Obl. 135º

No. Analyzed

27

4

3

11

7

Δ ±1SD (mm)

-0.3±0.4

0.0±0.6

-0.1±0.4

-0.2±0.7

0.0±0.4

For the point dose comparison, both PF and Pinnacle show agreement with measurement
largely to within ±3%, which is satisfactory, particularly for the targets less than 1 cm in size
(Figure 7.5). For all targets, the average dose-errors were -0.4% ± 1.3% (range -2.2 to 2.4%, 99%
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CI -1.1 to 0.3%) and 0.1% ± 1.6% (range -2.7 to 3.2%, 99% CI -0.8 to 1.0%) for PF and Pinnacle
respectively. Both distributions did not show significant deviation from normal by the
D'Agostino & Pearson normality test (p-value ≥0.2). There was no correlation between the doseerror and the target size (Pearson correlation coefficient r = 0.23 and 0.21 for PF and Pinnacle,
respectively). Similarly, there was no correlation between the dose-error and the target distance
from isocenter (r = 0.1 and -0.1 for PF and Pinnacle, respectively).

Figure 7.5. Percent point dose errors sampled at the center of the targets for PF and Pinnacle vs. film.

7.4

Discussion
While the recent AAPM TG-218 report [23] prescribes the error thresholds and action

levels for gamma analysis comparison between measured and planned dose distributions, there is
no such clear guidance for purely calculational or semi-empirical verification. We chose to
retain the 3% dose-error threshold from TG-218, which is also similar to the point-dose
verification recommendations for complex non-IMRT beams [41]. Given the tight SRS spatial
accuracy expectations, a 1 mm distance-to-agreement threshold seemed desirable. Finally, the
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TG-218 report unequivocally justifies global dose-error normalization for routine patient-specific
QA. With these criteria, the system in question – PerFRACTION – was able to achieve on
average 99.2±1.1% agreement rate with absolute film measurements. Volumetrically, all voxels
in all plans agreed between PF and the TPS at the same 3%/1mm level. The point doses near the
target center agreed between PF and film to better than 3%, for the target sizes ranging from 0.8
to 3.6 cm. The reconstructed dose centroid positions derived from the EPID-measured MLC
apertures on a well-aligned accelerator showed on average sub-millimeter displacements from
film measurements. The studied system is thus sufficiently accurate in the radiosurgical setting
for routine semi-empirical dose reconstruction.
However a bigger question remains on the role of calculations vs. measurements in
patient-specific dosimetric QA. It is a subject of ongoing debate [39] , with the latest TG-218
report acknowledging but not adjudicating the issue. We characterize the approach described in
this study as semi-empirical or hybrid, as some of the information (MLC apertures) is derived
from independent measurements, while other elements are harvested from the accelerator log
files. In addition to the delivered MLC leaf positons, such approach definitively tests the
integrity of the data transfer chain all the way from the TPS to the accelerator, which is one of
the most important aspects of the patient-specific end-to-end tests. The beam model quality,
which is the frequent culprit in the end-to-end head and neck phantom irradiation failures [208]
is also tested, but not by direct dose measurements. We would argue that this level of scrutiny is
acceptable for routine QA (as opposed to system commissioning), and furthermore 3D
reconstruction with small voxels is more comprehensive than, for example, experimental planar
sampling with large detector pitch arrays. Studying the sensitivity of the method to induced MLC
errors is outside the scope of this work, but it is likely to be similar to the results demonstrated by
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others in the related work with high-resolution systems [209, 210].

While the risk of a false

positive findings (an error reported when there is none) is easily mitigated by measurement if
necessary, a potential false negative (no error reported when there is one) is more likely to slip
through. The risk of accelerator absolute calibration changes after the morning checkout has
always been considered sufficiently mitigated in conventional treatments by the redundancy of
the dosimetry chain, and the TG-218 specifically recommends the IMRT QA measured dose to
be normalized to the daily output [23] to exclude the influence of the fluctuations, which could
otherwise consume a substantial part of the error budget. Thus the remaining weakest link in the
tested PF configuration (and there are other options, not described in this work) is the lack of
independent verification of the accelerator axes positions (fractional MU, gantry angle, etc.)
other than the MLC. If an accelerator fails in such a fashion that the log files reflect the intended
plan that diverges from the delivered treatment, a dosimetric error may go unnoticed. It should
be, however, argued that a random accelerator failure during treatment by definition cannot be
reliably caught by pre-treatment measurements in the first place, while any gradual parameter
drift is more appropriately addressed by an ongoing comprehensive QA program. Regarding
systematic delivery deficiencies, with modern digital accelerators, the known issues such as the
overshoot phenomenon [211]

are largely considered mitigated [69]. For example, for the

TrueBeam accelerator with its 20 ms controller interrogation cycle and strict delivery linearity
enforcement inside each control point [212], even the gantry acceleration trajectory is highly
predictable and reproducible [213]. Therefore, while not going as far as endorsing the log file
analysis as a “premier SRS/SBRT QA tool” [214], it is nevertheless suggested that coupled with
thorough TPS commissioning and comprehensive ongoing accelerator QA program, the hybrid
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verification method validated in this study is a viable tool that could be applied in clinical
practice.
7.5

Conclusions
A semi-empirical volumetric dose verification system extracts MLC positions from the

EPID movies, while the rest of the delivery control point information comes from the accelerator
log files. This combination is used to reconstruct dose on a patient CT dataset with a fast
superposition/convolution algorithm. The method was comprehensively validated for singleisocenter multi-target VMAT SRS treatments against absolute film measurements. With proper
understanding of its advantages and shortcomings, the tool can be used in routine clinical
practice.
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8

8.1

CONCLUSIONS AND FUTURE DIRECTIONS

Conclusions
This work was primarily focused on the clinical applications of specific, recently released

PSQA devices and software for advanced radiotherapy techniques (IMRT/VMAT/SRS). The
investigations included a tool to aid in the efficient treatment plan optimization and to gauge the
plan quality (PlanIQ), independent dose calculation algorithm (DoseCHECK) for dose
verification, 3D and 2D true composite measurement based dose verification techniques
(ArcCHECK & 3DVH and SRS MapCHECK) and a hybrid technique (PerFRACTION) to
reconstruct volumetric dose. Thus it encompassed a large sample of PSQA techniques. All
methods were subjected to rigorous clinical evaluations against the standard dosimeters (IC, film,
scintillator detector) to test their limits and ascertain clinical suitability. Overall, the dosimetry
systems were found feasible for their intended applications by generating excellent to acceptable
gamma passing rates or point dose differences against the standard detectors. Although the true
composite measurement based methods are preferred [23], there is an on-going debate [28, 39]
over the relative merits of different approaches. Currently there is no system that could catch
every possible error and the path to development of such system is not clear. In the meantime,
each one has its advantages and disadvantages which should be weighed by the individual clinic
based on their needs and resources.
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8.2

Future Directions
The PSQA needs to grow as the radiotherapy becomes more specialized as well as

personalized. The special procedures like SRS, robotic SRS and MR guided radiotherapy
challenge the contemporary PSQA methods.
1. The SRS procedures require detectors with high spatial resolution for dose
verifications. Also, a stringent gamma criteria is implemented for the comparison
between the predicted and measured dose. To date, only 2D detector planes are
investigated for SRS true composite measurements [174]. A better solution however
would be a high-resolution (quasi) 3D array compatible with the full range of gantry
and couch angles.
2. MR-guided radiotherapy is gaining popularity in the clinic. This modality also poses
challenges for the existing PSQA methods as it requires at least static field compatible dosimeters. The next level of complexity is arrays compatible with MR
imaging. The current EPID-based methods are not likely to be applicable as the
current MR-guided LINACs do not include an EPID.
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